Effects	O	O
of	O	O
a	O	O
leukemia-associated	O	O
gain-of-function	O	O
mutation	O	O
of	O	O
SHP-2	O	O
phosphatase	O	O
on	O	O
interleukin-3	O	O
signaling	O	O
.	O	O

Mutations	B-Var	B-Var
in	O	O
SHP-2	B-Gene	O
phosphatase	B-Enzyme	O
that	O	O
cause	O	O
hyperactivation	B-PosReg	O
of	O	O
its	O	O
catalytic	B-MPA	O
activity	I-MPA	O
have	O	O
been	O	O
identified	O	O
in	O	O
human	B-Disease	O
leukemias	I-Disease	O
,	O	O
particularly	O	O
juvenile	B-Disease	O
myelomonocytic	I-Disease	O
leukemia	I-Disease	O
,	O	O
which	O	O
is	O	O
characterized	O	O
by	O	O
hypersensitivity	O	O
of	O	O
myeloid	O	O
progenitor	O	O
cells	O	O
to	O	O
granulocyte	O	O
macrophage	O	O
colony-stimulating	O	O
factor	O	O
and	O	O
interleukin	O	O
(	O	O
IL)-3	O	O
.	O	O

However	O	O
,	O	O
the	O	O
molecular	O	O
mechanisms	O	O
by	O	O
which	O	O
gain-of-function	O	O
(	O	O
GOF	O	O
)	O	O
mutations	O	B-Var
of	O	O
SHP-2	O	O
induce	O	O
hematopoietic	O	B-Disease
malignancies	O	I-Disease
are	O	O
not	O	O
fully	O	O
understood	O	O
.	O	O

Our	O	O
previous	O	O
studies	O	O
have	O	O
shown	O	O
that	O	O
SHP-2	O	O
plays	O	O
an	O	O
essential	O	O
role	O	O
in	O	O
IL-3	O	O
signal	O	O
transduction	O	O
in	O	O
both	O	O
catalytic-dependent	O	O
and	O	O
-independent	O	O
manners	O	O
and	O	O
that	O	O
overexpression	O	O
(	O	O
5-6-fold	O	O
)	O	O
of	O	O
wild	O	O
type	O	O
(	O	O
WT	O	O
)	O	O
SHP-2	O	O
attenuates	O	O
IL-3-mediated	O	O
hematopoietic	O	O
cell	O	O
function	O	O
through	O	O
accelerated	O	B-PosReg
dephosphorylation	O	B-MPA
of	O	I-MPA
STAT5	O	I-MPA
.	O	O

These	O	O
results	O	O
raised	O	O
the	O	O
possibility	O	O
that	O	O
SHP-2-associated	O	O
leukemias	O	O
are	O	O
not	O	O
solely	O	O
attributed	O	O
to	O	O
the	O	O
increased	O	B-PosReg
catalytic	O	B-MPA
activity	O	I-MPA
of	O	O
GOF	O	O
mutant	O	O
SHP-2	O	O
.	O	O

GOF	O	O
mutant	O	O
SHP-2	O	O
must	O	O
have	O	O
gained	O	O
additional	O	O
capacities	O	O
.	O	O

To	O	O
test	O	O
this	O	O
possibility	O	O
,	O	O
we	O	O
investigated	O	O
effects	O	O
of	O	O
a	O	O
GOF	O	O
mutation	O	O
of	O	O
SHP-2	O	O
(	O	O
SHP-2	O	O
E76	O	O
K	O	O
)	O	O
on	O	O
hematopoietic	O	O
cell	O	O
function	O	O
and	O	O
IL-3	O	O
signal	O	O
transduction	O	O
by	O	O
comparing	O	O
with	O	O
those	O	O
of	O	O
overexpressed	O	O
WT	O	O
SHP-2	O	O
.	O	O

Our	O	O
results	O	O
showed	O	O
that	O	O
SHP-2	B-Gene	O
E76	B-Var	O
K	I-Var	O
mutation	O	O
caused	O	O
myeloproliferative	B-Disease	O
disease	I-Disease	O
in	I-Disease	O
mice	I-Disease	O
,	O	O
while	O	O
overexpression	O	O
of	O	O
WT	O	O
SHP-2	O	O
decreased	O	O
hematopoietic	O	O
potential	O	O
of	O	O
the	O	O
transduced	O	O
cells	O	O
in	O	O
recipient	O	O
animals	O	O
.	O	O

The	O	O
E76	B-Var	B-Var
K	I-Var	O
mutation	I-Var	O
in	I-Var	O
the	I-Var	O
N-terminal	I-Var	O
Src	I-Var	O
homology	I-Var	O
2	I-Var	O
domain	O	O
increased	B-PosReg	B-PosReg
interactions	B-Interaction	B-Interaction
of	O	O
mutant	B-Var	O
SHP-2	B-Gene	O
with	O	O
Grb2	B-Protein	O
,	O	O
Gab2	O	O
,	O	O
and	O	O
p85	O	O
,	O	O
leading	O	O
to	O	O
hyperactivation	B-PosReg	O
of	O	O
IL-3-induced	B-Pathway	O
Erk	I-Pathway	O
and	I-Pathway	O
phosphatidylinositol	I-Pathway	O
3-kinase	I-Pathway	O
(	I-Pathway	O
PI3	I-Pathway	O
K	O	O
)	O	O
pathways	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
despite	O	O
the	O	O
substantial	O	O
increase	B-PosReg	O
in	O	O
the	O	O
catalytic	B-MPA	B-MPA
activity	I-MPA	I-MPA
,	O	O
dephosphorylation	B-MPA	O
of	I-MPA	O
STAT5	I-MPA	O
by	O	O
SHP-2	B-Gene	O
E76	B-Var	O
K	O	O
was	O	O
dampened	B-NegReg	O
.	O	O

Furthermore	O	O
,	O	O
catalytically	B-Var	O
inactive	I-Var	O
SHP-2	I-Var	O
E76	I-Var	O
K	I-Var	O
with	I-Var	O
an	I-Var	O
additional	I-Var	O
C459S	I-Var	O
mutation	O	O
retained	O	O
the	O	O
capability	O	O
to	O	O
increase	B-PosReg	B-PosReg
the	O	O
interaction	B-Interaction	O
with	O	O
Gab2	B-Protein	O
and	O	O
to	O	O
enhance	B-PosReg	O
the	O	O
activation	B-Pathway	O
of	I-Pathway	O
the	I-Pathway	O
PI3	I-Pathway	O
K	I-Pathway	O
Genetic	O	O
modifiers	O	O
of	O	O
the	O	O
Drosophila	O	O
blue	O	O
cheese	O	O
gene	O	O
link	O	O
defects	O	O
in	O	O
lysosomal	O	O
transport	O	O
with	O	O
decreased	O	O
life	O	O
span	O	O
and	O	O
altered	O	O
ubiquitinated-protein	O	O
profiles	O	O
.	O	O

Defects	O	O
in	O	O
lysosomal	O	O
trafficking	O	O
pathways	O	O
lead	O	O
to	O	O
decreased	O	B-NegReg
cell	O	B-CPA
viability	O	I-CPA
and	O	O
are	O	O
associated	O	O
with	O	O
progressive	O	O
disorders	O	O
in	O	O
humans	O	O
.	O	O

Previously	O	O
we	O	O
have	O	O
found	O	O
that	O	O
loss-of-function	O	B-NegReg
(	O	O
LOF	O	O
)	O	O
mutations	B-Var	B-Var
in	O	O
the	O	O
Drosophila	B-Gene	O
gene	I-Gene	O
blue	I-Gene	O
cheese	I-Gene	O
(	O	O
bchs	O	O
)	O	O
lead	O	O
to	O	O
reduced	B-NegReg	B-NegReg
adult	B-CPA	O
life	I-CPA	O
span	I-CPA	O
,	O	O
increased	B-PosReg	B-PosReg
neuronal	B-CPA	B-MPA
death	I-CPA	I-MPA
,	O	O
and	O	O
widespread	B-CPA	O
CNS	I-CPA	O
degeneration	B-NegReg	O
that	O	O
is	O	O
associated	O	O
with	O	O
the	O	O
formation	O	O
of	O	O
ubiquitinated-protein	O	O
aggregates	O	O
.	O	O

To	O	O
identify	O	O
potential	O	O
genes	O	O
that	O	O
participate	O	O
in	O	O
the	O	O
bchs	O	O
functional	O	O
pathway	O	O
,	O	O
we	O	O
conducted	O	O
a	O	O
genetic	O	O
modifier	O	O
screen	O	O
based	O	O
on	O	O
alterations	O	O
of	O	O
an	O	O
eye	O	O
phenotype	O	O
that	O	O
arises	O	O
from	O	O
high-level	O	O
overexpression	O	O
of	O	O
Bchs	O	O
.	O	O

We	O	O
found	O	O
that	O	O
mutations	O	B-Var
in	O	O
select	O	O
autophagic	O	O
and	O	O
endocytic	O	O
trafficking	O	O
genes	O	O
,	O	O
defects	O	O
in	O	O
cytoskeletal	O	O
and	O	O
motor	O	O
proteins	O	O
,	O	O
as	O	O
well	O	O
as	O	O
mutations	O	O
in	O	O
the	O	O
SUMO	O	O
and	O	O
ubiquitin	O	O
signaling	O	O
pathways	O	O
behave	O	O
as	O	O
modifiers	O	O
of	O	O
the	O	O
Bchs	O	O
gain-of-function	O	O
(	O	O
GOF	O	O
)	O	O
eye	O	O
phenotype	O	O
.	O	O

Individual	O	O
mutant	O	O
alleles	O	O
that	O	O
produced	O	O
viable	O	O
adults	O	O
were	O	O
further	O	O
examined	O	O
for	O	O
bchs-like	O	O
phenotypes	O	O
.	O	O

Mutations	B-Var	B-Var
in	O	O
several	O	O
lysosomal	B-Gene	O
trafficking	I-Gene	O
genes	I-Gene	O
resulted	O	O
in	O	O
significantly	O	O
decreased	B-NegReg	O
adult	B-CPA	O
life	I-CPA	O
spans	I-CPA	O
and	O	O
several	O	O
mutants	O	O
showed	O	O
changes	B-Reg	O
in	O	O
ubiquitinated	B-MPA	O
protein	I-MPA	O
profiles	I-MPA	O
Isolation	O	O
and	O	O
characterization	O	O
of	O	O
a	O	O
novel	O	O
human	O	O
RGS	O	O
mutant	O	O
displaying	O	O
gain-of-function	O	O
activity	O	O
.	O	O

Regulator	O	O
of	O	O
G	O	O
protein	O	O
signaling	O	O
(	O	O
RGS	O	O
)	O	O
proteins	O	O
play	O	O
a	O	O
crucial	O	O
role	O	O
in	O	O
the	O	O
adaptation	O	O
of	O	O
cells	O	O
to	O	O
stimulation	B-PosReg	O
by	O	O
G	B-Protein	O
protein-coupled	I-Protein	O
receptors	I-Protein	O
via	O	O
heterotrimeric	B-Protein	O
G	I-Protein	O
proteins	I-Protein	O
.	O	O

Alterations	B-Var	O
in	O	O
RGS	B-Protein	O
function	O	O
have	O	O
been	O	O
implicated	B-Reg	O
in	O	O
a	O	O
wide	O	O
range	O	O
of	O	O
disease	B-Disease	O
states	O	O
,	O	O
leading	O	O
to	O	O
many	O	O
researchers	O	O
focusing	O	O
on	O	O
controlling	O	O
the	O	O
action	O	O
of	O	O
these	O	O
regulatory	O	O
proteins	O	O
.	O	O

Previous	O	O
studies	O	O
have	O	O
centered	O	O
on	O	O
reducing	B-NegReg	O
or	O	O
inhibiting	B-NegReg	B-NegReg
the	O	O
action	O	O
of	O	O
RGS	B-Protein	O
proteins	I-Protein	O
,	O	O
utilizing	O	O
inactive	O	B-NegReg
mutants	O	B-Var
or	O	O
small	O	O
molecular	O	O
RGS	O	O
inhibitors	O	O
.	O	O

Here	O	O
we	O	O
describe	O	O
the	O	O
isolation	O	O
and	O	O
characterization	O	O
of	O	O
a	O	O
novel	O	O
human	O	O
RGS4	B-Var	O
mutant	I-Var	B-Var
which	O	O
displays	O	O
enhanced	B-PosReg	B-PosReg
or	O	B-Gene
gain-of-function	B-PosReg	B-PosReg
(	O	O
GOF	O	O
)	O	O
activity	O	O
.	O	O

RGS4(S30C	O	O
)	O	O
demonstrates	O	O
GOF	O	O
activity	O	O
both	O	O
in	O	O
an	O	O
in	O	O
vivo	O	O
yeast-based	B-Pathway	O
signalling	I-Pathway	O
pathway	I-Pathway	O
and	O	O
in	O	O
vitro	O	O
against	O	O
the	O	O
Galpha(o1	B-Protein	O
)	I-Protein	O
subunit	I-Protein	O
contained	I-Protein	O
in	I-Protein	O
an	I-Protein	O
alpha(2A)-adrenoreceptor-Galpha(o1)(C351I	I-Protein	O
)	I-Protein	O
fusion	O	O
protein	O	O
.	O	O

Mutational	O	O
analysis	O	O
of	O	O
serine	O	O
30	O	O
identified	O	O
a	O	O
number	O	O
of	O	O
alternative	O	O
substitutions	O	O
that	O	O
result	O	O
in	O	O
GOF	O	O
activity	O	O
.	O	O

GOF	O	O
activity	O	O
was	O	O
retained	O	O
upon	O	O
transposition	O	O
of	O	O
the	O	O
serine	O	O
30-cysteine	O	O
mutation	O	O
to	O	O
the	O	O
equivalent	O	O
serine	O	O
residue	O	O
in	O	O
human	O	O
RGS16	O	O
.	O	O

As	O	O
with	O	O
previously	O	O
identified	O	O
GOF	O	O
mutants	O	O
,	O	O
RGS4(S30C	B-Var	O
/	O	O
S30F	O	O
/	O	O
S30	O	O
K	O	O
)	O	O
demonstrate	O	O
increased	O	B-PosReg
steady	O	B-MPA
state	O	I-MPA
protein	O	I-MPA
levels	O	I-MPA
,	O	O
however	O	O
these	O	O
mutants	O	O
also	O	O
demonstrate	O	O
enhanced	O	B-PosReg
GAP	O	B-MPA
activity	O	I-MPA
through	O	O
an	O	O
additional	O	O
mechanism	O	O
distinct	O	O
from	O	O
the	O	O
increased	O	O
protein	O	O
content	O	O
.	O	O

The	O	O
identification	O	O
of	O	O
human	O	O
RGS	O	O
mutants	O	O
with	O	O
GOF	O	O
activity	O	O
may	O	O
provide	O	O
novel	O	O
therapeutic	O	O
agents	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
signaling-based	O	O
diseases	O	O
and	O	O
the	O	O
ability	O	O
to	O	O
transpose	O	O
these	O	O
mutations	O	O
to	O	O
other	O	O
human	O	O
RGS	O	O
proteins	O	O
extends	O	O
their	O	O
application	O	O
to	O	O
multiple	O	O
pathways	O	O
.	O	O

Conditional	O	O
RNA	O	O
interference	O	O
in	O	O
vivo	O	O
to	O	O
study	O	O
mutant	O	O
p53	O	O
oncogenic	O	O
gain	O	B-PosReg
of	O	I-PosReg
function	O	I-PosReg
on	O	O
tumor	O	O
malignancy	O	O
.	O	O

Mutant	B-Var	B-Var
p53	B-Gene	B-Gene
proteins	B-Protein	B-Protein
are	O	O
thought	O	O
to	O	O
have	O	O
acquired	O	O
a	O	O
"	O	O
gain	O	B-PosReg
of	O	I-PosReg
function	O	I-PosReg
"	O	O
(	O	O
GOF	O	O
)	O	O
activity	O	O
that	O	O
mainly	O	O
contributes	B-PosReg	O
to	O	O
tumor	B-CPA	O
aggressiveness	I-CPA	O
.	O	O

Previously	O	O
we	O	O
reported	O	O
that	O	O
constitutive	O	O
downregulation	B-NegReg	O
of	O	O
mutant	B-Var	O
p53	B-Gene	O
by	O	O
RNA	B-MPA	O
interference	I-MPA	O
reduces	B-NegReg	B-NegReg
the	O	O
tumorigenicity	B-CPA	O
of	I-CPA	O
cancer	I-CPA	O
cells	I-CPA	O
in	I-CPA	O
an	I-CPA	O
animal	I-CPA	O
model	I-CPA	O
;	O	O
however	O	O
,	O	O
effects	O	O
of	O	O
adaptation	O	O
to	O	O
long-term	O	O
mutant	O	O
p53	O	O
inhibition	O	O
could	O	O
not	O	O
be	O	O
excluded	O	O
.	O	O

To	O	O
address	O	O
this	O	O
point	O	O
,	O	O
mimicking	O	O
more	O	O
physiological	O	O
conditions	O	O
,	O	O
we	O	O
now	O	O
describe	O	O
the	O	O
establishment	O	O
of	O	O
a	O	O
lentiviral-based	O	O
system	O	O
for	O	O
conditional	O	O
interference	O	O
with	O	O
mutant	O	B-Var
p53	O	B-Gene
expression	O	O
.	O	O

In	O	O
vivo	O	O
studies	O	O
assessed	O	O
the	O	O
efficacy	O	O
of	O	O
conditional	B-MPA	O
RNA	I-MPA	O
interference	I-MPA	O
in	O	O
inhibiting	B-NegReg	B-Gene
gain	O	B-PosReg
of	O	I-PosReg
function	O	I-PosReg
activity	B-MPA	O
of	O	O
mutant	B-Var	B-Var
p53	B-Gene	B-Gene
proteins	B-Protein	B-Protein
by	O	O
reducing	O	O
tumor	O	O
growth	O	O
ability	O	O
.	O	O

Moreover	O	O
by	O	O
using	O	O
this	O	O
system	O	O
,	O	O
microarray	O	O
data	O	O
were	O	O
validated	O	O
in	O	O
vitro	O	O
and	O	O
in	O	O
vivo	O	O
and	O	O
putative	O	O
mutant	O	O
p53	O	O
target	O	O
genes	O	O
that	O	O
may	O	O
contribute	O	O
to	O	O
its	O	O
gain	O	B-PosReg
of	O	I-PosReg
function	O	I-PosReg
effects	O	O
in	O	O
cancer	O	O
were	O	O
identified	O	O
.	O	O

Results	O	O
are	O	O
confirmatory	O	O
that	O	O
depletion	B-MPA	O
of	O	O
mutant	B-Var	O
p53	B-Gene	O
protein	B-Protein	O
impacts	B-Reg	O
on	O	O
tumor	B-CPA	O
malignancy	I-CPA	O
Identification	O	O
and	O	O
functional	O	O
analysis	O	O
of	O	O
novel	O	O
variants	O	O
of	O	O
the	O	O
human	O	O
melanocortin	O	O
1	O	O
receptor	O	O
found	O	O
in	O	O
melanoma	O	O
patients	O	O
.	O	O

The	O	O
melanocortin	O	O
1	O	O
receptor	O	O
,	O	O
a	O	O
Gs	O	O
protein-coupled	O	O
receptor	O	O
expressed	O	O
in	O	O
epidermal	O	O
melanocytes	O	O
,	O	O
is	O	O
a	O	O
major	O	O
determinant	O	O
of	O	O
skin	O	O
pigmentation	O	O
and	O	O
phototype	O	O
and	O	O
an	O	O
important	O	O
contributor	O	O
to	O	O
melanoma	O	O
risk	O	O
.	O	O

MC1R	O	O
activation	O	O
stimulates	O	O
synthesis	O	O
of	O	O
black	O	O
,	O	O
strongly	O	O
photoprotective	O	O
eumelanin	O	O
pigments	O	O
.	O	O

Several	O	O
MC1R	O	O
alleles	O	O
are	O	O
associated	O	O
with	O	O
red	O	O
hair	O	O
,	O	O
fair	O	O
skin	O	O
,	O	O
increased	O	B-PosReg
sensitivity	O	B-MPA
to	O	O
ultraviolet	O	O
radiation	O	O
,	O	O
and	O	O
increased	O	O
skin	O	O
cancer	O	O
risk	O	O
.	O	O

The	O	O
MC1R	O	O
gene	O	O
is	O	O
highly	O	O
polymorphic	O	O
,	O	O
but	O	O
only	O	O
a	O	O
few	O	O
naturally	O	O
occurring	O	O
alleles	O	O
have	O	O
been	O	O
functionally	O	O
characterized	O	O
,	O	O
which	O	O
complicates	O	O
the	O	O
establishment	O	O
of	O	O
accurate	O	O
correlations	O	O
between	O	O
the	O	O
signaling	O	O
properties	O	O
of	O	O
mutant	O	O
alleles	O	O
and	O	O
defined	O	O
cutaneous	O	O
phenotypes	O	O
.	O	O

We	O	O
report	O	O
the	O	O
functional	O	O
characterization	O	O
of	O	O
six	O	O
MC1R	O	O
alleles	O	O
found	O	O
in	O	O
Spanish	O	O
melanoma	B-Disease	O
patients	O	O
.	O	O

Two	O	O
variants	O	O
(	O	O
c.152T	O	O
>	O	O
C	O	O
,	O	O
p	O	B-Var
.	O	O

Val51Ala	O	O
and	O	O
c.865T	O	B-Var
>	O	O
C	O	O
,	O	O
p	O	B-Var
.	O	O

Cys289Arg	O	O
)	O	O
have	O	O
never	O	O
been	O	O
described	O	O
,	O	O
and	O	O
the	O	O
others	O	O
(	O	O
c.112G	O	O
>	O	O
A	O	O
,	O	O
p	O	B-Var
.	O	O

Val38Met	O	O
;	O	O
c.122C	O	O
>	O	O
T	O	O
,	O	O
p	O	B-Var
.	O	O

Ser41Phe	O	O
;	O	O
c.383T	O	O
>	O	O
C	O	O
,	O	O
p	O	B-Var
.	O	O

Met128Thr	O	O
;	O	O
and	O	O
c.842A	O	B-Var
>	O	O
G	O	O
,	O	O
p	O	B-Var
.	O	O

Asn281Ser	O	O
)	O	O
have	O	O
not	O	O
been	O	O
analyzed	O	O
for	O	O
function	O	O
.	O	O

p	B-Var	B-Var
.	O	O

Asn281Ser	O	O
corresponds	O	O
to	O	O
a	O	O
functionally	O	O
silent	B-NegReg	O
polymorphism	B-MPA	O
.	O	O

The	O	O
other	O	O
mutations	O	O
are	O	O
associated	O	O
with	O	O
varying	O	O
degrees	O	O
of	O	O
loss	O	O
of	O	O
function	O	O
(	O	O
LOF	O	O
)	O	O
,	O	O
from	O	O
moderate	O	O
decreases	B-NegReg	O
in	O	O
coupling	B-MPA	O
to	O	O
the	O	O
cAMP	B-Pathway	O
pathway	I-Pathway	O
(	O	O
p	B-Var	O
.	O	O

Val38Met	O	O
and	O	O
p	B-Var	B-Var
.	O	O

Val51Ala	O	O
)	O	O
to	O	O
nearly	O	O
complete	O	O
absence	B-NegReg	O
of	O	O
functional	B-MPA	O
coupling	I-MPA	O
(	O	O
p	B-Var	O
.	O	O

Ser41Phe	O	O
,	O	O
p	B-Var	B-Var
.	O	O

Met128Thr	O	O
,	O	O
and	O	O
p	B-Var	B-Var
.	O	O

Cys289Arg	O	O
)	O	O
.	O	O

The	O	O
LOF	O	O
p	B-Var	B-Var
.	O	O

Met128Thr	O	O
and	O	O
p	B-Var	B-Var
.	O	O

Cys289Arg	O	O
mutants	O	O
are	O	O
trafficked	O	O
to	O	O
the	O	O
cell	O	O
surface	O	O
,	O	O
but	O	O
are	O	O
unable	B-NegReg	B-NegReg
to	O	O
bind	B-Interaction	O
agonists	O	O
efficiently	O	O
.	O	O

Conversely	O	O
,	O	O
LOF	O	O
of	O	O
p	B-Var	O
.	I-Var	O
Val38Met	I-Var	O
,	I-Var	O
p	O	B-Var
.	O	O

Ser41Phe	O	O
,	O	O
and	O	O
p	O	B-Var
.	O	O

Val51Ala	O	O
is	O	O
due	O	O
to	O	O
reduced	B-NegReg	O
cell	B-CPA	O
surface	I-CPA	O
expression	I-CPA	O
Elevated	O	O
expression	O	O
of	O	O
p53	O	B-Gene
gain-of-function	O	B-PosReg
mutation	O	B-Var
R175H	O	O
in	O	O
endometrial	O	O
cancer	O	O
cells	O	O
can	O	O
increase	O	B-PosReg
the	O	O
invasive	O	O
phenotypes	O	O
by	O	O
activation	O	O
of	O	O
the	O	O
EGFR	O	O
/	O	O
PI3K	O	O
/	O	O
AKT	O	O
pathway	O	O
.	O	O

BACKGROUND	O	O
:	O	O
p53	O	O
is	O	O
the	O	O
most	O	O
commonly	O	O
mutated	O	O
tumor	O	O
suppressor	O	O
gene	O	O
in	O	O
human	O	O
cancers	O	O
.	O	O

In	O	O
addition	O	O
to	O	O
the	O	O
loss	O	O
of	O	O
tumor	O	B-MPA
suppression	O	I-MPA
function	O	I-MPA
and	O	O
exertion	O	O
of	O	O
dominant-negative	O	O
effects	O	O
over	O	O
the	O	O
remaining	O	O
wild-type	O	O
protein	O	O
,	O	O
several	O	O
p53	O	O
mutants	O	O
can	O	O
gain	O	O
novel	O	O
oncogenic	O	O
functions	O	O
(	O	O
gain-of-function	O	O
,	O	O
GOF	O	O
)	O	O
that	O	O
actively	O	O
regulate	O	O
cancer	O	O
development	O	O
and	O	O
progression	O	O
.	O	O

In	O	O
human	O	O
endometrial	O	O
cancer	O	O
,	O	O
p53	B-Gene	O
mutation	B-Var	O
is	O	O
more	O	O
often	O	O
associated	B-Reg	O
with	O	O
aggressive	B-Disease	O
nonendometrioid	I-Disease	O
cancer	I-Disease	O
.	O	O

However	O	O
,	O	O
it	O	O
was	O	O
unknown	O	O
if	O	O
p53	O	O
mutants	O	O
contributed	O	O
to	O	O
endometrial	O	O
cancer	O	O
progression	O	O
through	O	O
the	O	O
GOF	O	O
properties	O	O
.	O	O

METHODS	O	O
:	O	O
To	O	O
clarify	O	O
the	O	O
relationship	O	O
between	O	O
expression	O	O
of	O	O
p53	O	O
GOF	O	O
mutation	O	O
(	O	O
p53-R175H	O	O
)	O	O
and	O	O
invasive	O	O
potential	O	O
of	O	O
human	O	O
endometrial	O	O
cancer	O	O
KLE	O	O
cells	O	O
,	O	O
we	O	O
tested	B-Reg	O
the	O	O
consequences	O	O
of	O	O
up-regulation	B-PosReg	O
and	O	O
down-regulation	B-NegReg	O
of	O	O
p53-R175H	O	O
in	O	O
KLE	O	O
cells	O	O
by	O	O
inducing	B-Reg	O
p53-R175H	B-Protein	O
expression	I-Protein	O
vector	I-Protein	O
or	O	O
suppressing	B-NegReg	B-NegReg
the	O	O
p53	B-Gene	O
gene	I-Gene	O
with	O	O
short	O	O
hairpin	O	O
RNA	O	O
.	O	O

RESULTS	O	O
:	O	O
We	O	O
found	O	O
that	O	O
forced	O	O
over-expression	B-PosReg	O
of	O	O
p53-R175H	B-Protein	O
significantly	O	O
promoted	O	O
cell	O	B-CPA
migration	O	I-CPA
and	O	O
invasion	O	O
,	O	O
and	O	O
induced	O	O
activation	O	O
of	O	O
the	O	O
epidermal	O	O
growth	O	O
factor	O	O
receptor	O	O
(	O	O
EGFR)/phosphatidylinositol	O	O
3-kinase	O	O
(	O	O
PI3K)/AKT	O	O
pathway	O	O
.	O	O

Conversely	O	O
,	O	O
suppression	O	O
of	O	O
p53-R175H	O	O
with	O	O
short	O	O
hairpin	O	O
RNA	O	O
significantly	O	O
inhibited	O	B-NegReg
cell	O	B-CPA
migration	O	I-CPA
and	O	O
invasion	O	O
,	O	O
and	O	O
resulted	O	O
in	O	O
attenuation	O	O
of	O	O
EGFR	O	O
/	O	O
PI3K	O	O
/	O	O
AKT	O	O
pathway	O	O
.	O	O

CONCLUSION	O	O
:	O	O
These	O	O
findings	O	O
show	O	O
for	O	O
the	O	O
first	O	O
time	O	O
that	O	O
elevated	O	O
expression	O	O
of	O	O
p53-R175H	O	O
mutant	O	O
may	O	O
exert	O	O
gain-of-function	O	B-PosReg
activity	O	B-MPA
to	O	O
activate	O	O
the	O	O
EGFR	O	O
/	O	O
PI3K	O	O
/	O	O
AKT	O	O
pathway	O	O
and	O	O
thus	O	O
may	O	O
contribute	O	O
to	O	O
the	O	O
invasive	O	O
phenotype	O	O
in	O	O
endometrial	O	O
cancer	O	O
.	O	O

The	O	O
tyrosine	O	O
phosphatase	O	O
Shp2	O	O
in	O	O
development	O	O
and	O	O
cancer	O	O
.	O	O

Deregulation	O	O
of	O	O
signaling	O	O
pathways	O	O
,	O	O
through	O	O
mutation	O	B-Var
or	O	O
other	O	O
molecular	O	O
changes	O	O
,	O	O
can	O	O
ultimately	O	O
result	O	O
in	O	O
disease	O	O
.	O	O

The	O	O
tyrosine	O	O
phosphatase	O	O
Shp2	O	O
has	O	O
emerged	O	O
as	O	O
a	O	O
major	O	O
regulator	O	O
of	O	O
receptor	O	O
tyrosine	O	O
kinase	O	O
(	O	O
RTK	O	O
)	O	O
and	O	O
cytokine	O	O
receptor	O	O
signaling	O	O
.	O	O

In	O	O
the	O	O
last	O	O
decade	O	O
,	O	O
germline	O	O
mutations	O	O
in	O	O
the	O	O
human	O	O
PTPN11	O	B-Gene
gene	O	O
,	O	O
encoding	O	O
Shp2	O	O
,	O	O
were	O	O
linked	O	O
to	O	O
Noonan	O	O
(	O	O
NS	O	O
)	O	O
and	O	O
LEOPARD	O	O
syndromes	O	O
,	O	O
two	O	O
multisymptomatic	O	O
developmental	O	O
disorders	O	O
that	O	O
are	O	O
characterized	O	O
by	O	O
short	O	O
stature	O	O
,	O	O
craniofacial	O	B-CPA
defects	O	I-CPA
,	O	O
cardiac	O	O
defects	O	O
,	O	O
and	O	O
mental	O	O
retardation	O	O
.	O	O

Somatic	O	O
Shp2	B-Gene	O
mutations	B-Var	B-Var
are	O	O
also	O	O
associated	B-Reg	O
with	O	O
several	O	O
types	O	O
of	O	O
human	O	B-Disease
malignancies	O	I-Disease
,	O	O
such	O	O
as	O	O
the	O	O
most	O	O
common	O	O
juvenile	B-Disease	O
leukemia	I-Disease	O
,	O	O
juvenile	B-Disease	O
myelomonocytic	I-Disease	O
leukemia	I-Disease	O
(	O	O
JMML	O	O
)	O	O
.	O	O

Whereas	O	O
NS	B-Disease	O
and	O	O
JMML	B-Disease	O
are	O	O
caused	O	B-Reg
by	O	I-Reg
gain-of-function	B-PosReg	O
(	O	O
GOF	O	O
)	O	O
mutations	B-Var	B-Var
of	O	O
Shp2	B-Gene	O
,	O	O
loss-of-function	B-NegReg	B-NegReg
(	O	O
LOF	O	O
)	O	O
mutations	B-Var	B-Var
are	O	O
thought	O	O
to	O	O
be	O	O
associated	O	O
with	O	O
LEOPARD	B-Disease	B-Disease
syndrome	I-Disease	I-Disease
Mutant	B-Var	B-Var
p53	B-Gene	B-Gene
facilitates	B-PosReg	O
somatic	B-CPA	O
cell	I-CPA	O
reprogramming	I-CPA	O
and	O	O
augments	B-NegReg	O
the	O	O
malignant	B-CPA	O
potential	I-CPA	O
of	I-CPA	O
reprogrammed	I-CPA	O
cells	I-CPA	O
.	O	O

p53	B-Gene	B-Gene
deficiency	B-Var	B-NegReg
enhances	B-PosReg	B-PosReg
the	O	O
efficiency	O	O
of	O	O
somatic	B-CPA	O
cell	I-CPA	O
reprogramming	I-CPA	O
to	O	O
a	O	O
pluripotent	O	O
state	O	O
.	O	O

As	O	O
p53	O	O
is	O	O
usually	O	O
mutated	O	O
in	O	O
human	O	O
tumors	O	O
and	O	O
many	O	O
mutated	B-Var	O
forms	I-Var	O
of	O	O
p53	B-Gene	B-Gene
gain	B-PosReg	B-PosReg
novel	O	I-PosReg
activities	B-MPA	B-MPA
,	O	O
we	O	O
studied	O	O
the	O	O
influence	O	O
of	O	O
mutant	O	O
p53	O	O
(	O	O
mut-p53	O	O
)	O	O
on	O	O
somatic	O	O
cell	O	O
reprogramming	O	O
.	O	O

Our	O	O
data	O	O
indicate	O	O
a	O	O
novel	O	O
gain	B-PosReg	B-PosReg
of	O	I-PosReg
function	B-MPA	I-PosReg
(	O	O
GOF	O	O
)	O	O
property	O	O
for	O	O
mut-p53	B-Var	O
,	O	O
which	O	O
markedly	O	O
enhanced	B-PosReg	O
the	O	O
efficiency	O	O
of	O	O
the	O	O
reprogramming	B-CPA	O
process	I-CPA	O
compared	O	O
with	O	O
p53	O	O
deficiency	O	O
.	O	O

Importantly	O	O
,	O	O
this	O	O
novel	O	O
activity	B-MPA	O
of	O	O
mut-p53	B-Var	O
induced	O	O
alterations	B-Reg	O
in	O	O
the	O	O
characteristics	B-CPA	O
of	I-CPA	O
the	I-CPA	O
reprogrammed	I-CPA	O
cells	I-CPA	O
.	O	O

Although	O	O
p53	O	O
knockout	O	O
(	O	O
KO	O	O
)	O	O
cells	O	O
reprogrammed	O	O
with	O	O
only	O	O
Oct4	O	O
and	O	O
Sox2	O	O
maintained	O	O
their	O	O
pluripotent	B-MPA	O
capacity	I-MPA	O
in	O	O
vivo	O	O
,	O	O
reprogrammed	O	O
cells	O	O
expressing	O	O
mutant	B-Var	B-Var
p53	B-Gene	B-Gene
lost	B-NegReg	B-NegReg
this	O	O
capability	O	O
and	O	O
gave	B-Reg	O
rise	I-Reg	O
to	O	O
malignant	B-CPA	O
tumors	I-CPA	O
.	O	O

This	O	O
novel	O	O
GOF	O	O
of	O	O
mut-p53	O	O
is	O	O
not	O	O
attributed	O	O
to	O	O
its	O	O
effect	O	O
on	O	O
proliferation	O	O
,	O	O
as	O	O
both	O	O
p53	O	O
KO	O	O
and	O	O
mut-p53	O	O
cells	O	O
displayed	O	O
similar	O	O
proliferation	O	O
rates	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
we	O	O
demonstrate	O	O
an	O	O
oncogenic	B-MPA	O
activity	I-MPA	O
of	O	O
Klf4	O	O
,	O	O
as	O	O
its	O	O
overexpression	B-PosReg	O
in	O	O
either	O	O
p53	B-Var	O
KO	I-Var	O
or	I-Var	O
mut-p53	I-Var	O
cells	O	O
induced	B-PosReg	O
aggressive	B-CPA	O
tumors	I-CPA	O
.	O	O

Overall	O	O
,	O	O
our	O	O
data	O	O
show	O	O
that	O	O
reprogrammed	O	O
cells	O	O
with	O	O
the	O	O
capacity	O	O
to	O	O
differentiate	O	O
into	O	O
the	O	O
three	O	O
germ	O	O
layers	O	O
in	O	O
vitro	O	O
can	O	O
form	O	O
malignant	O	O
tumors	O	O
,	O	O
suggesting	O	O
that	O	O
in	O	O
genetically	O	O
unstable	O	O
cells	O	O
,	O	O
such	O	O
as	O	O
those	O	O
in	O	O
which	O	O
p53	B-Gene	O
is	O	O
mutated	B-Var	O
,	O	O
reprogramming	B-CPA	O
may	O	O
result	B-Reg	O
in	I-Reg	O
the	O	O
generation	O	O
of	O	O
cells	B-CPA	O
with	I-CPA	O
malignant	I-CPA	O
tumor-forming	I-CPA	O
potential	I-CPA	O
The	O	O
combined	O	O
impact	O	O
of	O	O
CYP2C19	O	O
and	O	O
CYP2B6	O	O
pharmacogenetics	O	O
on	O	O
cyclophosphamide	O	O
bioactivation	O	O
.	O	O

AIMS	O	O
:	O	O
The	O	O
role	O	O
of	O	O
CYP	O	O
pharmacogenetics	O	O
in	O	O
the	O	O
bioactivation	O	O
of	O	O
cyclophosphamide	O	O
is	O	O
still	O	O
controversial	O	O
.	O	O

Recent	O	O
clinical	O	O
studies	O	O
have	O	O
suggested	O	O
a	O	O
role	O	O
for	O	O
either	O	O
CYP2C19	O	O
or	O	O
CYP2B6	O	O
.	O	O

The	O	O
aim	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
clarify	O	O
the	O	O
role	O	O
of	O	O
these	O	O
pharmacogenes	O	O
.	O	O

METHODS	O	O
:	O	O
We	O	O
used	O	O
a	O	O
combined	O	O
in	O	O
vitro-in	O	O
vivo	O	O
approach	O	O
to	O	O
determine	O	O
the	O	O
role	O	O
of	O	O
these	O	O
pharmacogenes	O	O
in	O	O
the	O	O
bioactivation	O	O
of	O	O
the	O	O
prodrug	O	O
to	O	O
4-hydroxy	O	O
cyclophosphamide	O	O
(	O	O
4-OHCP	O	O
)	O	O
.	O	O

Cyclophosphamide	O	O
metabolism	O	O
was	O	O
determined	O	O
in	O	O
a	O	O
human	O	O
liver	O	O
biobank	O	O
(	O	O
n=	O	O
14	O	O
)	O	O
and	O	O
in	O	O
patients	O	O
receiving	O	O
the	O	O
drug	O	O
for	O	O
treatment	O	O
of	O	O
lupus	O	O
nephritis	O	O
(	O	O
n=	O	O
16	O	O
)	O	O
RESULTS	O	O
:	O	O
In	O	O
livers	O	O
of	O	O
known	O	O
CYP2C19	O	O
and	O	O
CYP2B6	O	O
genotype	O	O
and	O	O
protein	O	O
expression	O	O
we	O	O
observed	O	O
that	O	O
there	O	O
was	O	O
a	O	O
combined	B-Interaction	O
role	O	O
for	O	O
both	O	O
CYP2C19	B-Var	O
and	O	O
CYP2B6	B-Var	O
in	O	O
the	O	O
bioactivation	B-MPA	O
of	I-MPA	O
cyclophosphamide	I-MPA	O
in	I-MPA	O
vitro	I-MPA	O
.	O	O

The	O	O
presence	O	O
of	O	O
at	O	O
least	O	O
one	O	O
loss	O	O
of	O	O
function	O	O
(	O	O
LoF	O	O
)	O	O
allele	O	O
at	O	O
either	O	O
CYP2C19	B-Var	O
or	O	O
CYP2B6	B-Var	O
resulted	O	O
in	O	O
a	O	O
significant	O	O
decrease	B-NegReg	B-NegReg
in	O	O
both	O	O
V(max	B-MPA	O
)	I-MPA	O
(	I-MPA	O
P=	I-MPA	O
0.028	I-MPA	O
)	I-MPA	O
and	I-MPA	O
CL(int	O	O
)	O	O
(	O	O
P=	O	O
0.0017	O	O
)	O	O
compared	O	O
with	O	O
livers	O	O
with	O	O
no	O	O
LoF	O	O
alleles	O	O
.	O	O

This	O	O
dual	O	O
genotype	O	O
relationship	O	O
was	O	O
also	O	O
observed	O	O
in	O	O
a	O	O
preliminary	O	O
clinical	O	O
study	O	O
,	O	O
with	O	O
patients	O	O
who	O	O
had	O	O
≥1	O	O
LoF	O	O
allele	O	O
at	O	O
either	O	O
CYP2C19	B-Var	O
or	O	O
CYP2B6	B-Var	O
also	O	O
displaying	O	O
significantly	O	O
(	O	O
P=	O	O
0.0316	O	O
)	O	O
lower	B-NegReg	O
bioactivation	B-MPA	O
of	I-MPA	O
cyclophosphamide	I-MPA	O
.	O	O

The	O	O
mean	O	O
4-OHCP	O	O
:	O	O
CP	O	O
bioactivation	O	O
ratio	O	O
was	O	O
0.0014	O	O
(	O	O
95	O	O
%	O	O
CI	O	O
0.0007	O	O
,	O	O
0.002	O	O
)	O	O
compared	O	O
with	O	O
0.0071	O	O
(	O	O
95	O	O
%	O	O
CI	O	O
0.0001	O	O
,	O	O
0.014	O	O
)	O	O
in	O	O
patients	O	O
with	O	O
no	O	O
LoF	O	O
alleles	O	O
at	O	O
either	O	O
of	O	O
these	O	O
genes	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
The	O	O
presence	O	O
of	O	O
≥1	O	O
LoF	O	O
allele(s	O	O
)	O	O
at	O	O
either	O	O
CYP2B6	B-Var	O
or	O	O
CYP2C19	B-Var	O
appeared	O	O
to	O	O
result	O	O
in	O	O
decreased	B-NegReg	O
bioactivation	B-MPA	O
of	I-MPA	O
cyclophosphamide	I-MPA	O
Mutant	O	B-Var
p53	O	B-Gene
R248Q	O	B-Var
but	O	O
not	O	O
R248W	O	O
enhances	O	O
in	O	O
vitro	O	O
invasiveness	O	O
of	O	O
human	O	O
lung	O	O
cancer	O	O
NCI-H1299	O	O
cells	O	O
.	O	O

More	O	O
than	O	O
half	O	O
of	O	O
all	O	O
human	B-Disease	O
cancers	I-Disease	O
are	O	O
associated	B-Reg	O
with	O	O
mutations	B-Var	O
of	O	O
the	O	O
TP53	B-Gene	B-Gene
gene	O	O
.	O	O

In	O	O
regard	O	O
to	O	O
the	O	O
functional	O	O
interaction	O	O
with	O	O
the	O	O
remaining	O	O
wild-type	O	O
(	O	O
WT	O	O
)	O	O
p53	O	O
allele	O	O
,	O	O
p53	O	O
mutations	O	O
are	O	O
classified	O	O
into	O	O
two	O	O
types	O	O
,	O	O
recessive	O	O
and	O	O
dominant-negative	B-Var	O
(	I-Var	O
DN	I-Var	O
)	O	O
mutations	O	O
.	O	O

The	O	O
latter	O	O
mutant	O	O
protein	O	O
has	O	O
a	O	O
DN	B-MPA	O
activity	I-MPA	O
over	B-PosReg	O
the	I-PosReg	O
remaining	I-PosReg	O
WT	I-PosReg	O
allele	I-PosReg	O
.	O	O

We	O	O
previously	O	O
showed	O	O
that	O	O
the	O	O
DN	O	O
p53	O	O
mutant	O	O
was	O	O
useful	O	O
as	O	O
a	O	O
predictor	O	O
of	O	O
poor	O	O
outcome	O	O
or	O	O
a	O	O
risk	O	O
factor	O	O
for	O	O
metastatic	O	O
recurrence	O	O
in	O	O
patients	O	O
with	O	O
some	O	O
types	O	O
of	O	O
cancers	O	O
,	O	O
regardless	O	O
of	O	O
the	O	O
presence	O	O
or	O	O
absence	O	O
of	O	O
loss	O	O
of	O	O
heterozygosity	O	O
(	O	O
LOH	O	O
)	O	O
of	O	O
WT	O	O
p53	O	O
,	O	O
suggesting	O	O
that	O	O
the	O	O
DN	B-Var	O
p53	B-Gene	O
had	O	O
'	B-PosReg	O
gain-of-function	I-PosReg	O
(	I-PosReg	O
GOF	O	O
)	O	O
'	O	O
activity	O	O
besides	O	O
the	O	O
transdominance	O	B-MPA
function	O	I-MPA
.	O	O

In	O	O
this	O	O
study	O	O
,	O	O
we	O	O
investigated	O	O
GOF	O	O
activity	O	O
of	O	O
two	O	O
DN	O	O
p53	O	O
mutants	O	B-Var
which	O	O
had	O	O
a	O	O
point	O	O
mutation	O	O
at	O	O
codon	O	O
248	O	O
(	O	O
R248Q	O	B-Var
and	O	O
R248W	O	O
)	O	O
,	O	O
one	O	O
of	O	O
the	O	O
hot	O	O
spots	O	O
,	O	O
by	O	O
transfecting	O	O
them	O	O
respectively	O	O
into	O	O
H1299	O	O
cells	O	O
which	O	O
originally	O	O
expressed	O	O
no	O	O
p53	O	O
protein	O	O
.	O	O

Growth	O	O
activity	O	O
of	O	O
the	O	O
transfectants	O	O
with	O	O
the	O	O
two	O	O
mutants	O	O
was	O	O
not	O	O
different	O	O
from	O	O
that	O	O
of	O	O
parent	O	O
or	O	O
Mock	O	O
transfectants	O	O
.	O	O

Meanwhile	O	O
,	O	O
in	O	O
vitro	B-CPA	O
invasions	I-CPA	O
of	I-CPA	O
Matrigel	I-CPA	O
and	I-CPA	O
type	I-CPA	O
I	I-CPA	O
collagen	I-CPA	O
gel	I-CPA	O
by	O	O
R248Q-transfectants	B-Var	O
were	O	O
significantly	O	O
higher	B-PosReg	B-NegReg
Gain-of-function	O	B-PosReg
mutant	B-Var	B-Var
p53	B-Gene	B-Gene
upregulates	B-PosReg	O
CXC	B-MPA	O
chemokines	I-MPA	O
and	O	O
enhances	B-PosReg	B-PosReg
cell	B-CPA	B-CPA
migration	I-CPA	I-CPA
.	O	O

The	O	O
role	O	O
of	O	O
dominant	O	O
transforming	O	O
p53	O	O
in	O	O
carcinogenesis	O	O
is	O	O
poorly	O	O
understood	O	O
.	O	O

Our	O	O
previous	O	O
data	O	O
suggested	O	O
that	O	O
aberrant	B-Var	O
p53	B-Protein	O
proteins	I-Protein	O
can	O	O
enhance	B-PosReg	O
tumorigenesis	B-CPA	O
and	I-CPA	O
metastasis	I-CPA	O
.	O	O

Here	O	O
,	O	O
we	O	O
examined	O	O
potential	O	O
mechanisms	O	O
through	O	O
which	O	O
gain-of-function	O	O
(	O	O
GOF	O	O
)	O	O
p53	O	O
proteins	O	O
can	O	O
induce	O	B-PosReg
motility	O	B-CPA
.	O	O

Cells	O	O
expressing	O	O
GOF	O	O
p53	B-Var	O
-R175H	I-Var	O
,	I-Var	O
-R273H	I-Var	O
and	I-Var	O
-D281	O	O
G	O	O
showed	O	O
enhanced	B-PosReg	B-PosReg
migration	B-CPA	B-MPA
,	O	O
which	O	O
was	O	O
reversed	O	O
by	O	O
RNA	O	O
interference	O	O
(	O	O
RNAi	O	O
)	O	O
or	O	O
transactivation-deficient	O	O
mutants	O	O
.	O	O

In	O	O
cells	O	O
with	O	O
engineered	O	O
or	O	O
endogenous	O	O
p53	O	O
mutants	O	O
,	O	O
enhanced	O	B-CPA
migration	O	I-CPA
was	O	O
reduced	O	B-NegReg
by	O	O
downregulation	O	O
of	O	O
nuclear	O	O
factor-kappaB2	O	O
,	O	O
a	O	O
GOF	O	O
p53	O	O
target	O	O
.	O	O

We	O	O
found	O	O
that	O	O
GOF	B-Var	O
p53	I-Var	O
proteins	O	O
upregulate	B-PosReg	O
CXC-chemokine	B-MPA	O
expression	I-MPA	O
,	O	O
the	O	O
inflammatory	O	O
mediators	O	O
that	O	O
contribute	O	O
to	O	O
multiple	O	O
aspects	O	O
of	O	O
tumorigenesis	O	O
.	O	O

Elevated	B-PosReg	O
expression	B-MPA	O
of	O	O
CXCL5	O	O
,	O	O
CXCL8	O	O
and	O	O
CXCL12	O	O
was	O	O
found	O	O
in	O	O
cells	O	O
expressing	O	O
oncogenic	B-Var	O
p53	I-Var	O
.	O	O

Transcription	B-MPA	O
was	O	O
elevated	B-PosReg	O
as	O	O
CXCL5	B-MPA	O
and	I-MPA	O
CXCL8	I-MPA	O
promoter	I-MPA	O
activity	I-MPA	O
was	O	O
higher	B-PosReg	O
in	O	O
cells	O	O
expressing	O	O
GOF	B-Var	O
p53	I-Var	O
,	O	O
whereas	O	O
wild-type	O	O
p53	O	O
repressed	O	O
promoter	O	O
activity	O	O
.	O	O

Chromatin	O	O
immunoprecipitation	O	O
assays	O	O
revealed	O	O
enhanced	O	O
presence	O	O
of	O	O
acetylated	O	O
histone	O	O
H3	O	O
on	O	O
the	O	O
CXCL5	O	O
promoter	O	O
in	O	O
H1299/R273H	O	O
cells	O	O
,	O	O
in	O	O
agreement	O	O
with	O	O
increased	O	B-PosReg
transcriptional	O	B-MPA
activity	O	I-MPA
of	O	O
the	O	O
promoter	O	O
,	O	O
whereas	O	O
RNAi-mediated	O	O
repression	O	O
of	O	O
CXCL5	O	O
inhibited	O	O
cell	O	O
migration	O	O
.	O	O

Consistent	O	O
with	O	O
this	O	O
,	O	O
knockdown	O	O
of	O	O
the	O	O
endogenous	B-Var	O
mutant	I-Var	B-Var
p53	B-Gene	B-Gene
in	O	O
lung	O	O
cancer	O	O
or	O	O
melanoma	O	O
cells	O	O
reduced	B-NegReg	O
CXCL5	B-MPA	O
expression	I-MPA	O
and	O	O
cell	B-CPA	B-CPA
migration	I-CPA	I-CPA
.	O	O

Furthermore	O	O
,	O	O
short	O	O
hairpin	O	O
RNA	O	O
knockdown	O	O
of	O	O
mutant	B-Var	O
p53	B-Gene	O
in	O	O
MDA-MB-231	O	O
cells	O	O
reduced	B-NegReg	B-NegReg
expression	B-MPA	B-MPA
of	I-MPA	O
a	I-MPA	O
number	I-MPA	O
of	I-MPA	O
key	I-MPA	O
targets	I-MPA	O
,	O	O
including	O	O
several	O	O
chemokines	O	O
and	O	O
other	O	O
inflammatory	O	O
mediators	O	O
.	O	O

Finally	O	O
,	O	O
CXCL5	B-MPA	O
expression	I-MPA	O
was	O	O
also	O	O
elevated	B-PosReg	O
in	O	O
lung	B-Disease	O
tumor	I-Disease	O
samples	O	O
containing	O	O
GOF	B-Var	O
p53	I-Var	O
Allele	O	O
specific	O	O
gain-of-function	B-PosReg	B-PosReg
activity	B-MPA	B-MPA
of	O	O
p53	B-Gene	O
mutants	B-Var	O
in	O	O
lung	B-Disease	O
cancer	I-Disease	O
cells	O	O
.	O	O

p53	B-Gene	O
mutations	B-Var	O
are	O	O
mostly	O	B-Var
single	O	I-Var
amino	O	I-Var
acid	O	I-Var
changes	O	O
resulting	B-Reg	O
in	I-Reg	O
expression	B-MPA	O
of	O	O
a	O	O
stable	O	O
mutant	O	O
protein	O	O
with	O	O
"	O	O
gain	B-PosReg	B-PosReg
of	I-PosReg	I-PosReg
function	I-PosReg	I-PosReg
"	O	O
(	O	O
GOF	O	O
)	O	O
activity	B-MPA	O
having	O	O
a	O	O
dominant	O	O
oncogenic	O	O
role	O	O
rather	O	O
than	O	O
simple	O	O
loss	O	B-NegReg
of	O	I-NegReg
function	O	I-NegReg
of	O	O
wild-type	O	O
p53	O	O
.	O	O

Knock-down	O	O
of	O	O
mutant	O	O
p53	O	O
in	O	O
human	O	O
lung	O	O
cancer	O	O
cell	O	O
lines	O	O
with	O	O
different	O	O
endogenous	O	O
p53	B-Gene	B-Gene
mutants	B-Var	B-Var
results	O	B-Reg
in	O	O
loss	B-NegReg	B-NegReg
of	O	O
GOF	O	O
activity	B-MPA	O
as	O	O
shown	O	O
by	O	O
lowering	B-NegReg	O
of	O	O
cell	B-CPA	O
growth	I-CPA	O
rate	I-CPA	O
.	O	O

Two	O	O
lung	O	O
cancer	O	O
cell	O	O
lines	O	O
,	O	O
ABC1	O	O
and	O	O
H1437	O	O
,	O	O
carrying	O	O
endogenous	O	O
mutants	B-Var	B-Var
p53-P278S	I-Var	O
and	I-Var	O
-R267P	I-Var	O
,	O	O
show	O	O
reduction	B-NegReg	O
in	O	O
growth	B-MPA	O
rate	I-MPA	O
on	O	O
knock-down	O	O
on	O	O
p53	O	O
levels	O	O
.	O	O

However	O	O
,	O	O
whereas	O	O
reduction	B-NegReg	O
of	O	O
the	O	O
p53	B-Var	B-MPA
level	O	I-MPA
induces	O	I-MPA
loss	B-NegReg	B-NegReg
of	O	O
tumorigenicity	B-MPA	O
in	O	O
nude	O	O
mice	O	O
for	O	O
ABC1	O	O
cells	O	O
,	O	O
it	O	O
escalates	B-PosReg	O
tumorigenicity	B-MPA	O
Gain-of-Function	O	B-PosReg
Activity	O	B-MPA
of	O	O
Mutant	O	O
p53	O	O
in	O	O
Lung	O	O
Cancer	O	O
through	O	O
Up-Regulation	O	O
of	O	O
Receptor	O	O
Protein	O	O
Tyrosine	O	O
Kinase	O	O
Axl	O	O
.	O	O

p53	O	O
mutations	O	O
are	O	O
present	O	O
in	O	O
up	O	O
to	O	O
70	O	O
%	O	O
of	O	O
lung	O	O
cancer	O	O
.	O	O

Cancer	O	O
cells	O	O
with	O	O
p53	B-Gene	O
mutations	B-Var	O
,	O	O
in	O	O
general	O	O
,	O	O
grow	B-CPA	O
more	O	O
aggressively	B-PosReg	O
than	O	O
those	O	O
with	O	O
wild-type	O	O
p53	O	O
or	O	O
no	O	O
p53	O	O
.	O	O

Expression	O	O
of	O	O
tumor-derived	O	O
mutant	B-Var	O
p53	B-Gene	O
in	O	O
cells	O	O
leads	O	O
to	O	O
up-regulated	B-PosReg	O
expression	B-MPA	O
of	I-MPA	O
genes	I-MPA	O
that	O	O
may	O	O
affect	B-Reg	O
cell	B-CPA	O
growth	I-CPA	O
and	O	O
oncogenesis	B-CPA	O
.	O	O

In	O	O
our	O	O
study	O	O
of	O	O
this	O	O
aggressive	O	O
phenotype	O	O
,	O	O
we	O	O
have	O	O
investigated	O	O
the	O	O
receptor	O	O
protein	O	O
tyrosine	B-Enzyme	O
kinase	I-Enzyme	O
Axl	I-Enzyme	O
,	O	O
which	O	O
is	O	O
up-regulated	B-PosReg	O
by	O	O
p53	B-Gene	O
mutants	B-Var	O
at	O	O
both	O	O
RNA	O	O
and	O	O
protein	O	O
levels	O	O
in	O	O
H1299	O	O
lung	O	O
cancer	O	O
cells	O	O
expressing	O	O
mutants	O	O
p53-R175H	O	O
,	O	O
-R273H	O	O
,	O	O
and	O	O
-D281G.	O	O
Knockdown	O	O
of	O	O
endogenous	O	O
mutant	O	B-Var
p53	O	B-Gene
levels	O	O
in	O	O
human	O	O
lung	O	O
cancer	O	O
cells	O	O
H1048	O	O
(	O	O
p53-R273C	O	O
)	O	O
and	O	O
H1437	O	O
(	O	O
p53-R267P	O	O
)	O	O
led	O	O
to	O	O
a	O	O
reduction	O	O
in	O	O
the	O	O
level	O	O
of	O	O
Axl	O	O
as	O	O
well	O	O
.	O	O

This	O	O
effect	O	O
on	O	O
Axl	O	O
expression	O	O
is	O	O
refractory	O	O
to	O	O
the	O	O
mutations	O	O
at	O	O
positions	O	O
22	O	O
and	O	O
23	O	O
of	O	O
p53	O	O
,	O	O
suggesting	O	O
that	O	O
p53	O	O
's	O	O
transactivation	O	O
domain	O	O
may	O	O
not	O	O
play	O	O
a	O	O
critical	O	O
role	O	O
in	O	O
the	O	O
up-regulation	O	O
of	O	O
Axl	O	O
gene	O	O
expression	O	O
.	O	O

Chromatin	O	O
immunoprecipitation	O	O
(	O	O
ChIP	O	O
)	O	O
assays	O	O
carried	O	O
out	O	O
with	O	O
acetylated	O	O
histone	O	O
antibodies	O	O
demonstrated	O	O
induced	O	O
histone	B-Reg	O
acetylation	B-MPA	O
on	I-MPA	O
the	I-MPA	O
Axl	I-MPA	O
promoter	I-MPA	O
region	I-MPA	O
by	O	O
mutant	B-Var	O
p53	B-Gene	O
.	O	O

Direct	O	O
mutant	O	O
p53	O	O
nucleation	O	O
on	O	O
the	O	O
Axl	O	O
promoter	O	O
was	O	O
demonstrated	O	O
by	O	O
ChIP	O	O
assays	O	O
using	O	O
antibodies	O	O
against	O	O
p53	O	O
.	O	O

The	O	O
Axl	O	O
promoter	O	O
has	O	O
a	O	O
p53/p63	O	O
binding	O	O
site	O	O
,	O	O
which	O	O
however	O	O
is	O	O
not	O	O
required	O	O
for	O	O
mutant	O	O
p53-mediated	O	O
transactivation	O	O
.	O	O

Knockdown	O	O
of	O	O
Axl	O	O
by	O	O
Axl-specific	O	O
RNAi	O	O
caused	O	O
a	O	O
reduction	O	O
of	O	O
gain-of-function	O	O
(	O	O
GOF	O	O
)	O	O
activities	O	O
,	O	O
reducing	O	B-NegReg
the	O	O
cell	O	O
growth	O	O
rate	O	O
and	O	O
motility	O	O
rate	O	O
in	O	O
lung	O	O
cancer	O	O
cells	O	O
expressing	O	O
mutant	O	O
p53	O	O
.	O	O

This	O	O
indicates	O	O
that	O	O
for	O	O
lung	O	O
cancer	O	O
cell	O	O
lines	O	O
with	O	O
mutant	B-Var	B-Var
p53	B-Gene	B-Gene
,	O	O
GOF	O	O
activities	B-MPA	O
are	O	O
mediated	B-Reg	O
in	O	O
part	O	O
through	O	O
Axl	B-Protein	O
Gain-of-function	O	O
mutations	O	O
in	O	O
PDR1	O	O
,	O	O
a	O	O
regulator	O	O
of	O	O
antifungal	O	O
drug	O	O
resistance	O	O
in	O	O
Candida	O	O
glabrata	O	O
,	O	O
control	O	O
adherence	O	O
to	O	O
host	O	O
cells	O	O
.	O	O

Candida	O	O
glabrata	O	O
is	O	O
an	O	O
emerging	O	O
opportunistic	O	O
pathogen	O	O
that	O	O
is	O	O
known	O	O
to	O	O
develop	O	O
resistance	O	O
to	O	O
azole	O	O
drugs	O	O
due	O	O
to	O	O
increased	O	O
drug	O	O
efflux	O	O
.	O	O

The	O	O
mechanism	O	O
consists	O	O
of	O	O
CgPDR1-mediated	O	O
upregulation	O	O
of	O	O
ATP-binding	O	O
cassette	O	O
transporters	O	O
.	O	O

A	O	O
range	O	O
of	O	O
gain-of-function	B-PosReg	O
(	O	O
GOF	O	O
)	O	O
mutations	B-Var	B-Var
in	O	O
CgPDR1	B-Gene	O
have	O	O
been	O	O
found	O	O
to	O	O
lead	B-PosReg	O
not	O	O
only	O	O
to	O	O
azole	B-MPA	O
resistance	I-MPA	O
but	O	O
also	O	O
to	O	O
enhanced	B-PosReg	B-PosReg
virulence	B-MPA	B-Disease
.	O	O

This	O	O
implicates	B-Reg	O
CgPDR1	B-Gene	O
in	O	O
the	O	O
regulation	B-MPA	O
of	O	O
the	O	O
interaction	B-Interaction	O
of	O	O
C.	O	O
glabrata	O	O
with	O	O
the	O	O
host	O	O
.	O	O

To	O	O
identify	O	O
specific	O	O
CgPDR1-regulated	O	O
steps	O	O
of	O	O
the	O	O
host-pathogen	O	B-MPA
interaction	O	I-MPA
,	O	O
we	O	O
investigated	O	O
in	O	O
this	O	O
work	O	O
the	O	O
interaction	O	O
of	O	O
selected	O	O
CgPDR1	O	O
GOF	O	O
mutants	O	O
with	O	O
murine	O	O
bone	O	O
marrow-derived	O	O
macrophages	O	O
and	O	O
human	O	O
acute	O	O
monocytic	O	O
leukemia	O	O
cell	O	O
line	O	O
(	O	O
THP-1)-derived	O	O
macrophages	O	O
,	O	O
as	O	O
well	O	O
as	O	O
different	O	O
epithelial	O	O
cell	O	O
lines	O	O
.	O	O

GOF	O	O
mutations	B-Var	O
in	O	O
CgPDR1	B-Gene	O
did	O	O
not	O	O
influence	O	O
survival	O	O
and	O	O
replication	O	O
within	O	O
macrophages	O	O
following	O	O
phagocytosis	O	O
but	O	O
led	O	O
to	O	O
decreased	B-NegReg	O
adherence	B-CPA	O
to	I-CPA	O
and	I-CPA	O
uptake	I-CPA	O
by	I-CPA	O
macrophages	I-CPA	O
.	O	O

This	O	O
may	O	O
allow	O	O
evasion	O	O
from	O	O
the	O	O
host	O	O
's	O	O
innate	O	O
cellular	O	O
immune	O	O
response	O	O
.	O	O

The	O	O
interaction	O	O
with	O	O
epithelial	O	O
cells	O	O
revealed	O	O
an	O	O
opposite	O	O
trend	O	O
,	O	O
suggesting	O	O
that	O	O
GOF	O	O
mutations	B-Var	O
in	O	O
CgPDR1	B-Gene	O
may	O	O
favor	B-PosReg	O
epithelial	B-CPA	O
colonization	I-CPA	O
of	O	O
the	O	O
host	O	O
by	O	O
C.	O	O
glabrata	O	O
through	O	O
increased	B-PosReg	O
adherence	B-CPA	O
to	O	O
epithelial	O	O
cell	O	O
layers	O	O
.	O	O

These	O	O
data	O	O
reveal	O	O
that	O	O
GOF	O	O
mutations	B-Var	O
in	O	O
CgPDR1	B-Gene	O
modulate	B-Reg	O
the	O	O
interaction	B-Interaction	O
with	O	O
host	O	O
cells	O	O
in	O	O
ways	O	O
that	O	O
may	O	O
contribute	O	O
to	O	O
increased	B-PosReg	O
virulence	B-MPA	O
Mutant	O	O
p53	O	O
prolongs	O	O
NF-κB	O	O
activation	O	O
and	O	O
promotes	O	O
chronic	O	O
inflammation	O	O
and	O	O
inflammation-associated	O	B-Reg
colorectal	O	B-Disease
cancer	O	I-Disease
.	O	O

The	O	O
tumor	O	O
suppressor	O	O
p53	O	O
is	O	O
frequently	O	O
mutated	O	O
in	O	O
human	O	O
cancer	O	O
.	O	O

Common	O	O
mutant	O	O
p53	O	O
(	O	O
mutp53	O	O
)	O	O
isoforms	O	O
can	O	O
actively	O	O
promote	O	O
cancer	O	O
through	O	O
gain-of-function	O	O
(	O	O
GOF	O	O
)	O	O
mechanisms	O	O
.	O	O

We	O	O
report	O	O
that	O	O
mutp53	O	O
prolongs	O	O
TNF-α-induced	O	O
NF-κB	O	O
activation	O	O
in	O	O
cultured	O	O
cells	O	O
and	O	O
intestinal	O	O
organoid	O	O
cultures	O	O
.	O	O

Remarkably	O	O
,	O	O
when	O	O
exposed	O	O
to	O	O
dextran	O	O
sulfate	O	O
sodium	O	O
,	O	O
mice	O	O
harboring	O	O
a	O	O
germline	O	O
p53	O	O
mutation	O	O
develop	O	O
severe	O	O
chronic	O	O
inflammation	O	O
and	O	O
persistent	O	O
tissue	O	O
damage	O	O
,	O	O
and	O	O
are	O	O
highly	O	O
prone	O	O
to	O	O
inflammation-associated	O	O
colon	O	B-Disease
cancer	O	I-Disease
.	O	O

This	O	O
mutp53	O	O
GOF	O	O
is	O	O
manifested	O	O
by	O	O
rapid	O	O
onset	O	O
of	O	O
flat	O	O
dysplastic	O	O
lesions	O	O
that	O	O
progress	B-PosReg	O
to	O	O
invasive	B-Disease	O
carcinoma	I-Disease	O
with	O	O
mutp53	B-Var	B-CPA
accumulation	B-PosReg	I-CPA
and	O	O
augmented	O	O
NF-κB	B-Protein	O
activation	B-PosReg	O
,	O	O
faithfully	O	O
recapitulating	O	O
features	O	O
frequently	O	O
observed	O	O
in	O	O
human	O	O
colitis-associated	B-Disease	O
colorectal	I-Disease	B-Disease
cancer	I-Disease	I-Disease
Clinical	O	O
relevance	O	O
of	O	O
gain-of-function	B-PosReg	B-PosReg
mutations	B-Var	B-Var
of	O	O
p53	B-Gene	O
in	O	O
high-grade	B-Disease	O
serous	I-Disease	O
ovarian	I-Disease	O
carcinoma	I-Disease	O
.	O	O

PURPOSE	O	O
:	O	O
Inactivation	O	B-Var
of	O	O
TP53	O	O
,	O	O
which	O	O
occurs	O	O
predominantly	O	O
by	O	O
missense	O	B-Var
mutations	O	I-Var
in	O	O
exons	O	O
4-9	O	O
,	O	O
is	O	O
a	O	O
major	O	O
genetic	O	O
alteration	O	O
in	O	O
a	O	O
subset	O	O
of	O	O
human	O	O
cancer	O	O
.	O	O

In	O	O
spite	O	O
of	O	O
growing	O	O
evidence	O	O
that	O	O
gain-of-function	B-PosReg	O
(	O	O
GOF	O	O
)	O	O
mutations	B-Var	B-Var
of	O	O
p53	B-Gene	O
also	O	O
have	O	O
oncogenic	B-CPA	O
activity	I-CPA	O
,	O	O
little	O	O
is	O	O
known	O	O
about	O	O
the	O	O
clinical	O	O
relevance	O	O
of	O	O
these	O	O
mutations	O	O
.	O	O

METHODS	O	O
:	O	O
The	O	O
clinicopathological	O	O
features	O	O
of	O	O
high-grade	O	O
serous	O	O
ovarian	O	O
carcinoma	O	O
(	O	O
HGS-OvCa	O	O
)	O	O
patients	O	O
with	O	O
GOF	O	O
p53	O	O
mutations	O	O
were	O	O
evaluated	O	O
according	O	O
to	O	O
a	O	O
comprehensive	O	O
somatic	O	O
mutation	O	O
profile	O	O
comprised	O	O
of	O	O
whole	O	O
exome	O	O
sequencing	O	O
,	O	O
mRNA	O	O
expression	O	O
,	O	O
and	O	O
protein	O	O
expression	O	O
profiles	O	O
obtained	O	O
from	O	O
the	O	O
Cancer	O	O
Genome	O	O
Atlas	O	O
(	O	O
TCGA	O	O
)	O	O
.	O	O

RESULTS	O	O
:	O	O
Patients	O	O
with	O	O
a	O	O
mutant	O	O
p53	B-Protein	O
protein	I-Protein	O
(	O	O
mutp53	O	O
)	O	O
with	O	O
a	O	O
GOF	O	O
mutation	B-Var	O
showed	O	O
higher	B-PosReg	O
p53	B-MPA	O
mRNA	I-MPA	O
and	I-MPA	O
protein	I-MPA	O
expression	I-MPA	O
levels	I-MPA	O
than	O	O
patients	O	O
with	O	O
p53	O	O
mutation	O	O
with	O	O
no	O	O
evidence	O	O
of	O	O
GOF	O	O
(	O	O
NE-GOF	O	O
)	O	O
.	O	O

GOF	O	O
mutations	O	O
were	O	O
more	O	O
likely	O	O
to	O	O
occur	O	O
within	O	O
mutational	O	O
hotspots	O	O
,	O	O
and	O	O
at	O	O
CpG	O	O
sites	O	O
,	O	O
and	O	O
resulted	O	O
in	O	O
mutp53	O	O
with	O	O
higher	O	O
functional	O	O
severity	O	O
(	O	O
FS	O	O
)	O	O
scores	O	O
.	O	O

Clinically	O	O
,	O	O
patients	O	O
with	O	O
GOF	O	O
mutations	B-Var	O
showed	O	O
a	O	O
higher	B-PosReg	O
frequency	O	O
of	O	O
platinum	B-CPA	O
resistance	I-CPA	O
(	O	O
22/58	O	O
,	O	O
37.9	O	O
%	O	O
)	O	O
than	O	O
patients	O	O
with	O	O
NE-GOF	O	O
mutations	O	O
(	O	O
12/56	O	O
,	O	O
21.4	O	O
%	O	O
)	O	O
(	O	O
p=0.054	O	O
)	O	O
.	O	O

Furthermore	O	O
,	O	O
patients	O	O
with	O	O
GOF	O	O
mutations	B-Var	O
were	O	O
more	O	O
likely	O	O
to	O	O
develop	B-PosReg	O
distant	B-CPA	O
metastasis	I-CPA	O
(	O	O
36/55	O	O
,	O	O
65.5	O	O
%	O	O
)	O	O
than	O	O
local	O	O
recurrence	O	O
(	O	O
19/55	O	O
,	O	O
34.5	O	O
%	O	O
)	O	O
,	O	O
whereas	O	O
patients	O	O
with	O	O
NE-GOF	O	O
mutations	O	O
showed	O	O
a	O	O
higher	O	O
frequency	O	O
of	O	O
locoregional	O	O
recurrence	O	O
(	O	O
26/47	O	O
,	O	O
55.3	O	O
%	O	O
)	O	O
than	O	O
distant	O	O
metastasis	O	O
(	O	O
21/47	O	O
,	O	O
44.7	O	O
%	O	O
)	O	O
(	O	O
p=0.035	O	O
)	O	O
.	O	O

There	O	O
were	O	O
no	O	O
differences	O	O
in	O	O
overall	O	O
or	O	O
progression-free	O	O
survival	O	O
between	O	O
patients	O	O
with	O	O
GOF	O	O
or	O	O
NE-GOF	O	O
mutp53	O	O
.	O	O

CONCLUSION	O	O
:	O	O
This	O	O
study	O	O
demonstrates	O	O
that	O	O
patient	O	O
with	O	O
GOF	B-PosReg	O
mutp53	B-Var	O
is	O	O
characterized	O	O
by	O	O
a	O	O
greater	B-PosReg	O
likelihood	O	O
of	O	O
platinum	B-CPA	O
treatment	I-CPA	O
resistance	I-CPA	O
and	O	O
distant	B-CPA	O
metastatic	I-CPA	O
properties	I-CPA	O
in	O	O
HGS-OvCa	B-Disease	O
Spliced	O	O
MDM2	O	O
isoforms	O	O
promote	O	O
mutant	O	B-Var
p53	O	B-Gene
accumulation	O	B-PosReg
and	O	O
gain-of-function	O	O
in	O	O
tumorigenesis	O	O
.	O	O

The	O	O
tumour	O	O
suppressor	O	O
p53	O	O
is	O	O
frequently	O	O
mutated	O	O
in	O	O
tumours	O	O
.	O	O

Mutant	B-Var	B-Var
p53	B-Protein	B-Gene
(	O	O
Mutp53	O	O
)	O	O
proteins	O	O
often	O	O
gain	B-PosReg	O
new	I-PosReg	O
activities	I-PosReg	O
in	O	O
promoting	B-CPA	O
tumorigenesis	I-CPA	O
,	O	O
defined	O	O
as	O	O
gain-of-function	O	O
(	O	O
GOF	O	O
)	O	O
.	O	O

Mutp53	O	O
can	O	O
accumulate	O	B-PosReg
to	O	B-MPA
high	O	I-MPA
levels	O	I-MPA
in	O	O
tumours	O	O
,	O	O
which	O	O
promotes	O	O
mutp53	B-Var	O
GOF	B-PosReg	O
in	O	O
tumorigenesis	B-CPA	O
.	O	O

The	O	O
mechanism	O	O
of	O	O
mutp53	O	B-Disease
accumulation	O	I-Disease
is	O	O
poorly	O	O
understood	O	O
.	O	O

Here	O	O
we	O	O
find	O	O
that	O	O
MDM2	O	O
isoforms	O	O
promote	O	B-PosReg
mutp53	O	B-CPA
accumulation	O	I-CPA
in	O	O
tumours	O	O
.	O	O

MDM2	O	O
isoform	O	O
B	O	O
(	O	O
MDM2-B	O	O
)	O	O
,	O	O
the	O	O
MDM2	O	O
isoform	O	O
most	O	O
frequently	O	O
over-expressed	O	O
in	O	O
human	O	O
tumours	O	O
,	O	O
interacts	O	O
with	O	O
full-length	O	O
MDM2	O	O
to	O	O
inhibit	O	B-NegReg
MDM2-mediated	O	B-MPA
mutp53	O	I-MPA
degradation	O	I-MPA
,	O	O
promoting	O	O
mutp53	O	O
accumulation	O	O
and	O	O
GOF	O	O
in	O	O
tumorigenesis	O	O
.	O	O

Furthermore	O	O
,	O	O
MDM2-B	O	O
overexpression	O	O
correlates	O	O
with	O	O
mutp53	O	B-CPA
accumulation	O	I-CPA
in	O	O
human	O	O
tumours	O	O
.	O	O

In	O	O
mutp53	O	O
knock-in	O	O
mice	O	O
,	O	O
a	O	O
MDM2	O	O
isoform	O	O
similar	O	O
to	O	O
human	O	O
MDM2-B	O	O
is	O	O
overexpressed	O	O
in	O	O
the	O	O
majority	O	O
of	O	O
tumours	O	O
,	O	O
which	O	O
promotes	O	O
mutp53	O	B-CPA
accumulation	O	I-CPA
and	O	O
tumorigenesis	O	O
.	O	O

Thus	O	O
,	O	O
overexpression	O	O
of	O	O
MDM2	O	O
isoforms	O	O
promotes	O	O
mutp53	O	B-CPA
accumulation	O	I-CPA
in	O	O
tumours	O	O
,	O	O
contributing	O	O
to	O	O
mutp53	B-Var	O
GOF	B-PosReg	O
in	O	O
tumorigenesis	B-CPA	O
Mutant	B-Var	B-Var
p53	B-Gene	B-Gene
gain	B-PosReg	B-PosReg
of	I-PosReg	I-PosReg
function	I-PosReg	I-PosReg
can	O	O
be	O	O
at	O	O
the	O	O
root	O	O
of	O	O
dedifferentiation	O	O
of	O	O
human	B-Disease	O
osteosarcoma	I-Disease	O
MG63	O	O
cells	O	O
into	O	O
3AB-OS	O	O
cancer	O	O
stem	O	O
cells	O	O
.	O	O

Osteosarcoma	O	O
is	O	O
a	O	O
highly	O	O
metastatic	O	O
tumor	O	O
affecting	O	O
adolescents	O	O
,	O	O
for	O	O
which	O	O
there	O	O
is	O	O
no	O	O
second-line	O	O
chemotherapy	O	O
.	O	O

As	O	O
suggested	O	O
for	O	O
most	O	O
tumors	O	O
,	O	O
its	O	O
capability	O	O
to	O	O
overgrow	O	O
is	O	O
probably	O	O
driven	O	O
by	O	O
cancer	O	O
stem	O	O
cells	O	O
(	O	O
CSCs	O	O
)	O	O
,	O	O
and	O	O
finding	O	O
new	O	O
targets	O	O
to	O	O
kill	O	O
CSCs	O	O
may	O	O
be	O	O
critical	O	O
for	O	O
improving	O	O
patient	O	O
survival	O	O
.	O	O

TP53	O	O
is	O	O
the	O	O
most	O	O
frequently	O	O
mutated	O	O
tumor	O	O
suppressor	O	O
gene	O	O
in	O	O
cancers	O	O
and	O	O
mutant	O	B-Var
p53	O	B-Gene
protein	O	O
(	O	O
mutp53	O	O
)	O	O
can	O	O
acquire	O	O
gain	O	O
of	O	O
function	O	O
(	O	O
GOF	O	O
)	O	O
strongly	O	O
contributing	O	B-Reg
to	O	O
malignancy	O	O
.	O	O

Studies	O	O
thus	O	O
far	O	O
have	O	O
not	O	O
shown	O	O
p53-GOF	O	O
in	O	O
osteosarcoma	O	O
.	O	O

Here	O	O
,	O	O
we	O	O
investigated	O	O
TP53	O	O
gene	O	O
status	O	O
/	O	O
role	O	O
in	O	O
3AB-OS	O	O
cells-a	O	O
highly	O	O
aggressive	O	O
CSC	O	O
line	O	O
previously	O	O
selected	O	O
from	O	O
human	O	O
osteosarcoma	O	O
MG63	O	O
cells-to	O	O
evaluate	O	O
its	O	O
involvement	O	O
in	O	O
promoting	O	O
proliferation	O	O
,	O	O
invasiveness	O	O
,	O	O
resistance	O	O
to	O	O
apoptosis	O	B-CPA
and	O	O
stemness	O	O
.	O	O

By	O	O
RT-PCR	O	O
,	O	O
methylation-specific	O	O
PCR	O	O
,	O	O
fluorescent	O	O
in	O	O
situ	O	O
hybridization	O	O
,	O	O
DNA	O	O
sequence	O	O
,	O	O
western	O	O
blot	O	O
and	O	O
immunofluorescence	O	O
analyses	O	O
,	O	O
we	O	O
have	O	O
shown	O	O
that-in	O	O
comparison	O	O
with	O	O
parental	O	O
MG63	O	O
cells	O	O
where	O	O
TP53	O	O
gene	O	O
is	O	O
hypermethylated	O	O
,	O	O
rearranged	O	O
and	O	O
in	O	O
single	O	O
copy-in	O	O
3AB-OS	O	O
cells	O	O
,	O	O
TP53	O	O
is	O	O
unmethylated	O	O
,	O	O
rearranged	O	O
and	O	O
in	O	O
multiple	O	O
copies	O	O
,	O	O
and	O	O
mutp53	O	O
(	O	O
p53-R248W	O	O
/	O	O
P72R	O	O
)	O	O
is	O	O
post-translationally	O	O
modified	O	O
and	O	O
with	O	O
nuclear	O	O
localization	O	O
.	O	O

p53-R248W	O	O
/	O	O
P72R-knockdown	O	O
by	O	O
short-interfering	O	O
RNA	O	O
reduced	O	B-NegReg
the	O	O
growth	O	O
and	O	O
replication	O	O
rate	O	O
of	O	O
3AB-OS	O	O
cells	O	O
,	O	O
markedly	O	O
increasing	O	B-PosReg
cell	O	B-CPA
cycle	O	I-CPA
inhibitor	O	I-MPA
levels	O	I-MPA
and	O	O
sensitized	O	O
3AB-OS	O	O
cells	O	O
to	O	O
TRAIL-induced	O	B-CPA
apoptosis	O	I-CPA
by	O	O
DR5	O	O
up-regulation	O	O
;	O	O
moreover	O	O
,	O	O
it	O	O
strongly	O	O
decreased	O	B-NegReg
the	O	O
levels	O	O
of	O	O
stemness	O	O
and	O	O
invasiveness	O	O
genes	O	O
.	O	O

We	O	O
have	O	O
also	O	O
found	O	O
that	O	O
the	O	O
ectopic	O	O
expression	O	O
of	O	O
p53-R248W	B-Var	O
/	O	O
P72R	O	O
in	O	O
MG63	O	O
cells	O	O
promoted	B-PosReg	O
cancer	B-CPA	O
stem-like	I-CPA	O
features	I-CPA	O
,	O	O
as	O	O
high	B-CPA	O
proliferation	I-CPA	O
rate	I-CPA	O
,	O	O
sphere	B-CPA	O
formation	I-CPA	O
,	O	O
clonogenic	B-CPA	O
growth	I-CPA	O
,	O	O
high	B-CPA	B-CPA
migration	I-CPA	I-CPA
and	O	O
invasive	B-CPA	O
ability	I-CPA	O
;	O	O
furthermore	O	O
,	O	O
it	O	O
strongly	O	O
increased	B-PosReg	B-PosReg
the	O	O
levels	B-MPA	O
of	I-MPA	O
stemness	I-MPA	O
proteins	I-MPA	O
.	O	O

Overall	O	O
,	O	O
the	O	O
findings	O	O
suggest	O	O
the	O	O
involvement	B-Reg	O
of	O	O
p53-R248W	B-Var	O
/	O	O
P72R	O	O
at	O	O
the	O	O
origin	B-CPA	O
of	I-CPA	O
the	I-CPA	O
aberrant	I-CPA	O
characters	I-CPA	O
of	I-CPA	O
the	I-CPA	O
3AB-OS	I-CPA	O
cells	I-CPA	O
Unequal	O	O
prognostic	O	O
potentials	O	O
of	O	O
p53	O	B-Gene
gain-of-function	O	B-PosReg
mutations	O	B-Var
in	O	O
human	O	O
cancers	O	O
associate	O	O
with	O	O
drug-metabolizing	O	O
activity	O	O
.	O	O

Mutation	O	O
of	O	O
p53	O	O
is	O	O
the	O	O
most	O	O
common	O	O
genetic	O	O
change	O	O
in	O	O
human	O	O
cancer	O	O
,	O	O
causing	O	O
complex	O	O
effects	O	O
including	O	O
not	O	O
only	O	O
loss	O	O
of	O	O
wild-type	O	O
function	O	O
but	O	O
also	O	O
gain	O	O
of	O	O
novel	O	O
oncogenic	O	O
functions	O	O
(	O	O
GOF	O	O
)	O	O
.	O	O

It	O	O
is	O	O
increasingly	O	O
likely	O	O
that	O	O
p53-hotspot	O	O
mutations	O	O
may	O	O
confer	O	O
different	O	O
types	O	O
and	O	O
magnitudes	O	O
of	O	O
GOF	O	O
,	O	O
but	O	O
the	O	O
evidences	O	O
are	O	O
mainly	O	O
supported	O	O
by	O	O
cellular	O	O
and	O	O
transgenic	O	O
animal	O	O
models	O	O
.	O	O

Here	O	O
we	O	O
combine	O	O
large-scale	O	O
cancer	O	O
genomic	O	O
data	O	O
to	O	O
characterize	O	O
the	O	O
prognostic	O	O
significance	O	O
of	O	O
different	O	O
p53	B-Gene	O
mutations	O	O
in	O	O
human	O	O
cancers	O	O
.	O	O

Unexpectedly	O	O
,	O	O
only	O	O
mutations	B-Var	O
on	I-Var	O
the	I-Var	O
Arg248	I-Var	O
and	I-Var	O
Arg282	I-Var	O
positions	O	O
displayed	O	O
significant	O	O
association	O	O
with	O	O
shorter	B-NegReg	O
patient	B-CPA	O
survival	I-CPA	O
,	O	O
but	O	O
such	O	O
association	O	O
was	O	O
not	O	O
evident	O	O
for	O	O
other	O	O
hotspot	O	O
GOF	O	O
mutations	O	O
.	O	O

Gene	O	O
set	O	O
enrichment	O	O
analysis	O	O
on	O	O
these	O	O
mutations	B-Var	O
revealed	O	O
higher	B-PosReg	O
activity	B-MPA	O
of	O	O
drug-metabolizing	B-Enzyme	O
enzymes	I-Enzyme	O
,	O	O
including	O	O
the	O	O
CYP3A4	B-Enzyme	O
cytochrome	I-Enzyme	O
P450	I-Enzyme	O
.	O	O

Ectopic	B-MPA	O
expression	I-MPA	O
of	O	O
p53	B-Gene	O
mutant	B-Var	O
R282W	I-Var	O
in	O	O
H1299	O	O
and	O	O
SaOS2	O	O
cells	O	O
significantly	O	O
upregulated	B-PosReg	O
CYP3A4	B-MPA	O
mRNA	I-MPA	O
and	I-MPA	O
protein	I-MPA	O
levels	I-MPA	O
,	O	O
and	O	O
cancer	O	O
cell	O	O
lines	O	O
bearing	O	O
mortality-associated	O	O
p53	B-Gene	O
mutations	B-Var	O
display	O	O
higher	B-PosReg	O
CYP3A4	B-Enzyme	O
expression	B-MPA	O
and	O	O
resistance	B-CPA	O
to	I-CPA	O
several	I-CPA	O
CYP3A4-metabolized	I-CPA	O
chemotherapeutic	I-CPA	O
drugs	I-CPA	O
Disruption	O	O
of	O	O
the	O	O
temporally	O	O
regulated	O	O
cloaca	O	O
endodermal	O	O
β-catenin	O	O
signaling	O	O
causes	O	O
anorectal	O	O
malformations	O	O
.	O	O

The	O	O
cloaca	O	O
is	O	O
temporally	O	O
formed	O	O
and	O	O
eventually	O	O
divided	O	O
by	O	O
the	O	O
urorectal	O	O
septum	O	O
(	O	O
URS	O	O
)	O	O
during	O	O
urogenital	O	O
and	O	O
anorectal	O	O
organ	O	O
development	O	O
.	O	O

Although	O	O
congenital	O	O
malformations	O	O
,	O	O
such	O	O
as	O	O
anorectal	O	O
malformations	O	O
(	O	O
ARMs	O	O
)	O	O
,	O	O
are	O	O
frequently	O	O
observed	O	O
during	O	O
this	O	O
process	O	O
,	O	O
the	O	O
underlying	O	O
pathogenic	O	O
mechanisms	O	O
remain	O	O
unclear	O	O
.	O	O

β-Catenin	O	O
is	O	O
a	O	O
critical	O	O
component	O	O
of	O	O
canonical	O	O
Wnt	O	O
signaling	O	O
and	O	O
is	O	O
essential	O	O
for	O	O
the	O	O
regulation	O	O
of	O	O
cell	O	O
differentiation	O	O
and	O	O
morphogenesis	O	O
during	O	O
embryogenesis	O	O
.	O	O

The	O	O
expression	O	O
of	O	O
β-catenin	O	O
is	O	O
observed	O	O
in	O	O
endodermal	O	O
epithelia	O	O
,	O	O
including	O	O
URS	O	O
epithelia	O	O
.	O	O

We	O	O
modulated	O	O
the	O	O
β-catenin	O	O
gene	O	O
conditionally	O	O
in	O	O
endodermal	O	O
epithelia	O	O
by	O	O
utilizing	O	O
tamoxifen-inducible	O	O
Cre	O	O
driver	O	O
line	O	O
(	O	O
Shh(CreERT2	O	O
)	O	O
)	O	O
.	O	O

Both	O	O
β-catenin	B-Protein	O
loss-	B-NegReg	O
and	O	O
gain-of-function	B-PosReg	O
(	O	O
LOF	O	O
and	O	O
GOF	O	O
)	O	O
mutants	B-Var	O
displayed	O	O
abnormal	O	O
clefts	B-CPA	O
in	I-CPA	O
the	I-CPA	O
perineal	I-CPA	O
region	I-CPA	O
and	O	O
hypoplastic	B-CPA	O
elongation	I-CPA	O
of	I-CPA	O
the	I-CPA	O
URS	I-CPA	O
.	O	O

The	O	O
mutants	B-Var	O
also	O	O
displayed	O	O
reduced	B-NegReg	B-NegReg
cell	B-CPA	B-CPA
proliferation	I-CPA	I-CPA
in	I-CPA	O
the	I-CPA	O
URS	I-CPA	O
mesenchyme	I-CPA	O
.	O	O

In	O	O
addition	O	O
,	O	O
the	O	O
β-catenin	B-Protein	O
GOF	O	O
mutants	B-Var	O
displayed	O	O
reduced	O	B-NegReg
apoptosis	O	B-CPA
and	O	O
subsequently	O	O
increased	O	B-PosReg
apoptosis	O	B-CPA
in	O	O
the	O	O
URS	O	O
epithelium	O	O
.	O	O

This	O	O
instability	O	O
possibly	O	O
resulted	O	O
in	O	O
reduced	B-NegReg	B-NegReg
expression	B-MPA	B-MPA
levels	I-MPA	O
of	O	O
differentiation	O	O
markers	O	O
,	O	O
such	O	O
as	O	O
keratin	B-Protein	O
1	I-Protein	O
and	O	O
filaggrin	B-Protein	O
,	O	O
in	O	O
the	O	O
perineal	O	O
epithelia	O	O
.	O	O

The	O	O
expression	B-MPA	O
of	O	O
bone	B-Gene	O
morphogenetic	I-Gene	O
protein	I-Gene	O
(	I-Gene	O
Bmp	I-Gene	O
)	O	O
genes	O	O
,	O	O
such	O	O
as	O	O
Bmp4	B-Gene	O
and	O	O
Bmp7	B-Gene	O
,	O	O
was	O	O
also	O	O
ectopically	O	O
induced	B-PosReg	O
in	O	O
the	O	O
epithelia	O	O
of	O	O
the	O	O
URS	O	O
in	O	O
the	O	O
β-catenin	B-Protein	O
GOF	O	O
mutants	B-Var	O
.	O	O

The	O	O
expression	B-MPA	O
of	O	O
the	O	O
Msx2	B-Gene	O
gene	I-Gene	O
and	O	O
phosphorylated-Smad1/5/8	O	O
,	O	O
possible	O	O
readouts	B-MPA	O
of	I-MPA	O
Bmp	I-MPA	O
signaling	I-MPA	O
,	O	O
was	O	O
also	O	O
increased	B-PosReg	O
in	O	O
the	O	O
mutants	B-Var	O
.	O	O

Moreover	O	O
,	O	O
we	O	O
introduced	O	O
an	O	O
additional	O	O
mutation	O	O
for	O	O
a	O	O
Bmp	O	O
receptor	O	O
gene	O	O
:	O	O
BmprIA	O	O
.	O	O

The	O	O
Shh(CreERT2/+	O	O
)	O	O
;	O	O
β-catenin(flox(ex3)/+	O	O
)	O	O
;	O	O
BmprIA(flox/-	O	O
)	O	O
mutants	O	O
displayed	O	O
partial	O	O
restoration	O	O
of	O	O
URS	O	O
elongation	O	O
compared	O	O
with	O	O
the	O	O
β-catenin	O	O
GOF	O	O
mutants	O	O
.	O	O

These	O	O
results	O	O
indicate	O	O
that	O	O
some	O	O
ARM	B-Disease	O
phenotypes	O	O
in	O	O
the	O	O
β-catenin	B-Protein	O
GOF	B-PosReg	O
mutants	B-Var	O
were	O	O
caused	B-Reg	O
by	I-Reg	O
abnormal	O	O
Bmp	B-MPA	O
signaling	I-MPA	O
Dysregulation	O	O
of	O	O
Wnt	O	O
inhibitory	O	O
factor	O	O
1	O	O
(	O	O
Wif1	O	O
)	O	O
expression	O	O
resulted	O	O
in	O	O
aberrant	O	O
Wnt-β-catenin	O	O
signaling	O	O
and	O	O
cell	O	B-CPA
death	O	I-CPA
of	O	I-CPA
the	O	O
cloaca	O	O
endoderm	O	O
,	O	O
and	O	O
anorectal	O	O
malformations	O	O
.	O	O

In	O	O
mammalian	O	O
urorectal	O	O
development	O	O
,	O	O
the	O	O
urorectal	O	O
septum	O	O
(	O	O
urs	O	O
)	O	O
descends	O	O
from	O	O
the	O	O
ventral	O	O
body	O	O
wall	O	O
to	O	O
the	O	O
cloaca	O	O
membrane	O	O
(	O	O
cm	O	O
)	O	O
to	O	O
partition	O	O
the	O	O
cloaca	O	O
into	O	O
urogenital	O	O
sinus	O	O
and	O	O
rectum	O	O
.	O	O

Defective	O	O
urs	O	O
growth	O	O
results	O	O
in	O	O
human	O	O
congenital	O	O
anorectal	O	O
malformations	O	O
(	O	O
ARMs	O	O
)	O	O
,	O	O
and	O	O
their	O	O
pathogenic	O	O
mechanisms	O	O
are	O	O
unclear	O	O
.	O	O

Recent	O	O
studies	O	O
only	O	O
focused	O	O
on	O	O
the	O	O
importance	O	O
of	O	O
urs	O	O
mesenchyme	O	O
proliferation	O	O
,	O	O
which	O	O
is	O	O
induced	O	O
by	O	O
endoderm-derived	O	O
Sonic	O	O
Hedgehog	O	O
(	O	O
Shh	O	O
)	O	O
.	O	O

Here	O	O
,	O	O
we	O	O
showed	O	O
that	O	O
the	O	O
programmed	O	O
cell	O	B-CPA
death	O	I-CPA
of	O	I-CPA
the	O	O
apical	O	O
urs	O	O
and	O	O
proximal	O	O
cm	O	O
endoderm	O	O
is	O	O
particularly	O	O
crucial	O	O
for	O	O
the	O	O
growth	O	O
of	O	O
urs	O	O
during	O	O
septation	O	O
.	O	O

The	O	O
apoptotic	O	O
endoderm	O	O
was	O	O
closely	O	O
associated	O	O
with	O	O
the	O	O
tempo-spatial	O	O
expression	O	O
of	O	O
Wnt	O	O
inhibitory	O	O
factor	O	O
1	O	O
(	O	O
Wif1	O	O
)	O	O
,	O	O
which	O	O
is	O	O
an	O	O
inhibitor	O	O
of	O	O
Wnt-β-catenin	O	O
signaling	O	O
.	O	O

In	O	O
Wif1(lacZ	O	O
/	O	O
lacZ	O	O
)	O	O
mutant	O	O
mice	O	O
and	O	O
cultured	O	O
urorectum	O	O
with	O	O
exogenous	O	O
Wif1	O	O
,	O	O
cloaca	O	O
septation	O	O
was	O	O
defective	O	B-NegReg
with	O	O
undescended	O	O
urs	O	O
and	O	O
hypospadias-like	O	O
phenotypes	O	O
,	O	O
and	O	O
such	O	O
septation	O	O
defects	O	O
were	O	O
also	O	O
observed	O	O
in	O	O
Shh(-/-	O	O
)	O	O
mutants	O	B-Var
and	O	O
in	O	O
endodermal	O	O
β-catenin	O	O
gain-of-function	O	O
(	O	O
GOF	O	O
)	O	O
mutants	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
Wif1	O	O
and	O	O
Shh	O	O
were	O	O
expressed	O	O
in	O	O
a	O	O
complementary	O	O
manner	O	O
in	O	O
the	O	O
cloaca	O	O
endoderm	O	O
,	O	O
and	O	O
Wif1	O	O
was	O	O
ectopically	O	O
expressed	O	O
in	O	O
the	O	O
urs	O	O
and	O	O
cm	O	O
associated	O	O
with	O	O
excessive	O	O
endodermal	O	O
apoptosis	O	B-CPA
and	O	O
septation	O	O
defects	O	O
in	O	O
Shh(-/-	O	O
)	O	O
mutants	O	O
.	O	O

Furthermore	O	O
,	O	O
apoptotic	B-CPA	O
cells	I-CPA	O
were	O	O
markedly	O	O
reduced	B-NegReg	B-NegReg
in	O	O
the	O	O
endodermal	B-Protein	O
β-catenin	I-Protein	O
GOF	B-PosReg	O
mutant	B-Var	O
Significance	O	O
of	O	O
the	O	O
melanocortin	O	O
1	O	O
receptor	O	O
in	O	O
the	O	O
DNA	O	O
damage	O	O
response	O	O
of	O	O
human	O	O
melanocytes	O	O
to	O	O
ultraviolet	O	O
radiation	O	O
.	O	O

Activation	O	O
of	O	O
the	O	O
melanocortin	O	O
1	O	O
receptor	O	O
(	O	O
MC1R	O	O
)	O	O
by	O	O
α-melanocortin	O	O
(	O	O
α-MSH	O	O
)	O	O
stimulates	O	O
eumelanin	O	O
synthesis	O	O
and	O	O
enhances	O	O
repair	O	O
of	O	O
ultraviolet	O	O
radiation	O	O
(	O	O
UV)-induced	O	O
DNA	O	O
damage	O	O
.	O	O

We	O	O
report	O	O
on	O	O
the	O	O
DNA	O	O
damage	O	O
response	O	O
(	O	O
DDR	O	O
)	O	O
of	O	O
human	O	O
melanocytes	O	O
to	O	O
UV	O	O
and	O	O
its	O	O
enhancement	O	O
by	O	O
α-MSH	O	O
.	O	O

α-MSH	O	O
up-regulated	O	O
the	O	O
levels	O	O
of	O	O
XPC	O	O
,	O	O
the	O	O
enzyme	O	O
that	O	O
recognizes	O	O
DNA	O	O
damage	O	O
sites	O	O
,	O	O
enhanced	O	B-PosReg
the	O	O
UV-induced	O	O
phosphorylation	O	O
of	O	O
the	O	O
DNA	O	O
damage	O	O
sensors	O	O
ataxia	O	O
telangiectasia	O	O
and	O	O
Rad3-related	O	O
(	O	O
ATR	O	O
)	O	O
and	O	O
ataxia	O	O
telangiectasia	O	O
mutated	O	O
(	O	O
ATM	O	O
)	O	O
and	O	O
their	O	O
respect-ive	O	O
substrates	O	O
checkpoint	O	O
kinases	O	O
1	O	O
and	O	O
2	O	O
,	O	O
and	O	O
increased	O	O
phosphorylated	O	O
H2AX	O	O
(	O	O
γH2AX	O	O
)	O	O
formation	O	O
.	O	O

These	O	O
effects	O	O
required	O	O
functional	O	O
MC1R	O	O
and	O	O
were	O	O
absent	O	O
in	O	O
melanocytes	O	O
expressing	O	O
loss	O	B-NegReg
of	O	I-NegReg
function	O	I-NegReg
(	O	O
LOF	O	O
)	O	O
MC1R.	O	O
The	O	O
levels	O	O
of	O	O
wild-type	O	O
p53-induced	O	O
phosphatase	O	O
1	O	O
(	O	O
Wip1	O	O
)	O	O
,	O	O
which	O	O
dephosphorylates	O	O
γH2AX	O	O
,	O	O
correlated	O	O
inversely	O	O
with	O	O
γH2AX	O	O
.	O	O

We	O	O
propose	O	O
that	O	O
α-MSH	O	O
increases	O	O
UV-induced	O	O
γH2AX	O	O
to	O	O
facilitate	O	O
formation	O	O
of	O	O
DNA	O	O
repair	O	O
complexes	O	O
and	O	O
repair	O	O
of	O	O
DNA	O	O
photoproducts	O	O
,	O	O
and	O	O
LOF	B-Var	O
of	O	O
MC1R	B-Protein	O
compromises	B-NegReg	O
the	O	O
DDR	B-MPA	O
and	O	O
genomic	B-CPA	O
stability	I-CPA	O
of	I-CPA	O
melanocytes	I-CPA	O
Assessing	O	O
the	O	O
functional	O	O
consequence	O	O
of	O	O
loss	O	O
of	O	O
function	O	O
variants	O	O
using	O	O
electronic	O	O
medical	O	O
record	O	O
and	O	O
large-scale	O	O
genomics	O	O
consortium	O	O
efforts	O	O
.	O	O

Estimates	O	O
from	O	O
large	O	O
scale	O	O
genome	O	O
sequencing	O	O
studies	O	O
indicate	O	O
that	O	O
each	O	O
human	O	O
carries	O	O
up	O	O
to	O	O
20	O	O
genetic	O	O
variants	O	O
that	O	O
are	O	O
predicted	O	O
to	O	O
results	O	O
in	O	O
loss	O	B-NegReg
of	O	I-NegReg
function	O	I-NegReg
(	O	O
LOF	O	O
)	O	O
of	O	O
protein-coding	O	O
genes	O	O
.	O	O

While	O	O
some	O	O
are	O	O
known	O	O
disease-causing	O	O
variants	O	O
or	O	O
common	O	O
,	O	O
tolerated	O	O
,	O	O
LOFs	O	O
in	O	O
non-essential	O	O
genes	O	O
,	O	O
the	O	O
majority	O	O
remain	O	O
of	O	O
unknown	O	O
consequence	O	O
.	O	O

We	O	O
explore	O	O
the	O	O
possibility	O	O
of	O	O
using	O	O
imputed	O	O
GWAS	O	O
data	O	O
from	O	O
large	O	O
biorepositories	O	O
such	O	O
as	O	O
the	O	O
electronic	O	O
medical	O	O
record	O	O
and	O	O
genomics	O	O
(	O	O
eMERGE	O	O
)	O	O
consortium	O	O
to	O	O
determine	O	O
the	O	O
effects	O	O
of	O	O
rare	O	O
LOFs	O	O
.	O	O

Here	O	O
,	O	O
we	O	O
show	O	O
that	O	O
two	O	O
hypocholesterolemia-associated	B-Disease	O
LOF	B-NegReg	B-NegReg
mutations	B-Var	B-Var
in	O	O
the	O	O
PCSK9	B-Gene	O
PDGF	O	O
,	O	O
pericytes	O	O
and	O	O
the	O	O
pathogenesis	O	O
of	O	O
idiopathic	O	O
basal	O	O
ganglia	O	O
calcification	O	O
(	O	O
IBGC	O	O
)	O	O
.	O	O

Platelet-derived	O	O
growth	O	O
factors	O	O
(	O	O
PDGFs	O	O
)	O	O
are	O	O
important	O	O
mitogens	O	O
for	O	O
various	O	O
types	O	O
of	O	O
mesenchymal	O	O
cells	O	O
,	O	O
and	O	O
as	O	O
such	O	O
,	O	O
they	O	O
exert	O	O
critical	O	O
functions	O	O
during	O	O
organogenesis	O	O
in	O	O
mammalian	O	O
embryonic	O	O
and	O	O
early	O	O
postnatal	O	O
development	O	O
.	O	O

Increased	O	B-PosReg
or	O	O
ectopic	B-Var	O
PDGF	B-Protein	O
activity	B-MPA	O
may	O	O
also	O	O
cause	B-Reg	O
or	O	O
contribute	B-Reg	O
to	O	O
diseases	O	O
such	O	O
as	O	O
cancer	B-Disease	O
and	O	O
tissue	B-Disease	O
fibrosis	I-Disease	O
.	O	O

Until	O	O
recently	O	O
,	O	O
no	O	O
loss-of-function	O	B-NegReg
(	O	O
LOF	O	O
)	O	O
mutations	O	B-Var
in	O	O
PDGF	O	B-Gene
or	O	O
PDGF	O	O
receptor	O	O
genes	O	O
were	O	O
reported	O	O
as	O	O
causally	O	O
linked	O	O
to	O	O
a	O	O
human	O	O
disease	O	O
.	O	O

This	O	O
changed	O	O
in	O	O
2013	O	O
when	O	O
reports	O	O
appeared	O	O
on	O	O
presumed	O	O
LOF	B-NegReg	B-NegReg
mutations	B-Var	B-Var
in	O	O
the	O	O
genes	O	O
encoding	O	O
PDGF-B	B-Gene	O
and	O	O
its	O	O
receptor	O	O
PDGF	O	O
receptor-beta	O	O
(	O	O
PDGF-Rβ	B-Gene	O
)	O	O
in	O	O
familial	B-Disease	O
idiopathic	I-Disease	O
basal	I-Disease	O
ganglia	I-Disease	O
calcification	I-Disease	O
Mutant	O	O
p53	O	O
gains	O	O
new	O	O
function	O	O
in	O	O
promoting	O	O
inflammatory	O	O
signals	O	O
by	O	O
repression	O	O
of	O	O
the	O	O
secreted	O	O
interleukin-1	O	O
receptor	O	O
antagonist	O	O
.	O	O

The	O	O
TP53	B-Gene	O
tumor-suppressor	I-Gene	O
gene	I-Gene	O
is	O	O
frequently	O	O
mutated	O	O
in	O	O
human	O	O
cancer	O	O
.	O	O

Missense	B-Var	O
mutations	I-Var	O
can	O	O
add	O	O
novel	O	O
functions	O	O
(	O	O
gain-of-function	O	O
,	O	O
GOF	O	O
)	O	O
that	O	O
promote	B-PosReg	B-PosReg
tumor	B-CPA	B-CPA
malignancy	I-CPA	O
.	O	O

Here	O	O
we	O	O
report	O	O
that	O	O
mutant	B-Var	O
(	O	O
mut	O	O
)	O	O
p53	B-Gene	O
promotes	B-PosReg	O
tumor	B-CPA	O
malignancy	I-CPA	O
by	O	O
suppressing	B-NegReg	O
the	O	O
expression	B-MPA	O
of	I-MPA	O
a	I-MPA	O
natural	I-MPA	O
occurring	I-MPA	O
anti-inflammatory	I-MPA	O
cytokine	I-MPA	O
,	O	O
the	O	O
secreted	O	O
interleukin-1	O	O
receptor	O	O
antagonist	O	O
(	O	O
sIL-1Ra	O	O
,	O	O
IL1RN	O	O
)	O	O
.	O	O

We	O	O
show	O	O
that	O	O
mutp53	B-Var	O
but	O	O
not	O	O
wild-type	O	O
(	O	O
wt	O	O
)	O	O
p53	O	O
suppresses	B-NegReg	O
the	O	O
sIL-1Ra	B-MPA	O
production	I-MPA	O
Rare	O	O
variants	O	O
in	O	O
PPARG	O	O
with	O	O
decreased	O	B-NegReg
activity	O	B-MPA
in	O	O
adipocyte	O	O
differentiation	O	O
are	O	O
associated	O	O
with	O	O
increased	O	O
risk	O	O
of	O	O
type	O	O
2	O	O
diabetes	O	O
.	O	O

Peroxisome	O	O
proliferator-activated	O	O
receptor	O	O
gamma	O	O
(	O	O
PPARG	O	O
)	O	O
is	O	O
a	O	O
master	O	O
transcriptional	O	O
regulator	O	O
of	O	O
adipocyte	O	O
differentiation	O	O
and	O	O
a	O	O
canonical	O	O
target	O	O
of	O	O
antidiabetic	O	O
thiazolidinedione	O	O
medications	O	O
.	O	O

In	O	O
rare	O	O
families	O	O
,	O	O
loss-of-function	B-NegReg	B-NegReg
(	O	O
LOF	O	O
)	O	O
mutations	B-Var	B-Var
in	O	O
PPARG	B-Gene	O
are	O	O
known	O	O
to	O	O
cosegregate	O	O
with	O	O
lipodystrophy	B-Disease	O
and	O	O
insulin	B-Disease	O
resistance	I-Disease	O
;	O	O
in	O	O
the	O	O
general	O	O
population	O	O
,	O	O
the	O	O
common	O	O
P12A	B-Var	O
variant	I-Var	O
is	O	O
associated	O	O
with	O	O
a	O	O
decreased	B-NegReg	O
risk	O	O
of	O	O
type	B-Disease	O
2	I-Disease	O
diabetes	I-Disease	O
(	O	O
T2D	O	O
)	O	O
.	O	O

Whether	O	O
and	O	O
how	O	O
rare	O	O
variants	O	O
in	O	O
PPARG	O	O
and	O	O
defects	O	O
in	O	O
adipocyte	O	O
differentiation	O	O
influence	O	O
risk	O	O
of	O	O
T2D	O	O
in	O	O
the	O	O
general	O	O
population	O	O
remains	O	O
undetermined	O	O
.	O	O

By	O	O
sequencing	O	O
PPARG	O	O
in	O	O
19,752	O	O
T2D	O	O
cases	O	O
and	O	O
controls	O	O
drawn	O	O
from	O	O
multiple	O	O
studies	O	O
and	O	O
ethnic	O	O
groups	O	O
,	O	O
we	O	O
identified	O	O
49	O	O
previously	O	O
unidentified	O	O
,	O	O
nonsynonymous	O	O
PPARG	O	O
variants	O	O
(	O	O
MAF	O	O
<	O	O
0.5	O	O
%	O	O
)	O	O
.	O	O

Considered	O	O
in	O	O
aggregate	O	O
(	O	O
with	O	O
or	O	O
without	O	O
computational	O	O
prediction	O	O
of	O	O
functional	O	O
consequence	O	O
)	O	O
,	O	O
these	O	O
rare	O	O
variants	O	O
showed	O	O
no	O	O
association	O	O
with	O	O
T2D	O	O
(	O	O
OR	O	O
=	O	O
1.35	O	O
;	O	O
P	O	O
=	O	O
0.17	O	O
)	O	O
.	O	O

The	O	O
function	O	O
of	O	O
the	O	O
49	O	O
variants	O	O
was	O	O
experimentally	O	O
tested	O	O
in	O	O
a	O	O
novel	O	O
high-throughput	O	O
human	O	O
adipocyte	O	O
differentiation	O	O
assay	O	O
,	O	O
and	O	O
nine	O	O
were	O	O
found	O	O
to	O	O
have	O	O
reduced	O	B-NegReg
activity	O	B-MPA
in	O	O
the	O	O
assay	O	O
.	O	O

Carrying	O	O
any	O	O
of	O	O
these	O	O
nine	O	O
LOF	O	O
variants	O	O
was	O	O
associated	O	O
with	O	O
a	O	O
substantial	O	O
increase	O	O
in	O	O
risk	O	O
of	O	O
T2D	O	O
(	O	O
OR	O	O
=	O	O
7.22	O	O
;	O	O
P	O	O
=	O	O
0.005	O	O
)	O	O
.	O	O

The	O	O
combination	O	O
of	O	O
large-scale	O	O
DNA	O	O
sequencing	O	O
and	O	O
functional	O	O
testing	O	O
in	O	O
the	O	O
laboratory	O	O
reveals	O	O
that	O	O
approximately	O	O
1	O	O
in	O	O
1,000	O	O
individuals	O	O
carries	O	O
a	O	O
variant	B-Var	O
in	O	O
PPARG	B-Gene	O
that	O	O
reduces	B-NegReg	B-NegReg
function	B-CPA	B-MPA
in	I-CPA	O
a	I-CPA	O
human	I-CPA	O
adipocyte	I-CPA	O
differentiation	I-CPA	O
assay	I-CPA	O
and	O	O
is	O	O
associated	B-Reg	O
with	O	O
a	O	O
substantial	O	O
risk	O	O
of	O	O
T2D.	B-Disease	O
Loss-of-function	O	O
de	O	O
novo	O	O
mutations	O	O
play	O	O
an	O	O
important	O	O
role	O	O
in	O	O
severe	O	O
human	O	O
neural	O	O
tube	O	O
defects	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Neural	O	O
tube	O	O
defects	O	O
(	O	O
NTDs	O	O
)	O	O
are	O	O
very	O	O
common	O	O
and	O	O
severe	O	O
birth	O	O
defects	O	O
that	O	O
are	O	O
caused	O	B-Reg
by	O	I-Reg
failure	O	O
of	O	O
neural	O	O
tube	O	O
closure	O	O
and	O	O
that	O	O
have	O	O
a	O	O
complex	O	O
aetiology	O	O
.	O	O

Anencephaly	O	O
and	O	O
spina	O	O
bifida	O	O
are	O	O
severe	O	O
NTDs	O	O
that	O	O
affect	O	O
reproductive	O	O
fitness	O	O
and	O	O
suggest	O	O
a	O	O
role	O	O
for	O	O
de	O	O
novo	O	O
mutations	O	O
(	O	O
DNMs	O	O
)	O	O
in	O	O
their	O	O
aetiology	O	O
.	O	O

METHODS	O	O
:	O	O
We	O	O
used	O	O
whole-exome	O	O
sequencing	O	O
in	O	O
43	O	O
sporadic	O	O
cases	O	O
affected	O	O
with	O	O
myelomeningocele	O	O
or	O	O
anencephaly	O	O
and	O	O
their	O	O
unaffected	O	O
parents	O	O
to	O	O
identify	O	O
DNMs	O	O
in	O	O
their	O	O
exomes	O	O
.	O	O

RESULTS	O	O
:	O	O
We	O	O
identified	O	O
42	O	O
coding	O	O
DNMs	O	O
in	O	O
25	O	O
cases	O	O
,	O	O
of	O	O
which	O	O
6	O	O
were	O	O
loss	O	O
of	O	O
function	O	O
(	O	O
LoF	O	O
)	O	O
showing	O	O
a	O	O
higher	O	B-PosReg
rate	O	O
of	O	O
LoF	O	O
DNM	O	O
in	O	O
our	O	O
cohort	O	O
compared	O	O
with	O	O
control	O	O
cohorts	O	O
.	O	O

Notably	O	O
,	O	O
we	O	O
identified	O	O
two	O	O
protein-truncating	B-Protein	O
DNMs	O	O
in	O	O
two	O	O
independent	O	O
cases	O	O
in	O	O
SHROOM3	O	O
,	O	O
previously	O	O
associated	O	O
with	O	O
NTDs	O	O
only	O	O
in	O	O
animal	O	O
models	O	O
.	O	O

We	O	O
have	O	O
demonstrated	O	O
a	O	O
significant	O	O
enrichment	O	O
of	O	O
LoF	O	O
DNMs	O	O
in	O	O
this	O	O
gene	O	O
in	O	O
NTDs	O	O
compared	O	O
with	O	O
the	O	O
gene	O	O
specific	O	O
DNM	O	O
rate	O	O
and	O	O
to	O	O
the	O	O
DNM	O	O
rate	O	O
estimated	O	O
from	O	O
control	O	O
cohorts	O	O
.	O	O

We	O	O
also	O	O
identified	O	O
one	O	O
nonsense	O	O
DNM	O	O
in	O	O
PAX3	O	O
and	O	O
two	O	O
potentially	O	O
causative	O	O
missense	O	O
DNMs	O	O
in	O	O
GRHL3	O	O
and	O	O
PTPRS	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Our	O	O
study	O	O
demonstrates	O	O
an	O	O
important	O	O
role	O	O
of	O	O
LoF	O	O
DNMs	O	O
in	O	O
the	O	O
development	O	O
of	O	O
NTDs	O	O
and	O	O
strongly	O	O
implicates	O	O
SHROOM3	O	O
in	O	O
its	O	O
aetiology	O	O
.	O	O

Analysis	O	O
of	O	O
loss-of-function	O	O
variants	O	B-Var
and	O	O
20	O	O
risk	O	O
factor	O	O
phenotypes	O	O
in	O	O
8,554	O	O
individuals	O	O
identifies	O	O
loci	O	O
influencing	O	O
chronic	O	O
disease	O	O
.	O	O

A	O	O
typical	O	O
human	O	O
exome	O	O
harbors	O	O
dozens	O	O
of	O	O
loss-of-function	O	O
(	O	O
LOF	O	O
)	O	O
variants	O	O
,	O	O
which	O	O
can	O	O
lower	O	O
disease	O	O
risk	O	O
factor	O	O
levels	O	O
and	O	O
affect	O	O
drug	O	O
efficacy	O	O
.	O	O

We	O	O
hypothesized	O	O
that	O	O
LOF	O	O
variants	O	B-Var
are	O	O
enriched	O	O
in	O	O
genes	O	O
influencing	O	O
risk	O	O
factor	O	O
levels	O	O
and	O	O
the	O	O
onset	O	O
of	O	O
common	O	O
chronic	O	O
diseases	O	O
,	O	O
such	O	O
as	O	O
cardiovascular	O	O
disease	O	O
and	O	O
diabetes	O	O
.	O	O

To	O	O
test	O	O
this	O	O
hypothesis	O	O
,	O	O
we	O	O
sequenced	O	O
the	O	O
exomes	O	O
of	O	O
8,554	O	O
individuals	O	O
and	O	O
analyzed	O	O
the	O	O
effects	O	O
of	O	O
predicted	O	O
LOF	O	O
variants	O	O
on	O	O
20	O	O
chronic	O	O
disease	O	O
risk	O	O
factor	O	O
phenotypes	O	O
.	O	O

Analysis	O	O
of	O	O
this	O	O
sample	O	O
as	O	O
discovery	O	O
and	O	O
replication	O	O
strata	O	O
of	O	O
equal	O	O
size	O	O
verified	O	O
two	O	O
relationships	O	O
in	O	O
well-studied	O	O
genes	O	O
(	O	O
PCSK9	O	O
and	O	O
APOC3	O	O
)	O	O
and	O	O
identified	O	O
eight	O	O
new	O	O
loci	O	O
.	O	O

Previously	O	O
unknown	O	O
relationships	O	O
included	O	O
elevated	B-PosReg	O
fasting	O	O
glucose	B-MPA	O
in	O	O
carriers	O	O
of	O	O
heterozygous	O	O
LOF	B-NegReg	B-Var
variation	B-Var	I-Var
in	O	O
TXNDC5	B-Gene	O
,	O	O
which	O	O
encodes	O	O
a	O	O
biomarker	O	O
for	O	O
type	O	O
1	O	O
diabetes	O	O
progression	O	O
,	O	O
and	O	O
apparent	O	O
recessive	B-NegReg	O
effects	I-NegReg	O
of	O	O
C1QTNF8	B-Gene	O
on	O	O
serum	B-MPA	O
magnesium	I-MPA	O
levels	I-MPA	O
Mutant	O	O
p53-Heat	O	O
Shock	O	O
Response	O	O
Oncogenic	O	O
Cooperation	O	O
:	O	O
A	O	O
New	O	O
Mechanism	O	O
of	O	O
Cancer	O	O
Cell	O	O
Survival	O	O
.	O	O

The	O	O
main	O	O
tumor	O	O
suppressor	O	O
function	O	O
of	O	O
p53	O	O
as	O	O
a	O	O
"	O	O
guardian	O	O
of	O	O
the	O	O
genome	O	O
"	O	O
is	O	O
to	O	O
respond	O	O
to	O	O
cellular	O	O
stress	O	O
by	O	O
transcriptional	O	O
activation	O	O
of	O	O
apoptosis	O	B-Disease
,	O	O
growth	O	O
arrest	O	O
,	O	O
or	O	O
senescence	O	O
in	O	O
damaged	O	O
cells	O	O
.	O	O

Not	O	O
surprisingly	O	O
,	O	O
mutations	O	B-Var
in	O	O
the	O	O
p53	O	O
gene	O	O
are	O	O
the	O	O
most	O	O
frequent	O	O
genetic	O	O
alteration	O	O
in	O	O
human	O	O
cancers	O	O
.	O	O

Importantly	O	O
,	O	O
mutant	B-Var	B-Var
p53	B-Gene	B-Gene
(	O	O
mutp53	O	O
)	O	O
proteins	B-Protein	O
not	O	O
only	O	O
lose	B-NegReg	O
their	O	O
wild-type	O	O
tumor	B-CPA	O
suppressor	I-CPA	O
activity	I-CPA	O
but	O	O
also	O	O
can	O	O
actively	B-PosReg	O
promote	I-PosReg	B-PosReg
tumor	B-CPA	B-CPA
development	I-CPA	I-CPA
.	O	O

Two	O	O
main	O	O
mechanisms	O	O
accounting	O	O
for	O	O
mutp53	B-Var	O
proto-oncogenic	O	O
activity	O	O
are	O	O
inhibition	O	O
of	O	O
the	O	O
wild-type	O	O
p53	O	O
in	O	O
a	O	O
dominant-negative	O	O
fashion	O	O
and	O	O
gain	B-PosReg	O
of	O	O
additional	B-CPA	O
oncogenic	I-CPA	O
activities	I-CPA	O
known	O	O
as	O	O
gain-of-function	O	O
(	O	O
GOF	O	O
)	O	O
.	O	O

Here	O	O
,	O	O
we	O	O
discuss	O	O
a	O	O
novel	O	O
mechanism	O	O
of	O	O
mutp53	B-Var	O
GOF	O	O
,	O	O
which	O	O
relies	O	O
on	O	O
its	O	O
oncogenic	O	O
cooperation	O	O
with	O	O
the	O	O
heat	O	O
shock	O	O
machinery	O	O
.	O	O

This	O	O
coordinated	O	O
adaptive	O	O
mechanism	O	O
renders	O	O
cancer	O	O
cells	O	O
more	B-PosReg	O
resistant	B-CPA	O
to	I-CPA	O
proteotoxic	I-CPA	O
stress	I-CPA	O
and	O	O
provides	O	O
both	O	O
,	O	O
a	O	O
strong	O	O
survival	B-CPA	O
advantage	I-CPA	O
Identification	O	O
and	O	O
functional	O	O
characterization	O	O
of	O	O
natural	O	O
human	O	O
melanocortin	O	O
1	O	O
receptor	O	O
mutant	O	O
alleles	O	O
in	O	O
Pakistani	O	O
population	O	O
.	O	O

Melanocortin	O	O
1	O	O
receptor	O	O
(	O	O
MC1R	O	O
)	O	O
,	O	O
a	O	O
Gs	O	O
protein-coupled	O	O
receptor	O	O
of	O	O
the	O	O
melanocyte	O	O
's	O	O
plasma	O	O
membrane	O	O
,	O	O
is	O	O
a	O	O
major	O	O
determinant	O	O
of	O	O
skin	O	O
pigmentation	O	O
and	O	O
phototype	O	O
.	O	O

Upon	O	O
activation	O	O
by	O	O
α-melanocyte	O	O
stimulating	O	O
hormone	O	O
,	O	O
MC1R	O	O
triggers	O	O
the	O	O
cAMP	O	O
cascade	O	O
to	O	O
stimulate	O	O
eumelanogenesis	O	O
.	O	O

We	O	O
used	O	O
whole-exome	O	O
sequencing	O	O
to	O	O
identify	O	O
causative	O	O
alleles	O	O
in	O	O
Pakistani	O	O
families	O	O
with	O	O
skin	O	O
and	O	O
hair	O	O
hypopigmentation	O	O
.	O	O

Six	O	O
MC1R	O	O
mutations	O	O
segregated	O	O
with	O	O
the	O	O
phenotype	O	O
in	O	O
seven	O	O
families	O	O
,	O	O
including	O	O
a	O	O
p	O	O
.	O	O

Val174del	O	O
in-frame	O	O
deletion	O	O
and	O	O
a	O	O
p	O	O
.	O	O

Tyr298	O	O
*	O	O
nonsense	O	O
mutation	O	O
,	O	O
that	O	O
were	O	O
analyzed	O	O
for	O	O
function	O	O
in	O	O
heterologous	O	O
HEK293	O	O
cells	O	O
.	O	O

p	B-Var	B-Var
.	O	O

Tyr298	O	O
*	O	O
MC1R	B-Gene	O
showed	O	O
no	B-NegReg	O
agonist-induced	B-MPA	O
signaling	I-MPA	O
to	O	O
the	O	O
cAMP	B-Pathway	O
or	O	O
ERK	B-Pathway	O
pathways	I-Pathway	O
,	O	O
nor	B-NegReg	O
detectable	O	O
agonist	B-Interaction	O
binding	I-Interaction	O
.	O	O

Conversely	O	O
,	O	O
signaling	O	O
was	O	O
comparable	O	O
for	O	O
p	B-Var	O
.	O	O

Val174del	O	O
and	O	O
wild-type	O	O
in	O	O
HEK	O	O
cells	O	O
overexpressing	O	O
the	O	O
proteins	O	O
,	O	O
but	O	O
binding	O	O
analysis	O	O
suggested	O	O
impaired	B-NegReg	O
cell	B-MPA	O
surface	I-MPA	O
expression	I-MPA	O
.	O	O

Flow	O	O
cytometry	O	O
and	O	O
confocal	O	O
imaging	O	O
studies	O	O
revealed	O	O
reduced	B-NegReg	O
plasma	B-MPA	O
membrane	I-MPA	O
expression	I-MPA	O
of	O	O
p	B-Var	O
.	O	O

Val174del	O	O
and	O	O
p	B-Var	B-Var
.	O	O

Tyr298*.	O	O
Therefore	O	O
,	O	O
p	B-Var	B-Var
.	O	O

Tyr298	O	O
*	O	O
was	O	O
a	O	O
total	O	O
loss-of-function	B-NegReg	B-NegReg
(	O	O
LOF	O	O
)	O	O
allele	O	O
,	O	O
while	O	O
p	B-Var	O
.	O	O

Val174del	O	O
displayed	O	O
a	O	O
partial	B-NegReg	O
LOF	I-NegReg	B-NegReg
Gain-of-function	O	O
p53	O	O
mutants	O	O
co-opt	O	O
chromatin	O	O
pathways	O	O
to	O	O
drive	O	O
cancer	O	O
growth	O	O
.	O	O

TP53	O	O
(	O	O
which	O	O
encodes	O	O
p53	O	O
protein	O	O
)	O	O
is	O	O
the	O	O
most	O	O
frequently	O	O
mutated	O	O
gene	O	O
among	O	O
all	O	O
human	O	O
cancers	O	O
.	O	O

Prevalent	O	O
p53	B-Gene	O
missense	B-Var	O
mutations	I-Var	O
abrogate	B-NegReg	O
its	O	O
tumour	B-CPA	O
suppressive	I-CPA	O
function	I-CPA	O
and	O	O
lead	O	B-Reg
to	O	I-Reg
a	O	O
'	O	O
gain-of-function	B-PosReg	O
'	O	O
(	O	O
GOF	O	O
)	O	O
that	O	O
promotes	B-PosReg	O
cancer	B-Disease	O
.	O	O

Here	O	O
we	O	O
show	O	O
that	O	O
p53	B-Gene	O
GOF	B-PosReg	O
mutants	B-Var	O
bind	O	O
to	O	O
and	O	O
upregulate	B-PosReg	O
chromatin	B-Gene	O
regulatory	I-Gene	O
genes	I-Gene	O
,	O	O
including	O	O
the	O	O
methyltransferases	B-Enzyme	O
MLL1	I-Enzyme	O
(	O	O
also	O	O
known	O	O
as	O	O
KMT2A	O	B-Gene
)	O	O
,	O	O
MLL2	B-Enzyme	O
(	O	O
also	O	O
known	O	O
as	O	O
KMT2D	O	O
)	O	O
,	O	O
and	O	O
acetyltransferase	B-Enzyme	O
MOZ	I-Enzyme	O
(	O	O
also	O	O
known	O	O
as	O	O
KAT6A	O	O
or	O	O
MYST3	O	O
)	O	O
,	O	O
resulting	O	O
in	O	O
genome-wide	O	O
increases	B-PosReg	O
of	O	O
histone	B-MPA	O
methylation	I-MPA	O
and	O	O
acetylation	B-MPA	O
.	O	O

Analysis	O	O
of	O	O
The	O	O
Cancer	O	O
Genome	O	O
Atlas	O	O
shows	O	O
specific	O	O
upregulation	B-PosReg	O
of	O	O
MLL1	B-Enzyme	O
,	O	O
MLL2	B-Enzyme	O
,	O	O
and	O	O
MOZ	B-Enzyme	O
in	O	O
p53	B-Gene	O
GOF	B-Var	O
DNA	O	O
damage-induced	O	O
ephrin-B2	O	O
reverse	O	O
signaling	O	O
promotes	O	O
chemoresistance	O	O
and	O	O
drives	O	O
EMT	O	O
in	O	O
colorectal	O	B-Disease
carcinoma	O	I-Disease
harboring	O	O
mutant	O	O
p53	O	O
.	O	O

Mutation	O	B-Var
in	O	O
the	O	O
TP53	O	B-Gene
gene	O	O
positively	O	O
correlates	O	O
with	O	O
increased	O	O
incidence	O	O
of	O	O
chemoresistance	O	O
in	O	O
different	O	O
cancers	O	O
.	O	O

In	O	O
this	O	O
study	O	O
,	O	O
we	O	O
investigated	O	O
the	O	O
mechanism	O	O
of	O	O
chemoresistance	O	O
and	O	O
epithelial-to-mesenchymal	O	O
transition	O	O
(	O	O
EMT	O	O
)	O	O
in	O	O
colorectal	O	B-Disease
cancer	O	I-Disease
involving	O	O
the	O	O
gain-of-function	O	O
(	O	O
GOF	O	O
)	O	O
mutant	O	O
p53/ephrin-B2	O	O
signaling	O	O
axis	O	O
.	O	O

Bioinformatic	O	O
analysis	O	O
of	O	O
the	O	O
NCI-60	O	O
data	O	O
set	O	O
and	O	O
subsequent	O	O
hub	O	O
prediction	O	O
identified	O	O
EFNB2	O	O
as	O	O
a	O	O
possible	O	O
GOF	O	O
mutant	O	O
p53	O	O
target	O	O
gene	O	O
,	O	O
responsible	O	O
for	O	O
chemoresistance	O	O
.	O	O

We	O	O
show	O	O
that	O	O
the	O	O
mutant	B-Var	O
p53-NF-Y	B-Gene	O
complex	O	O
transcriptionally	O	O
upregulates	B-PosReg	O
EFNB2	B-Gene	O
expression	B-MPA	O
in	O	O
response	B-MPA	O
to	I-MPA	O
DNA	I-MPA	O
damage	I-MPA	O
.	O	O

Moreover	O	O
,	O	O
the	O	O
acetylated	O	O
form	O	O
of	O	O
mutant	B-Var	O
p53	B-Gene	O
protein	B-Protein	O
is	O	O
recruited	B-PosReg	O
on	O	O
the	O	O
EFNB2	O	O
promoter	O	O
and	O	O
positively	O	O
regulates	B-Reg	O
its	O	O
expression	B-MPA	O
in	O	O
conjunction	O	O
with	O	O
coactivator	O	O
p300	O	O
.	O	O

In	O	O
vitro	O	O
cell	O	O
line	O	O
and	O	O
in	O	O
vivo	O	O
nude	O	O
mice	O	O
data	O	O
show	O	O
that	O	O
EFNB2	O	O
silencing	O	O
restores	O	O
chemosensitivity	O	O
in	O	O
mutant	O	O
p53-harboring	O	O
tumors	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
we	O	O
observed	O	O
high	O	O
expression	O	O
of	O	O
EFNB2	O	O
in	O	O
patients	O	O
having	O	O
neoadjuvant	O	O
non-responder	O	O
colorectal	O	B-Disease
carcinoma	O	I-Disease
compared	O	O
with	O	O
those	O	O
having	O	O
responder	O	O
version	O	O
of	O	O
the	O	O
disease	O	O
.	O	O

In	O	O
the	O	O
course	O	O
of	O	O
deciphering	O	O
the	O	O
drug	O	O
resistance	O	O
mechanism	O	O
,	O	O
we	O	O
also	O	O
show	O	O
that	O	O
ephrin-B2	O	O
reverse	O	O
signaling	O	O
induces	B-PosReg	O
ABCG2	B-Gene	O
expression	B-MPA	O
after	O	O
drug	O	O
treatment	O	O
that	O	O
involves	O	O
JNK-c-Jun	B-MPA	O
signaling	I-MPA	O
in	O	O
mutant	B-Var	O
p53	B-Gene	O
Urine-sample-derived	O	O
human	O	O
induced	O	O
pluripotent	O	O
stem	O	O
cells	O	O
as	O	O
a	O	O
model	O	O
to	O	O
study	O	O
PCSK9-mediated	O	O
autosomal	O	O
dominant	O	O
hypercholesterolemia	O	O
.	O	O

Proprotein	O	O
convertase	O	O
subtilisin	O	O
kexin	O	O
type	O	O
9	O	O
(	O	O
PCSK9	O	O
)	O	O
is	O	O
a	O	O
critical	O	O
modulator	O	O
of	O	O
cholesterol	O	O
homeostasis	O	O
.	O	O

Whereas	O	O
PCSK9	B-Gene	B-Gene
gain-of-function	B-PosReg	B-PosReg
(	O	O
GOF	O	O
)	O	O
mutations	B-Var	B-Var
are	O	O
associated	O	O
with	O	O
autosomal	B-Disease	B-Disease
dominant	I-Disease	I-Disease
hypercholesterolemia	I-Disease	I-Disease
(	O	O
ADH	O	O
)	O	O
and	O	O
premature	B-Disease	O
atherosclerosis	I-Disease	O
,	O	O
PCSK9	B-Gene	B-Gene
loss-of-function	B-NegReg	B-NegReg
(	O	O
LOF	O	O
)	O	O
mutations	B-Var	O
have	B-PosReg	O
a	O	O
cardio-protective	B-CPA	O
effect	I-CPA	O
and	O	O
in	O	O
some	O	O
cases	O	O
can	O	O
lead	O	B-Reg
to	O	I-Reg
familial	B-Disease	B-Disease
hypobetalipoproteinemia	I-Disease	I-Disease
Recurrent	O	O
MLK4	B-Gene	O
Loss-of-Function	B-NegReg	B-NegReg
Mutations	B-Var	B-Var
Suppress	B-NegReg	O
JNK	B-Pathway	O
Signaling	I-Pathway	O
to	O	O
Promote	B-PosReg	B-PosReg
Colon	B-Disease	B-Disease
Tumorigenesis	I-Disease	I-Disease
.	O	O

MLK4	O	O
is	O	O
a	O	O
member	O	O
of	O	O
the	O	O
mixed-lineage	O	O
family	O	O
of	O	O
kinases	O	O
that	O	O
regulate	O	O
the	O	O
JNK	O	O
,	O	O
p38	O	O
,	O	O
and	O	O
ERK	O	O
kinase	O	O
signaling	O	O
pathways	O	O
.	O	O

MLK4	O	O
mutations	O	O
have	O	O
been	O	O
identified	O	O
in	O	O
various	O	O
human	O	O
cancers	O	O
,	O	O
including	O	O
frequently	O	O
in	O	O
colorectal	O	B-Disease
cancer	O	I-Disease
,	O	O
where	O	O
their	O	O
function	O	O
and	O	O
pathobiological	O	O
importance	O	O
have	O	O
been	O	O
uncertain	O	O
.	O	O

In	O	O
this	O	O
study	O	O
,	O	O
we	O	O
assessed	O	O
the	O	O
functional	O	O
consequences	O	O
of	O	O
MLK4	O	O
mutations	O	O
in	O	O
colon	O	B-Disease
tumorigenesis	O	I-Disease
.	O	O

Biochemical	O	O
data	O	O
indicated	O	O
that	O	O
a	O	O
majority	O	O
of	O	O
MLK4	B-Gene	O
mutations	B-Var	O
are	O	O
loss-of-function	B-NegReg	B-NegReg
(	O	O
LOF	O	O
)	O	O
mutations	O	O
that	O	O
can	O	O
exert	O	O
dominant-negative	O	O
effects	O	O
.	O	O

In	O	O
seeking	O	O
to	O	O
understand	O	O
the	O	O
abrogated	O	O
activity	O	O
of	O	O
these	O	O
mutants	O	O
,	O	O
we	O	O
elucidated	O	O
a	O	O
new	O	O
MLK4	O	O
catalytic	O	O
domain	O	O
structure	O	O
.	O	O

To	O	O
determine	O	O
whether	O	O
MLK4	O	O
is	O	O
required	O	O
to	O	O
maintain	O	O
tumorigenic	O	O
phenotypes	O	O
,	O	O
we	O	O
reconstituted	O	O
its	O	O
signaling	O	O
axis	O	O
in	O	O
colon	O	B-Disease
cancer	O	O
cells	O	O
harboring	O	O
MLK4-inactivating	O	O
mutations	O	O
.	O	O

We	O	O
found	O	O
that	O	O
restoring	O	O
MLK4	O	O
activity	O	O
reduced	O	O
cell	O	O
viability	O	O
,	O	O
proliferation	O	O
,	O	O
and	O	O
colony	O	O
formation	O	O
in	O	O
vitro	O	O
and	O	O
delayed	O	O
tumor	O	O
growth	O	O
in	O	O
vivo	O	O
.	O	O

Mechanistic	O	O
investigations	O	O
established	O	O
that	O	O
restoring	O	O
the	O	O
function	O	O
of	O	O
MLK4	O	O
selectively	O	O
induced	O	O
the	O	O
JNK	O	O
pathway	O	O
and	O	O
its	O	O
downstream	O	O
targets	O	O
,	O	O
cJUN	O	O
,	O	O
ATF3	O	O
,	O	O
and	O	O
the	O	O
cyclin-dependent	O	O
kinase	O	O
inhibitors	O	O
CDKN1A	O	O
and	O	O
CDKN2B.	O	O
Our	O	O
work	O	O
indicates	O	O
that	O	O
MLK4	B-Gene	O
is	O	O
a	O	O
novel	O	O
tumor-suppressing	O	O
kinase	O	O
harboring	O	O
frequent	O	O
LOF	B-NegReg	B-NegReg
mutations	B-Var	B-Var
that	O	O
lead	O	O
to	O	O
diminished	B-NegReg	O
signaling	B-MPA	O
in	O	O
the	O	O
JNK	B-Pathway	O
pathway	I-Pathway	O
and	O	O
enhanced	B-PosReg	B-CPA
proliferation	B-CPA	I-CPA
Transcriptome	O	O
profiling	O	O
identifies	O	O
genes	O	O
and	O	O
pathways	O	O
deregulated	O	O
upon	O	O
floxuridine	O	O
treatment	O	O
in	O	O
colorectal	O	B-Disease
cancer	O	O
cells	O	O
harboring	O	O
GOF	O	O
mutant	O	O
p53	O	O
.	O	O

Mutation	O	B-Var
in	O	O
TP53	O	O
is	O	O
a	O	O
common	O	O
genetic	O	O
alteration	O	O
in	O	O
human	O	O
cancers	O	O
.	O	O

Certain	O	O
tumor	O	O
associated	O	O
p53	B-Gene	O
missense	B-Var	O
mutants	I-Var	O
acquire	O	O
gain-of-function	B-PosReg	O
(	O	O
GOF	O	O
)	O	O
properties	O	O
and	O	O
confer	O	O
oncogenic	O	O
phenotypes	O	O
including	O	O
enhanced	B-PosReg	B-PosReg
chemoresistance	B-CPA	B-MPA
.	O	O

The	O	O
colorectal	O	B-Disease
cancers	O	I-Disease
(	O	O
CRC	O	O
)	O	O
harboring	O	O
mutant	O	B-Var
p53	O	B-Gene
are	O	O
generally	O	O
aggressive	O	O
in	O	O
nature	O	O
and	O	O
difficult	O	O
to	O	O
treat	O	O
.	O	O

To	O	O
identify	O	O
a	O	O
potential	O	O
gene	O	O
expression	O	O
signature	O	O
of	O	O
GOF	O	O
mutant	O	O
p53-driven	O	O
acquired	O	O
chemoresistance	O	O
in	O	O
CRC	O	O
,	O	O
we	O	O
performed	O	O
transcriptome	O	O
profiling	O	O
of	O	O
floxuridine	O	O
(	O	O
FUdR	O	O
)	O	O
treated	O	O
SW480	O	O
cells	O	O
expressing	O	O
mutant	O	O
p53(R273H	O	O
)	O	O
(	O	O
GEO	O	O
#	O	O
:	O	O
GSE77533	O	O
)	O	O
.	O	O

We	O	O
obtained	O	O
several	O	O
genes	O	O
differentially	O	O
regulated	O	O
between	O	O
FUdR	O	O
treated	O	O
and	O	O
untreated	O	O
cells	O	O
.	O	O

Further	O	O
,	O	O
functional	O	O
characterization	O	O
and	O	O
pathway	O	O
analysis	O	O
revealed	O	O
significant	O	O
enrichment	O	O
of	O	O
crucial	O	O
biological	O	O
processes	O	O
and	O	O
pathways	O	O
upon	O	O
FUdR	O	O
treatment	O	O
in	O	O
SW480	O	O
cells	O	O
.	O	O

Our	O	O
data	O	O
suggest	O	O
that	O	O
in	O	O
response	O	O
to	O	O
chemotherapeutics	O	O
treatment	O	O
,	O	O
cancer	O	O
cells	O	O
with	O	O
GOF	B-PosReg	O
mutant	B-Var	O
p53	B-Gene	O
can	O	O
modulate	B-Reg	O
key	B-Pathway	O
cellular	I-Pathway	O
pathways	I-Pathway	O
to	O	O
withstand	B-CPA	O
the	I-CPA	O
cytotoxic	I-CPA	O
effect	I-CPA	O
of	I-CPA	O
the	I-CPA	O
drugs	I-CPA	O
TBR1	O	O
regulates	O	O
autism	O	O
risk	O	O
genes	O	O
in	O	O
the	O	O
developing	O	O
neocortex	O	O
.	O	O

Exome	O	O
sequencing	O	O
studies	O	O
have	O	O
identified	O	O
multiple	O	O
genes	O	O
harboring	O	O
de	O	O
novo	O	O
loss-of-function	B-NegReg	B-NegReg
(	O	O
LoF	O	O
)	O	O
variants	B-Var	O
in	O	O
individuals	O	O
with	O	O
autism	B-Disease	O
spectrum	I-Disease	O
disorders	I-Disease	O
(	O	O
ASD	O	O
)	O	O
,	O	O
including	O	O
TBR1	B-Gene	O
A	O	O
rare	O	O
DNA	O	O
contact	O	O
mutation	B-Var	O
in	O	O
cancer	O	O
confers	B-PosReg	O
p53	B-Gene	B-Gene
gain-of-function	B-PosReg	B-PosReg
and	O	O
tumor	B-CPA	O
cell	I-CPA	O
survival	I-CPA	O
via	O	O
TNFAIP8	B-Gene	O
induction	O	O
.	O	O

The	O	O
p53	O	O
tumor	O	O
suppressor	O	O
gene	O	O
encodes	O	O
a	O	O
sequence-specific	O	O
transcription	O	O
factor	O	O
.	O	O

Mutations	B-Var	B-Var
in	O	O
the	O	O
coding	O	O
sequence	O	O
of	O	O
p53	B-Gene	O
occur	O	O
frequently	O	O
in	O	O
human	O	O
cancer	O	O
and	O	O
often	O	O
result	B-Reg	O
in	I-Reg	O
single	B-Var	B-Var
amino	I-Var	I-Var
acid	I-Var	I-Var
substitutions	I-Var	I-Var
(	I-Var	O
missense	I-Var	O
mutations	I-Var	O
)	I-Var	O
in	I-Var	O
the	I-Var	O
DNA	I-Var	O
binding	O	O
domain	O	O
(	O	O
DBD	O	O
)	O	O
,	O	O
blocking	B-NegReg	O
normal	O	O
tumor	B-CPA	O
suppressive	I-CPA	O
functions	I-CPA	O
.	O	O

In	O	O
addition	O	O
to	O	O
the	O	O
loss	O	O
of	O	O
canonical	O	O
functions	O	O
,	O	O
some	O	O
missense	B-Var	B-Var
mutations	I-Var	I-Var
in	O	O
p53	B-Gene	O
confer	O	O
gain-of-function	B-PosReg	O
(	O	O
GOF	O	O
)	O	O
activities	B-CPA	O
to	I-CPA	O
tumor	I-CPA	O
cells	I-CPA	O
.	O	O

While	O	O
many	O	O
missense	O	O
mutations	O	O
in	O	O
p53	O	O
cluster	O	O
at	O	O
six	O	O
"	O	O
hotspot	O	O
"	O	O
amino	O	O
acids	O	O
,	O	O
the	O	O
majority	O	O
of	O	O
mutations	O	O
in	O	O
human	O	O
cancer	O	O
occur	O	O
elsewhere	O	O
in	O	O
the	O	O
DBD	O	O
and	O	O
at	O	O
a	O	O
much	O	O
lower	O	O
frequency	O	O
.	O	O

We	O	O
report	O	O
here	O	O
that	O	O
mutations	B-Var	O
at	I-Var	O
K120	I-Var	O
,	O	O
a	O	O
non-hotspot	O	O
DNA	O	O
contact	O	O
residue	O	O
,	O	O
confer	B-PosReg	O
p53	B-Gene	O
with	O	O
the	O	O
previously	O	O
unrecognized	O	O
ability	B-MPA	O
to	O	O
bind	B-Interaction	O
and	O	O
activate	B-PosReg	O
the	O	O
transcription	B-MPA	O
of	O	O
the	O	O
pro-survival	O	O
TNFAIP8	B-Gene	O
gene	O	O
.	O	O

Mutant	O	O
K120	O	O
p53	O	O
binds	O	O
the	O	O
TNFAIP8	O	O
locus	O	O
at	O	O
a	O	O
cryptic	O	O
p53	O	O
response	O	O
element	O	O
that	O	O
is	O	O
not	O	O
occupied	O	O
by	O	O
wild-type	O	O
p53	O	O
.	O	O

Furthermore	O	O
,	O	O
induction	O	O
of	O	O
TNFAIP8	O	O
is	O	O
critical	O	O
for	O	O
the	O	O
evasion	O	O
of	O	O
apoptosis	O	B-Disease
by	O	O
tumor	O	O
cells	O	O
expressing	O	O
the	O	O
K120R	O	O
variant	O	O
of	O	O
p53	O	O
.	O	O

These	O	O
findings	O	O
identify	O	O
induction	O	O
of	O	O
pro-survival	O	O
targets	O	O
as	O	O
a	O	O
mechanism	O	O
of	O	O
gain-of-function	B-PosReg	O
activity	B-MPA	O
for	O	O
mutant	B-Var	O
p53	B-Gene	O
De	O	O
Novo	O	O
Mutations	B-Var	O
in	O	O
SON	B-Gene	O
Disrupt	O	O
RNA	O	O
Splicing	O	O
of	O	O
Genes	O	O
Essential	O	O
for	O	O
Brain	O	B-CPA
Development	O	I-CPA
and	O	O
Metabolism	O	O
,	O	O
Causing	B-Reg	O
an	O	O
Intellectual-Disability	B-Disease	B-Disease
Syndrome	I-Disease	I-Disease
.	O	O

The	O	O
overall	O	O
understanding	O	O
of	O	O
the	O	O
molecular	O	O
etiologies	O	O
of	O	O
intellectual	O	B-Disease
disability	O	I-Disease
(	O	O
ID	O	O
)	O	O
and	O	O
developmental	O	B-CPA
delay	O	I-CPA
(	O	O
DD	O	O
)	O	O
is	O	O
increasing	O	B-PosReg
as	O	O
next-generation	O	O
sequencing	O	O
technologies	O	O
identify	O	O
genetic	O	O
variants	O	O
in	O	O
individuals	O	O
with	O	O
such	O	O
disorders	O	O
.	O	O

However	O	O
,	O	O
detailed	O	O
analyses	O	O
conclusively	O	O
confirming	O	O
these	O	O
variants	O	O
,	O	O
as	O	O
well	O	O
as	O	O
the	O	O
underlying	O	O
molecular	O	O
mechanisms	O	O
explaining	O	O
the	O	O
diseases	O	O
,	O	O
are	O	O
often	O	O
lacking	O	O
.	O	O

Here	O	O
,	O	O
we	O	O
report	O	O
on	O	O
an	O	O
ID	B-Disease	B-Disease
syndrome	I-Disease	I-Disease
caused	O	B-Reg
by	O	I-Reg
de	O	O
novo	O	O
heterozygous	O	O
loss-of-function	B-NegReg	B-NegReg
(	O	O
LoF	O	O
)	O	O
mutations	B-Var	B-Var
in	O	O
SON	B-Gene	O
.	O	O

The	O	O
syndrome	O	O
is	O	O
characterized	O	O
by	O	O
ID	O	O
and/or	O	O
DD	O	O
,	O	O
malformations	O	O
of	O	O
the	O	O
cerebral	O	O
cortex	O	O
,	O	O
epilepsy	O	O
,	O	O
vision	O	O
problems	O	O
,	O	O
musculoskeletal	O	O
abnormalities	O	O
,	O	O
and	O	O
congenital	O	O
malformations	O	O
.	O	O

Knockdown	O	O
of	O	O
son	O	O
in	O	O
zebrafish	O	O
resulted	O	O
in	O	O
severe	O	O
malformation	O	O
of	O	O
the	O	O
spine	O	O
,	O	O
brain	O	O
,	O	O
and	O	O
eyes	O	O
.	O	O

Importantly	O	O
,	O	O
analyses	O	O
of	O	O
RNA	O	O
from	O	O
affected	O	O
individuals	O	O
revealed	O	O
that	O	O
genes	O	O
critical	O	O
for	O	O
neuronal	B-CPA	O
migration	I-CPA	O
and	O	O
cortex	B-CPA	O
organization	I-CPA	O
(	O	O
TUBG1	O	O
,	O	O
FLNA	O	B-Gene
,	O	O
PNKP	O	O
,	O	O
WDR62	O	O
,	O	O
PSMD3	O	O
,	O	O
and	O	O
 	O	O
HDAC6	O	O
)	O	O
and	O	O
metabolism	B-CPA	O
(	O	O
PCK2	O	O
,	O	O
PFKL	O	O
,	O	O
IDH2	O	O
,	O	O
ACY1	O	O
,	O	O
and	O	O
ADA	O	O
)	O	O
are	O	O
significantly	O	O
downregulated	B-NegReg	B-NegReg
because	O	O
of	O	O
the	O	O
accumulation	B-PosReg	O
of	O	O
mis-spliced	O	O
transcripts	O	O
resulting	O	O
from	O	O
erroneous	B-Var	O
SON-mediated	I-Var	O
RNA	I-Var	O
splicing	I-Var	O
The	O	O
anti-adipogenic	B-MPA	O
effect	I-MPA	O
of	O	O
peripheral	O	O
blood	O	O
mononuclear	O	O
cells	O	O
is	O	O
absent	B-NegReg	O
with	O	O
PCSK9	B-Gene	B-Gene
loss-of-function	B-NegReg	B-NegReg
variants	B-Var	O
.	O	O

OBJECTIVE	O	O
:	O	O
To	O	O
determine	O	O
the	O	O
effect	O	O
of	O	O
(	O	O
1	O	O
)	O	O
an	O	O
oral	O	O
fat	O	O
load	O	O
and	O	O
(	O	O
2	O	O
)	O	O
pro-protein	O	O
convertase	O	O
subtilisin	O	O
/	O	O
kexin	O	O
type	O	O
(	O	O
PCSK	O	O
)	O	O
9	O	O
loss-of-function	B-NegReg	B-NegReg
(	O	O
LOF	O	O
)	O	O
variant	B-Var	O
status	O	O
on	O	O
the	O	O
ability	O	O
of	O	O
peripheral	O	O
blood	O	O
mononuclear	O	O
cells	O	O
(	O	O
PBMC	O	O
)	O	O
to	O	O
inhibit	B-NegReg	O
human	B-MPA	O
adipogenesis	I-MPA	O
.	O	O

METHODS	O	O
:	O	O
PBMC	O	O
from	O	O
subjects	O	O
with	O	O
one	O	O
or	O	O
more	O	O
PCSK9	O	O
LOF	O	O
variants	O	O
versus	O	O
non-variant	O	O
controls	O	O
were	O	O
compared	O	O
in	O	O
the	O	O
fasting	O	O
state	O	O
and	O	O
after	O	O
an	O	O
oral	O	O
fat	O	O
load	O	O
.	O	O

RESULTS	O	O
:	O	O
Fasting	O	O
triglyceride	O	O
(	O	O
TG	O	O
)	O	O
levels	O	O
were	O	O
lower	O	O
in	O	O
the	O	O
LOF	O	O
variant	O	O
versus	O	O
non-variant	O	O
group	O	O
but	O	O
rose	O	O
to	O	O
the	O	O
same	O	O
level	O	O
after	O	O
the	O	O
oral	O	O
fat	O	O
load	O	O
.	O	O

Conditioned	O	O
medium	O	O
from	O	O
PBMC	O	O
was	O	O
obtained	O	O
in	O	O
fasting	O	O
(	O	O
PBMC-CM-F	O	O
)	O	O
and	O	O
4-h	O	O
postprandial	O	O
(	O	O
PBMC-CM-PP	O	O
)	O	O
states	O	O
.	O	O

PBMC-CM-PP	O	O
from	O	O
non-variant	O	O
controls	O	O
inhibited	O	O
adipogenesis	O	O
of	O	O
human	O	O
preadipocytes	O	O
more	O	O
than	O	O
did	O	O
PBMC-CM-F.	O	O
In	O	O
contrast	O	O
,	O	O
PBMC-CM-F	O	O
or	O	O
-PP	O	O
from	O	O
PCSK9	B-Gene	O
LOF	B-NegReg	O
variant	B-Var	O
subjects	O	O
had	O	O
no	O	O
effect	O	O
on	O	O
adipogenesis	B-MPA	O
.	O	O

After	O	O
the	O	O
oral	O	O
fat	O	O
load	O	O
,	O	O
PBMC	O	O
from	O	O
PCSK9	B-Gene	O
LOF	B-NegReg	O
variant	B-Var	O
subjects	O	O
showed	O	O
significant	O	O
increases	B-PosReg	B-PosReg
in	O	O
mRNA	B-MPA	O
levels	I-MPA	O
of	I-MPA	O
interleukin-1β	I-MPA	O
,	O	O
tumor	B-MPA	O
necrosis	I-MPA	O
factor-α	I-MPA	O
,	O	O
sterol	B-MPA	O
regulatory	I-MPA	O
element	I-MPA	O
binding	I-MPA	O
protein-1c	I-MPA	O
,	O	O
CD36	B-MPA	O
,	O	O
and	O	O
monocyte	O	O
chemoattractant	O	O
protein-1	O	O
(	O	O
MCP-1	O	O
)	O	O
,	O	O
only	O	O
MCP-1	O	O
mRNA	O	O
levels	O	O
increased	O	O
in	O	O
PBMC	O	O
from	O	O
non-variant	O	O
controls	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
The	O	O
absence	B-NegReg	O
of	O	O
anti-adipogenic	B-MPA	O
action	I-MPA	O
of	O	O
PBMC	O	O
from	O	O
PCSK9	B-Gene	O
LOF	O	O
variant	B-Var	O
subjects	O	O
points	O	O
to	O	O
a	O	O
novel	B-PosReg	O
role	I-PosReg	O
for	O	O
PCSK9	O	O
in	O	O
PBMC-adipose	O	O
cell	O	O
interactions	B-Interaction	B-Interaction
Atopic	O	B-Disease
Dermatitis	O	I-Disease
Susceptibility	O	O
Variants	O	O
in	O	O
Filaggrin	O	O
Hitchhike	O	O
Hornerin	O	O
Selective	O	O
Sweep	O	O
.	O	O

Human	O	O
skin	O	O
has	O	O
evolved	O	O
rapidly	O	O
,	O	O
leaving	O	O
evolutionary	O	O
signatures	O	O
in	O	O
the	O	O
genome	O	O
.	O	O

The	O	O
filaggrin	O	O
(	O	O
FLG	B-Gene	B-Gene
)	O	O
gene	O	O
is	O	O
widely	O	O
studied	O	O
for	O	O
its	O	O
skin-barrier	O	O
function	O	O
in	O	O
humans	O	O
.	O	O

The	O	O
extensive	B-Var	O
genetic	I-Var	O
variation	I-Var	O
in	O	O
this	O	O
gene	O	O
,	O	O
especially	O	O
common	O	O
loss-of-function	B-NegReg	O
(	O	O
LoF	O	O
)	O	O
mutations	B-Var	O
,	O	O
has	O	O
been	O	O
established	O	O
as	O	O
primary	O	O
risk	O	O
factors	O	O
for	O	O
atopic	B-Disease	B-Disease
dermatitis	I-Disease	I-Disease
Variants	O	O
of	O	O
genes	O	O
encoding	O	O
collagens	O	O
and	O	O
matrix	O	O
metalloproteinase	O	O
system	O	O
increased	O	B-PosReg
the	O	O
risk	O	O
of	O	O
aortic	O	O
dissection	O	O
.	O	O

Aortic	O	O
dissection	O	O
(	O	O
AD	O	O
)	O	O
is	O	O
a	O	O
devastating	O	O
,	O	O
heterogeneous	O	O
condition	O	O
of	O	O
aorta	O	O
.	O	O

The	O	O
homeostasis	O	O
between	O	O
collagens	O	O
and	O	O
matrix	O	O
metalloproteases	O	O
(	O	O
MMPs)/tissue	O	O
inhibitors	O	O
of	O	O
MMPs	O	O
(	O	O
TIMPs	O	O
)	O	O
system	O	O
in	O	O
the	O	O
extracellular	O	O
matrix	O	O
plays	O	O
an	O	O
important	O	O
role	O	O
for	O	O
structure	O	O
and	O	O
functions	O	O
of	O	O
aorta	O	O
.	O	O

However	O	O
,	O	O
our	O	O
knowledge	O	O
on	O	O
association	O	O
between	O	O
variants	O	O
of	O	O
genes	O	O
in	O	O
this	O	O
system	O	O
and	O	O
pathogenesis	O	O
of	O	O
AD	O	O
is	O	O
very	O	O
limited	O	O
.	O	O

We	O	O
analyzed	O	O
all	O	O
yet	O	O
known	O	O
coding	O	O
human	O	O
genes	O	O
of	O	O
collagens	O	O
(	O	O
45	O	O
genes	O	O
)	O	O
,	O	O
MMPs	O	O
/	O	O
TIMPs	O	O
(	O	O
27	O	O
genes	O	O
)	O	O
in	O	O
702	O	O
sporadic	O	O
AD	O	O
patients	O	O
and	O	O
in	O	O
163	O	O
matched	O	O
healthy	O	O
controls	O	O
,	O	O
by	O	O
using	O	O
massively	O	O
targeted	O	O
next-generation	O	O
and	O	O
Sanger	O	O
sequencing	O	O
.	O	O

To	O	O
define	O	O
the	O	O
pathogenesis	O	O
of	O	O
potential	O	O
disease-causing	O	O
candidate	O	O
genes	O	O
,	O	O
we	O	O
performed	O	O
transcriptome	O	O
sequencing	O	O
and	O	O
pedigree	O	O
co-segregation	O	O
analysis	O	O
in	O	O
some	O	O
genes	O	O
and	O	O
generated	O	O
Col5a2	O	O
knockout	O	O
rats	O	O
.	O	O

We	O	O
identified	O	O
257	O	O
pathogenic	O	O
or	O	O
likely	O	O
pathogenic	O	O
variants	O	O
which	O	O
involved	O	O
88.89	O	O
%	O	O
(	O	O
64/72	O	O
)	O	O
genes	O	O
in	O	O
collagens-MMPs	O	O
/	O	O
TIMPs	O	O
system	O	O
and	O	O
accounted	O	O
for	O	O
31.05	O	O
%	O	O
(	O	O
218/702	O	O
)	O	O
sporadic	O	O
AD	O	O
patients	O	O
.	O	O

In	O	O
them	O	O
,	O	O
84.86	O	O
%	O	O
patients	O	O
(	O	O
185/218	O	O
)	O	O
carried	O	O
one	O	O
variant	O	O
,	O	O
12.84	O	O
%	O	O
two	O	O
variants	O	O
and	O	O
2.30	O	O
%	O	O
more	O	O
than	O	O
two	O	O
variants	O	O
.	O	O

Importantly	O	O
,	O	O
we	O	O
identified	O	O
52	O	O
novel	O	O
probably	O	O
pathogenic	O	O
loss-of-function	O	O
(	O	O
LOF	O	O
)	O	O
variants	O	O
(	O	O
20	O	O
nonsense	O	O
,	O	O
16	O	O
frameshift	O	O
,	O	O
14	O	O
splice	O	O
sites	O	O
,	O	O
one	O	O
stop-loss	O	O
,	O	O
one	O	O
initiation	O	O
codon	O	O
)	O	O
in	O	O
11.06	O	O
%	O	O
(	O	O
50/452	O	O
)	O	O
AD	O	O
patients	O	O
,	O	O
which	O	O
were	O	O
absent	O	O
in	O	O
163	O	O
controls	O	O
(	O	O
P=2.5×10(-5	O	O
)	O	O
)	O	O
.	O	O

Transcriptome	O	O
sequencing	O	O
revealed	O	O
that	O	O
identified	O	O
variants	B-Var	B-Var
induced	O	O
dyshomeostasis	B-Reg	O
in	O	O
expression	B-CPA	O
of	I-CPA	O
collagens-TIMPs	I-CPA	O
/	I-CPA	O
MMPs	O	O
systems	O	O
.	O	O

The	O	O
Col5a2	B-Gene	O
(	O	O
-/-	O	O
)	O	O
rats	O	O
manifested	O	O
growth	B-CPA	O
retardation	I-CPA	O
and	O	O
aortic	B-CPA	B-Disease
dysplasia	I-CPA	I-Disease
Alanine-scanning	O	O
mutagenesis	O	O
of	O	O
human	O	O
signal	O	O
transducer	O	O
and	O	O
activator	O	O
of	O	O
transcription	O	O
1	O	O
to	O	O
estimate	O	O
loss-	O	O
or	O	O
gain-of-function	O	O
variants	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Germline	B-Var	O
heterozygous	I-Var	O
mutations	I-Var	B-Var
in	O	O
human	O	O
signal	B-Gene	O
transducer	I-Gene	O
and	O	O
activator	B-Gene	O
of	I-Gene	O
transcription	I-Gene	O
1	I-Gene	O
(	O	O
STAT1	O	O
)	O	O
can	O	O
cause	O	O
loss	B-NegReg	B-NegReg
of	I-NegReg	I-NegReg
function	I-NegReg	I-NegReg
(	O	O
LOF	O	O
)	O	O
,	O	O
as	O	O
in	O	O
patients	O	O
with	O	O
Mendelian	O	O
susceptibility	O	O
to	O	O
mycobacterial	B-Disease	O
diseases	I-Disease	O
,	O	O
or	O	O
gain	B-PosReg	B-PosReg
of	I-PosReg	I-PosReg
function	I-PosReg	I-PosReg
(	O	O
GOF	O	O
)	O	O
,	O	O
as	O	O
in	O	O
patients	O	O
with	O	O
chronic	B-Disease	B-Disease
mucocutaneous	I-Disease	I-Disease
candidiasis	I-Disease	I-Disease
.	O	O

LOF	O	O
and	O	O
GOF	O	O
mutations	B-Var	O
are	O	O
equally	O	O
rare	O	O
and	O	O
can	O	O
affect	B-Reg	O
the	O	O
same	O	O
domains	B-MPA	O
of	O	O
STAT1	B-Gene	B-Gene
,	O	O
especially	O	O
the	O	O
coiled-coil	B-MPA	O
domain	I-MPA	O
(	O	O
CCD	O	O
)	O	O
and	O	O
DNA-binding	B-MPA	O
domain	I-MPA	O
Ruxolitinib	O	O
reverses	O	O
dysregulated	O	O
T	O	O
helper	O	O
cell	O	O
responses	O	O
and	O	O
controls	O	O
autoimmunity	O	O
caused	O	B-Reg
by	O	I-Reg
a	O	O
novel	O	O
signal	O	O
transducer	O	O
and	O	O
activator	O	O
of	O	O
transcription	O	O
1	O	O
(	O	O
STAT1	O	O
)	O	O
gain-of-function	O	O
mutation	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Gain-of-function	B-PosReg	O
(	O	O
GOF	O	O
)	O	O
mutations	B-Var	B-Var
in	O	O
the	O	O
human	B-Gene	O
signal	I-Gene	O
transducer	I-Gene	O
and	I-Gene	O
activator	I-Gene	O
of	I-Gene	O
transcription	I-Gene	O
1	I-Gene	O
(	O	O
STAT1	O	O
)	O	O
manifest	O	O
in	O	O
immunodeficiency	O	O
and	O	O
autoimmunity	O	O
with	O	O
impaired	B-NegReg	B-NegReg
TH17	B-CPA	B-MPA
 	I-CPA	O
cell	O	O
differentiation	O	O
and	O	O
exaggerated	B-PosReg	O
responsiveness	B-Interaction	O
to	I-Interaction	O
type	I-Interaction	O
I	I-Interaction	O
and	I-Interaction	O
II	I-Interaction	O
interferons	I-Interaction	O
.	O	O

Allogeneic	O	O
bone	O	O
marrow	O	O
transplantation	O	O
has	O	O
been	O	O
attempted	O	O
in	O	O
severely	O	O
affected	O	O
patients	O	O
,	O	O
but	O	O
outcomes	O	O
have	O	O
been	O	O
poor	O	O
.	O	O

OBJECTIVE	O	O
:	O	O
We	O	O
sought	O	O
to	O	O
define	O	O
the	O	O
effect	O	O
of	O	O
increased	O	B-PosReg
STAT1	O	B-MPA
activity	O	I-MPA
on	O	O
T	O	O
helper	O	O
cell	O	O
polarization	O	O
and	O	O
to	O	O
investigate	O	O
the	O	O
therapeutic	O	O
potential	O	O
of	O	O
ruxolitinib	O	O
in	O	O
treating	O	O
autoimmunity	O	O
secondary	O	O
to	O	O
STAT1	O	O
GOF	O	O
mutations	O	O
.	O	O

METHODS	O	O
:	O	O
We	O	O
used	O	O
in	O	O
 	O	O
vitro	O	O
polarization	O	O
assays	O	O
,	O	O
as	O	O
well	O	O
as	O	O
phenotypic	O	O
and	O	O
functional	O	O
analysis	O	O
of	O	O
STAT1-mutated	O	O
patient	O	O
cells	O	O
.	O	O

RESULTS	O	O
:	O	O
We	O	O
report	O	O
a	O	O
child	O	O
with	O	O
a	O	O
novel	O	O
mutation	B-Var	O
in	I-Var	O
the	I-Var	O
linker	I-Var	O
domain	I-Var	O
of	O	O
STAT1	B-Gene	O
who	O	O
had	O	O
life-threatening	O	O
autoimmune	O	O
cytopenias	O	O
and	O	O
chronic	O	B-Disease
mucocutaneous	O	I-Disease
candidiasis	O	I-Disease
.	O	O

Naive	O	O
lymphocytes	O	O
from	O	O
the	O	O
affected	O	O
patient	O	O
displayed	O	O
increased	B-PosReg	O
TH1	B-CPA	O
and	I-CPA	O
follicular	I-CPA	O
T	I-CPA	O
helper	I-CPA	O
cell	I-CPA	O
and	O	O
suppressed	B-NegReg	O
TH17	B-CPA	O
 	I-CPA	O
cell	O	O
responses	O	O
.	O	O

The	O	O
mutation	B-Var	B-Var
augmented	B-PosReg	B-PosReg
cytokine-induced	B-MPA	B-MPA
STAT1	I-MPA	I-MPA
phosphorylation	I-MPA	I-MPA
without	O	O
affecting	O	O
dephosphorylation	O	O
kinetics	O	O
.	O	O

Treatment	O	O
with	O	O
the	O	O
Janus	O	O
kinase	O	O
1/2	O	O
inhibitor	O	O
ruxolitinib	O	O
reduced	O	O
hyperresponsiveness	O	O
to	O	O
type	O	O
I	O	O
and	O	O
II	O	O
interferons	O	O
,	O	O
normalized	O	O
TH1	O	O
and	O	O
follicular	O	O
T	O	O
helper	O	O
cell	O	O
responses	O	O
,	O	O
improved	O	O
TH17	O	O
differentiation	O	O
,	O	O
cured	O	O
mucocutaneous	O	O
candidiasis	O	O
,	O	O
and	O	O
maintained	O	O
remission	O	O
of	O	O
immune-mediated	O	O
cytopenias	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Autoimmunity	O	O
and	O	O
infection	O	O
caused	O	O
by	O	O
STAT1	B-Gene	O
GOF	B-PosReg	O
mutations	B-Var	O
are	O	O
the	O	O
result	O	O
of	O	O
dysregulated	O	O
T	B-CPA	O
helper	I-CPA	O
cell	I-CPA	O
responses	I-CPA	O
Complexity	O	O
of	O	O
mechanisms	O	O
among	O	O
human	O	O
proprotein	O	O
convertase	O	O
subtilisin-kexin	O	O
type	O	O
9	O	O
variants	O	O
.	O	O

PURPOSE	O	O
OF	O	O
REVIEW	O	O
:	O	O
There	O	O
are	O	O
many	O	O
reports	O	O
of	O	O
human	O	O
variants	B-Var	O
in	O	O
proprotein	O	O
convertase	O	O
subtilisin-kexin	O	O
type	O	O
9	O	O
(	O	O
PCSK9	B-Gene	O
)	O	O
that	O	O
are	O	O
either	O	O
gain-of-function	B-PosReg	O
(	O	O
GOF	O	O
)	O	O
or	O	O
loss-of-function	B-NegReg	B-NegReg
(	O	O
LOF	O	O
)	O	O
,	O	O
with	O	O
downstream	O	O
effects	B-Reg	O
on	O	O
LDL	B-Disease	O
cholesterol	I-Disease	O
and	O	O
cardiovascular	B-Disease	B-Disease
disease	I-Disease	I-Disease
(	O	O
CVD	O	O
)	O	O
risk	O	O
.	O	O

However	O	O
,	O	O
data	O	O
on	O	O
particular	O	O
mechanisms	O	O
have	O	O
only	O	O
been	O	O
minimally	O	O
curated	O	O
.	O	O

RECENT	O	O
FINDINGS	O	O
:	O	O
GOF	B-PosReg	O
variants	B-Var	O
are	O	O
individually	O	O
ultrarare	O	O
,	O	O
affect	B-Reg	O
all	O	O
domains	B-Protein	O
of	I-Protein	O
the	I-Protein	O
protein	I-Protein	O
,	O	O
act	O	O
to	O	O
reduce	B-NegReg	O
LDL	B-Protein	O
receptor	I-Protein	O
expression	B-MPA	O
through	O	O
several	O	O
mechanisms	O	O
,	O	O
are	O	O
a	O	O
minor	O	O
cause	B-Reg	O
of	O	O
familial	B-Disease	B-Disease
hypercholesterolemia	I-Disease	I-Disease
,	O	O
have	O	O
been	O	O
reported	O	O
mainly	O	O
within	O	O
families	O	O
,	O	O
have	O	O
variable	O	O
LDL	O	O
cholesterol-raising	O	O
effects	O	O
,	O	O
and	O	O
are	O	O
associated	O	O
with	O	O
increased	O	O
CVD	O	O
risk	O	O
mainly	O	O
through	O	O
observational	O	O
studies	O	O
in	O	O
families	O	O
and	O	O
small	O	O
cohorts	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
LOF	B-NegReg	O
variants	B-Var	O
can	O	O
be	O	O
either	O	O
ultrarare	O	O
mutations	O	B-Var
or	O	O
relatively	O	O
more	O	O
common	O	O
polymorphisms	O	O
seen	O	O
in	O	O
populations	O	O
,	O	O
affect	B-Reg	O
all	O	O
domains	B-Protein	O
of	I-Protein	O
the	I-Protein	O
protein	I-Protein	O
,	O	O
act	O	O
to	O	O
increase	B-PosReg	O
LDL	B-Protein	O
receptor	I-Protein	O
expression	B-MPA	O
through	O	O
several	O	O
mechanisms	O	O
,	O	O
have	O	O
variable	O	O
LDL	B-MPA	O
cholesterol-lowering	I-MPA	O
effects	O	O
,	O	O
and	O	O
have	O	O
been	O	O
associated	O	O
with	O	O
decreased	O	O
CVD	O	O
risk	O	O
mainly	O	O
through	O	O
Mendelian	O	O
randomization	O	O
studies	O	O
in	O	O
epidemiologic	O	O
populations	O	O
.	O	O

SUMMARY	O	O
:	O	O
There	O	O
is	O	O
considerable	O	O
complexity	O	O
underlying	O	O
the	O	O
clinical	O	O
concept	O	O
of	O	O
both	O	O
LOF	O	O
and	O	O
GOF	O	O
variants	O	O
of	O	O
PCSK9	O	O
.	O	O

But	O	O
despite	O	O
the	O	O
underlying	O	O
mechanistic	O	O
heterogeneity	O	O
,	O	O
altered	O	O
PCSK9	O	O
secretion	O	O
or	O	O
function	O	O
is	O	O
ultimately	O	O
correlated	O	O
with	O	O
plasma	O	O
LDL	O	O
cholesterol	O	O
level	O	O
,	O	O
which	O	O
is	O	O
also	O	O
the	O	O
driver	O	O
of	O	O
CVD	O	O
outcomes	O	O
.	O	O

Towards	O	O
trans-diagnostic	O	O
mechanisms	O	O
in	O	O
psychiatry	O	O
:	O	O
neurobehavioral	O	O
profile	O	O
of	O	O
rats	O	O
with	O	O
a	O	O
loss-of-function	O	B-NegReg
point	O	B-Var
mutation	O	I-Var
in	O	O
the	O	O
dopamine	O	O
transporter	O	O
gene	O	O
.	O	O

The	O	O
research	O	O
domain	O	O
criteria	O	O
(	O	O
RDoC	O	O
)	O	O
matrix	O	O
has	O	O
been	O	O
developed	O	O
to	O	O
reorient	O	O
psychiatric	O	O
research	O	O
towards	O	O
measurable	O	O
behavioral	O	O
dimensions	O	O
and	O	O
underlying	O	O
mechanisms	O	O
.	O	O

Here	O	O
,	O	O
we	O	O
used	O	O
a	O	O
new	O	O
genetic	O	O
rat	O	O
model	O	O
with	O	O
a	O	O
loss-of-function	O	B-NegReg
point	O	B-Var
mutation	O	I-Var
in	O	O
the	O	O
dopamine	O	O
transporter	O	O
(	O	O
DAT	O	O
)	O	O
gene	O	O
(	O	O
Slc6a3_N157	O	O
K	O	O
)	O	O
to	O	O
systematically	O	O
study	O	O
the	O	O
RDoC	O	O
matrix	O	O
.	O	O

First	O	O
,	O	O
we	O	O
examined	O	O
the	O	O
impact	O	O
of	O	O
the	O	O
Slc6a3_N157	O	O
K	O	O
mutation	O	O
on	O	O
monoaminergic	O	O
signaling	O	O
.	O	O

We	O	O
then	O	O
performed	O	O
behavioral	O	O
tests	O	O
representing	O	O
each	O	O
of	O	O
the	O	O
five	O	O
RDoC	O	O
domains	O	O
:	O	O
negative	O	O
and	O	O
positive	O	O
valence	O	O
systems	O	O
,	O	O
cognitive	O	O
,	O	O
social	O	O
and	O	O
arousal	O	O
/	O	O
regulatory	O	O
systems	O	O
.	O	O

The	O	O
use	O	O
of	O	O
RDoC	O	O
may	O	O
be	O	O
particularly	O	O
helpful	O	O
for	O	O
drug	O	O
development	O	O
.	O	O

We	O	O
studied	O	O
the	O	O
effects	O	O
of	O	O
a	O	O
novel	O	O
pharmacological	O	O
approach	O	O
metabotropic	O	O
glutamate	O	O
receptor	O	O
mGluR2/3	O	O
antagonism	O	O
,	O	O
in	O	O
DAT	O	O
mutants	O	O
in	O	O
a	O	O
comparative	O	O
way	O	O
with	O	O
standard	O	O
medications	O	O
.	O	O

Loss	B-NegReg	O
of	O	O
DAT	B-Gene	O
functionality	O	O
in	O	O
mutant	B-Var	O
rats	O	O
not	O	O
only	O	O
elevated	B-PosReg	O
subcortical	B-MPA	O
extracellular	I-MPA	O
dopamine	I-MPA	O
concentration	I-MPA	O
but	O	O
also	O	O
altered	B-Reg	B-Reg
the	O	O
balance	B-MPA	O
of	I-MPA	O
monoaminergic	I-MPA	O
transmission	I-MPA	O
Conformational	O	O
disruption	O	O
of	O	O
PI3Kδ	O	O
regulation	O	O
by	O	O
immunodeficiency	O	O
mutations	O	O
in	O	O
PIK3CD	O	O
and	O	O
PIK3R1	O	O
.	O	O

Activated	B-Disease	O
PI3	I-Disease	O
K	I-Disease	O
Delta	I-Disease	O
Syndrome	O	O
(	O	O
APDS	O	O
)	O	O
is	O	O
a	O	O
primary	O	B-Disease
immunodeficiency	O	I-Disease
disease	O	I-Disease
caused	B-Reg	O
by	O	O
activating	O	O
mutations	B-Var	O
in	O	O
either	O	O
the	O	O
leukocyte-restricted	O	O
p110δ	O	O
catalytic	O	O
(	O	O
PIK3CD	B-Gene	O
)	O	O
subunit	O	O
or	O	O
the	O	O
ubiquitously	O	O
expressed	O	O
p85α	O	O
regulatory	O	O
(	O	O
PIK3R1	O	O
)	O	O
subunit	O	O
of	O	O
class	O	O
IA	O	O
phosphoinositide	O	O
3-kinases	O	O
(	O	O
PI3Ks	O	O
)	O	O
.	O	O

There	O	O
are	O	O
two	O	O
classes	O	O
of	O	O
APDS	O	O
:	O	O
APDS1	O	O
that	O	O
arises	O	O
from	O	O
p110δ	O	O
mutations	O	O
that	O	O
are	O	O
analogous	O	O
to	O	O
oncogenic	O	O
mutations	O	O
found	O	O
in	O	O
the	O	O
broadly	O	O
expressed	O	O
p110α	O	O
subunit	O	O
and	O	O
APDS2	O	O
that	O	O
occurs	O	O
from	O	O
a	O	O
splice	O	O
mutation	O	O
resulting	O	O
in	O	O
p85α	O	O
with	O	O
a	O	O
central	O	O
deletion	O	O
(	O	O
Δ434-475	O	O
)	O	O
.	O	O

As	O	O
p85	O	O
regulatory	O	O
subunits	O	O
associate	O	O
with	O	O
and	O	O
inhibit	O	O
all	O	O
class	O	O
IA	O	O
catalytic	O	O
subunits	O	O
,	O	O
APDS2	O	O
mutations	O	O
are	O	O
expected	O	O
to	O	O
similarly	O	O
activate	O	O
p110α	O	O
,	O	O
β	O	O
,	O	O
and	O	O
δ	O	O
,	O	O
yet	O	O
APDS2	O	O
largely	O	O
phenocopies	O	O
APDS1	O	O
without	O	O
dramatic	O	O
effects	O	O
outside	O	O
the	O	O
immune	O	O
system	O	O
.	O	O

We	O	O
have	O	O
examined	O	O
the	O	O
molecular	O	O
mechanism	O	O
of	O	O
activation	O	O
of	O	O
both	O	O
classes	O	O
of	O	O
APDS	O	O
mutations	O	O
using	O	O
a	O	O
combination	O	O
of	O	O
biochemical	O	O
assays	O	O
and	O	O
hydrogen-deuterium	O	O
exchange	O	B-Var
mass	O	O
spectrometry	O	O
.	O	O

Intriguingly	O	O
,	O	O
we	O	O
find	O	O
that	O	O
an	O	O
APDS2	B-Gene	O
mutation	B-Var	O
in	O	O
p85α	O	O
leads	O	O
to	O	O
substantial	O	O
basal	O	O
activation	B-PosReg	O
of	O	O
p110δ	B-MPA	O
(	I-MPA	O
>	O	O
300-fold	O	O
)	O	O
and	O	O
disrupts	B-NegReg	B-MPA
inhibitory	B-MPA	I-MPA
interactions	I-MPA	I-MPA
N-cadherin	O	O
Regulation	O	O
of	O	O
Bone	O	O
Growth	O	O
and	O	O
Homeostasis	O	O
Is	O	O
Osteolineage	O	O
Stage-Specific	O	O
.	O	O

N-cadherin	O	O
inhibits	O	O
osteogenic	O	O
cell	O	O
differentiation	O	O
and	O	O
canonical	O	O
Wnt/β-catenin	O	O
signaling	O	O
in	O	O
vitro	O	O
.	O	O

However	O	O
,	O	O
in	O	O
vivo	O	O
both	O	O
conditional	O	O
Cdh2	O	O
ablation	O	O
and	O	O
overexpression	O	O
in	O	O
osteoblasts	O	O
lead	O	O
to	O	O
low	O	O
bone	O	O
mass	O	O
.	O	O

We	O	O
tested	O	O
the	O	O
hypothesis	O	O
that	O	O
N-cadherin	O	O
has	O	O
different	O	O
effects	O	O
on	O	O
osteolineage	O	O
cells	O	O
depending	O	O
upon	O	O
their	O	O
differentiation	O	O
stage	O	O
.	O	O

Embryonic	O	O
conditional	O	O
osteolineage	O	O
Cdh2	B-Gene	O
deletion	B-Var	O
in	O	O
mice	O	O
results	O	O
in	O	O
defective	B-NegReg	O
growth	B-MPA	O
,	O	O
low	B-NegReg	O
bone	B-MPA	O
mass	I-MPA	O
,	O	O
and	O	O
reduced	B-NegReg	B-NegReg
osteoprogenitor	B-MPA	B-CPA
number	I-MPA	O
MAX	O	O
inactivation	O	B-Var
is	O	O
an	O	O
early	O	O
event	O	O
in	O	O
GIST	O	O
development	O	O
that	O	O
regulates	O	O
p16	O	O
and	O	O
cell	O	B-CPA
proliferation	O	I-CPA
.	O	O

KIT	B-Gene	O
,	O	O
PDGFRA	B-Gene	O
,	O	O
NF1	B-Gene	O
and	O	O
SDH	B-Gene	O
mutations	B-Var	O
are	O	O
alternate	O	O
initiating	O	O
events	O	O
,	O	O
fostering	B-Reg	O
hyperplasia	O	O
in	O	O
gastrointestinal	B-MPA	O
stromal	I-MPA	O
tumours	I-MPA	O
ATR	B-Gene	O
Mutations	B-Var	B-Var
Promote	B-PosReg	B-PosReg
the	O	O
Growth	B-MPA	O
of	O	O
Melanoma	B-Disease	O
Tumors	I-Disease	O
by	O	O
Modulating	O	O
the	O	O
Immune	O	O
Microenvironment	O	O
.	O	O

Melanomas	O	O
accumulate	O	B-PosReg
a	O	O
high	O	O
burden	O	O
of	O	O
mutations	B-Var	O
that	O	O
could	O	O
potentially	O	O
generate	B-Reg	O
neoantigens	B-MPA	O
,	O	O
yet	O	O
somehow	O	O
suppress	B-NegReg	O
the	O	O
immune	B-MPA	O
response	I-MPA	O
to	I-MPA	O
facilitate	I-MPA	O
continued	I-MPA	O
growth	I-MPA	O
.	O	O

In	O	O
this	O	O
study	O	O
,	O	O
we	O	O
identify	O	O
a	O	O
subset	O	O
of	O	O
human	O	O
melanomas	O	O
that	O	O
have	O	O
loss-of-function	O	B-NegReg
mutations	O	B-Var
in	O	O
ATR	O	O
,	O	O
a	O	O
kinase	O	O
that	O	O
recognizes	O	O
and	O	O
repairs	O	O
UV-induced	O	O
DNA	O	O
damage	O	O
and	O	O
is	O	O
required	O	O
for	O	O
cellular	O	O
proliferation	O	O
.	O	O

ATR	B-Gene	O
mutant	B-Var	O
tumors	O	O
exhibit	O	O
both	O	O
the	O	O
accumulation	O	O
of	O	O
multiple	O	O
mutations	O	O
and	O	O
the	O	O
altered	O	O
expression	O	O
of	O	O
inflammatory	O	B-Gene
genes	O	O
,	O	O
resulting	O	O
in	O	O
decreased	B-NegReg	O
T	B-MPA	O
 	I-MPA	O
cell	O	O
recruitment	O	O
and	O	O
increased	B-PosReg	O
recruitment	B-MPA	O
of	I-MPA	O
macrophages	I-MPA	O
Regulation	O	O
of	O	O
endometrial	O	O
cell	O	B-CPA
proliferation	O	I-CPA
by	O	O
estrogen-induced	O	O
BDNF	O	O
signaling	O	O
pathway	O	O
.	O	O

Brain-derived	O	O
neurotrophic	O	O
factor	O	O
(	O	O
BDNF	O	O
)	O	O
is	O	O
a	O	O
member	O	O
of	O	O
the	O	O
neurotrophin	O	O
growth	O	O
factors	O	O
family	O	O
.	O	O

Recent	O	O
studies	O	O
indicated	O	O
that	O	O
the	O	O
level	O	O
of	O	O
BDNF	O	O
in	O	O
follicular	O	O
fluid	O	O
is	O	O
a	O	O
marker	O	O
for	O	O
oocyte	O	O
quality	O	O
and	O	O
infertility	O	O
.	O	O

Here	O	O
,	O	O
we	O	O
intend	O	O
to	O	O
further	O	O
investigate	O	O
the	O	O
function	O	O
of	O	O
BDNF	O	O
and	O	O
its	O	O
signaling	O	O
pathway	O	O
in	O	O
the	O	O
regulation	O	O
of	O	O
endometrial	O	O
cells	O	O
proliferation	O	O
.	O	O

We	O	O
found	O	O
that	O	O
BDNF	O	O
is	O	O
a	O	O
critical	O	O
growth	O	O
factor	O	O
in	O	O
endometrial	O	O
cells	O	O
.	O	O

Activation	O	O
of	O	O
signal	O	O
transducer	O	O
and	O	O
activator	O	O
of	O	O
transcription	O	O
3	O	O
signaling	O	O
pathway	O	O
is	O	O
required	O	O
for	O	O
BNDF-regulated	O	O
endometrial	O	O
cell	O	O
proliferation	O	O
.	O	O

Furthermore	O	O
,	O	O
BDNF	O	O
is	O	O
an	O	O
effector	O	O
of	O	O
estrogen	O	O
in	O	O
endometrial	O	O
cells	O	O
.	O	O

Finally	O	O
,	O	O
we	O	O
investigated	O	O
the	O	O
different	O	O
role	O	O
of	O	O
Val66Met	O	O
,	O	O
a	O	O
single-nucleotide	O	O
polymorphism	O	O
of	O	O
the	O	O
BDNF	O	O
gene	O	O
,	O	O
in	O	O
regulating	O	O
endometrial	O	O
cells	O	O
proliferation	O	O
.	O	O

The	O	O
results	O	O
showed	O	O
that	O	O
BDNF(V66	B-Gene	O
M	O	O
)	O	O
polymorphism	B-Var	O
is	O	O
a	O	O
loss-of-function	B-NegReg	B-NegReg
polymorphism	B-Var	O
in	O	O
the	O	O
regulation	B-MPA	O
of	I-MPA	O
endometrial	I-MPA	O
cells	I-MPA	O
growth	I-MPA	O
Impact	O	O
of	O	O
gain-of-function	B-PosReg	B-PosReg
mutations	B-Var	B-Var
in	O	O
the	O	O
low-density	O	O
lipoprotein	O	O
receptor-related	O	O
protein	O	O
5	O	O
(	O	O
LRP5	B-Gene	O
)	O	O
on	O	O
glucose	B-MPA	O
and	I-MPA	O
lipid	I-MPA	O
homeostasis	I-MPA	O
.	O	O

LRP5	B-Gene	O
loss-of-function	B-NegReg	B-NegReg
mutations	B-Var	B-Var
have	O	O
been	O	O
shown	O	O
to	O	O
cause	O	B-Reg
profound	B-MPA	B-Disease
osteoporosis	I-MPA	I-Disease
and	O	O
have	O	O
been	O	O
associated	O	O
with	O	O
impaired	B-MPA	B-NegReg
insulin	I-MPA	B-MPA
sensitivity	I-MPA	I-MPA
and	O	O
dysregulated	B-MPA	O
lipid	I-MPA	O
metabolism	I-MPA	O
.	O	O

We	O	O
hypothesized	O	O
that	O	O
gain-of-function	O	B-PosReg
mutations	O	B-Var
in	O	O
LRP5	O	O
would	O	O
also	O	O
affect	O	O
these	O	O
parameters	O	O
.	O	O

We	O	O
therefore	O	O
studied	O	O
individuals	O	O
with	O	O
LRP5	B-Gene	O
gain-of-function	B-PosReg	O
mutations	B-Var	O
exhibiting	O	O
high	O	O
bone	O	O
mass	O	O
(	O	O
HBM	O	O
)	O	O
phenotypes	O	O
and	O	O
found	O	O
that	O	O
while	O	O
there	O	O
was	O	O
no	O	O
detected	O	O
change	O	O
in	O	O
insulin	O	B-MPA
sensitivity	O	I-MPA
,	O	O
there	O	O
was	O	O
a	O	O
significant	O	O
reduction	B-NegReg	B-NegReg
in	O	O
serum	B-MPA	O
LDL	I-MPA	O
.	O	O

INTRODUCTION	O	O
:	O	O
Wnt	O	O
signaling	O	O
through	O	O
LRP5	O	O
represents	O	O
a	O	O
newly	O	O
appreciated	O	O
metabolic	O	O
pathway	O	O
,	O	O
which	O	O
potentially	O	O
represents	O	O
a	O	O
target	O	O
for	O	O
drug	O	O
discovery	O	O
in	O	O
type	O	O
2	O	O
diabetes	O	O
and	O	O
hyperlipidemia	O	B-Disease
.	O	O

Studies	O	O
in	O	O
animal	O	O
models	O	O
suggest	O	O
a	O	O
physiologic	O	O
link	O	O
between	O	O
LRP5	O	O
and	O	O
glucose	O	O
and	O	O
lipid	O	O
homeostasis	O	O
;	O	O
however	O	O
,	O	O
whether	O	O
it	O	O
plays	O	O
a	O	O
similar	O	O
role	O	O
in	O	O
humans	O	O
is	O	O
unclear	O	O
.	O	O

As	O	O
current	O	O
literature	O	O
links	O	O
loss-of-function	O	O
LRP5	O	O
to	O	O
impaired	O	B-NegReg
glucose	O	B-MPA
and	O	O
lipid	O	O
metabolism	O	O
,	O	O
we	O	O
hypothesized	O	O
that	O	O
individuals	O	O
with	O	O
an	O	O
HBM-causing	O	O
mutation	O	O
in	O	O
LRP5	O	O
would	O	O
exhibit	O	O
improved	O	O
glucose	O	O
and	O	O
lipid	O	O
homeostasis	O	O
.	O	O

Since	O	O
studies	O	O
in	O	O
animal	O	O
models	O	O
have	O	O
suggested	O	O
that	O	O
Wnt	O	O
signaling	O	O
augments	O	B-PosReg
insulin	O	B-MPA
secretion	O	I-MPA
,	O	O
we	O	O
also	O	O
examined	O	O
the	O	O
effect	O	O
of	O	O
Wnt	O	O
signaling	O	O
on	O	O
glucose-stimulated	O	O
insulin	O	O
secretion	O	O
on	O	O
human	O	O
pancreatic	O	O
islets	O	O
.	O	O

METHODS	O	O
:	O	O
This	O	O
was	O	O
a	O	O
matched	O	O
case-control	O	O
study	O	O
.	O	O

We	O	O
used	O	O
several	O	O
methods	O	O
to	O	O
assess	O	O
glucose	O	O
and	O	O
lipid	O	O
metabolism	O	O
in	O	O
11	O	O
individuals	O	O
with	O	O
HBM-causing	O	O
mutations	O	O
in	O	O
LRP5	O	O
.	O	O

Affected	O	O
study	O	O
participants	O	O
were	O	O
recruited	O	O
from	O	O
previously	O	O
identified	O	O
kindreds	O	O
with	O	O
HBM-causing	O	O
LRP5	O	O
mutations	O	O
and	O	O
included	O	O
9	O	O
males	O	O
and	O	O
2	O	O
females	O	O
.	O	O

Two	O	O
subjects	O	O
that	O	O
were	O	O
being	O	O
treated	O	O
with	O	O
insulin	O	O
for	O	O
type	O	O
2	O	O
diabetes	O	O
were	O	O
excluded	O	O
from	O	O
our	O	O
analysis	O	O
,	O	O
as	O	O
this	O	O
would	O	O
have	O	O
obscured	O	O
our	O	O
ability	O	O
to	O	O
determine	O	O
the	O	O
impact	O	O
of	O	O
gain-of-function	O	O
LRP5	O	O
mutations	O	O
on	O	O
glucose	O	O
metabolism	O	O
.	O	O

The	O	O
mean	O	O
age	O	O
of	O	O
the	O	O
evaluated	O	O
study	O	O
subjects	O	O
was	O	O
55	O	O
 	O	O
±	O	O
 	O	O
7	O	O
with	O	O
a	O	O
mean	O	O
BMI	O	O
of	O	O
27.2	O	O
 	O	O
±	O	O
 	O	O
2.0	O	O
.	O	O

Control	O	O
subjects	O	O
were	O	O
matched	O	O
and	O	O
recruited	O	O
from	O	O
the	O	O
general	O	O
community	O	O
at	O	O
an	O	O
equivalent	O	O
ratio	O	O
,	O	O
with	O	O
18	O	O
males	O	O
and	O	O
4	O	O
females	O	O
(	O	O
mean	O	O
age	O	O
56	O	O
 	O	O
±	O	O
 	O	O
4	O	O
;	O	O
mean	O	O
BMI	O	O
27.2	O	O
 	O	O
±	O	O
 	O	O
1.0	O	O
)	O	O
.	O	O

Study	O	O
testing	O	O
was	O	O
conducted	O	O
at	O	O
an	O	O
academic	O	O
medical	O	O
center	O	O
.	O	O

RESULTS	O	O
:	O	O
There	O	O
were	O	O
no	O	O
statistically	O	O
significant	O	O
differences	O	O
between	O	O
affected	O	O
and	O	O
matched	O	O
control	O	O
populations	O	O
for	O	O
HbA1c	O	O
(	O	O
p	O	B-Var
 	O	O
=	O	O
 	O	O
0.06	O	O
)	O	O
,	O	O
eAG	O	O
(	O	O
p	O	B-Var
 	O	O
=	O	O
 	O	O
0.06	O	O
)	O	O
,	O	O
insulin	O	O
(	O	O
p	O	B-Var
 	O	O
=	O	O
 	O	O
0.82	O	O
)	O	O
,	O	O
HOMA-B	O	O
(	O	O
p	O	B-Var
 	O	O
=	O	O
 	O	O
0.34	O	O
)	O	O
,	O	O
or	O	O
HOMA-IR	O	O
(	O	O
p	O	B-Var
 	O	O
=	O	O
 	O	O
0.66	O	O
)	O	O
.	O	O

The	O	O
mean	O	O
Insulin	O	B-MPA
Sensitivity	O	I-MPA
Index	O	I-MPA
(	O	O
ISI	O	O
)	O	O
was	O	O
also	O	O
similar	O	O
between	O	O
control	O	O
and	O	O
affected	O	O
individuals	O	O
.	O	O

Total	O	O
cholesterol	O	O
(	O	O
p	O	B-Var
 	O	O
=	O	O
 	O	O
0.43	O	O
)	O	O
,	O	O
triglycerides	O	O
(	O	O
TG	O	O
)	O	O
(	O	O
p	O	B-Var
 	O	O
=	O	O
 	O	O
0.56	O	O
)	O	O
,	O	O
and	O	O
HDL	O	O
(	O	O
p	O	B-Var
 	O	O
=	O	O
 	O	O
0.32	O	O
)	O	O
were	O	O
not	O	O
different	O	O
between	O	O
the	O	O
same	O	O
two	O	O
groups	O	O
.	O	O

In	O	O
a	O	O
small	O	O
subset	O	O
of	O	O
studied	O	O
subjects	O	O
,	O	O
intramyocellular	O	O
and	O	O
hepatic	O	O
lipid	O	O
content	O	O
were	O	O
similar	O	O
in	O	O
the	O	O
affected	O	O
individuals	O	O
and	O	O
controls	O	O
when	O	O
quantified	O	O
by	O	O
proton	O	O
magnetic	O	O
resonance	O	O
spectroscopy	O	O
(	O	O
MRS	O	O
)	O	O
.	O	O

However	O	O
,	O	O
the	O	O
mean	O	O
value	O	O
for	O	O
serum	O	O
LDL	O	O
was	O	O
significantly	O	O
lower	O	B-NegReg
(	O	O
p	O	B-Var
 	O	O
=	O	O
 	O	O
0.04	O	O
)	O	O
in	O	O
affected	O	O
individuals	O	O
.	O	O

In	O	O
primary	O	O
human	O	O
islets	O	O
,	O	O
there	O	O
were	O	O
no	O	O
differences	O	O
between	O	O
control	O	O
and	O	O
Wnt	O	O
treatment	O	O
groups	O	O
for	O	O
insulin	O	O
secretion	O	O
measured	O	O
as	O	O
area	O	O
under	O	O
the	O	O
curve	O	O
(	O	O
AUC	O	O
)	O	O
for	O	O
first	O	O
phase	O	O
(	O	O
p	O	B-Var
 	O	O
=	O	O
 	O	O
0.17	O	O
)	O	O
or	O	O
second	O	O
phase	O	O
(	O	O
p	O	B-Var
 	O	O
=	O	O
 	O	O
0.33	O	O
)	O	O
insulin	O	O
secretion	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Although	O	O
our	O	O
sample	O	O
size	O	O
was	O	O
small	O	O
,	O	O
our	O	O
data	O	O
do	O	O
not	O	O
support	O	O
the	O	O
hypothesis	O	O
that	O	O
HBM-causing	O	O
LRP5	O	O
mutations	O	O
,	O	O
associated	O	O
with	O	O
increased	O	O
Wnt	O	O
signaling	O	O
,	O	O
improve	O	O
glucose	O	O
metabolism	O	O
in	O	O
humans	O	O
.	O	O

However	O	O
,	O	O
it	O	O
does	O	O
appear	O	O
that	O	O
LRP5	B-Gene	O
variants	B-Var	O
may	O	O
affect	B-Reg	O
LDL	B-MPA	O
metabolism	I-MPA	O
The	O	O
Microtubule-Associated	O	O
Protein	O	O
MAP18	O	O
Affects	O	O
ROP2	O	O
GTPase	O	O
Activity	O	O
during	O	O
Root	O	O
Hair	O	O
Growth	O	O
.	O	O

Establishment	O	O
and	O	O
maintenance	O	O
of	O	O
the	O	O
polar	O	B-Var
site	O	I-Var
are	O	O
important	O	O
for	O	O
root	O	O
hair	O	O
tip	O	O
growth	O	O
.	O	O

We	O	O
previously	O	O
reported	O	O
that	O	O
Arabidopsis	O	O
(	O	O
Arabidopsis	O	O
thaliana	O	O
)	O	O
MICROTUBULE-ASSOCIATED	O	O
PROTEIN18	O	O
(	O	O
MAP18	O	O
)	O	O
functions	O	O
in	O	O
controlling	O	O
the	O	O
direction	O	O
of	O	O
pollen	O	O
tube	O	O
growth	O	O
and	O	O
root	O	O
hair	O	O
elongation	O	O
.	O	O

Additionally	O	O
,	O	O
the	O	O
Rop	O	O
GTPase	O	O
ROP2	O	O
was	O	O
reported	O	O
as	O	O
a	O	O
positive	O	O
regulator	O	O
of	O	O
both	O	O
root	O	O
hair	O	O
initiation	O	O
and	O	O
tip	O	O
growth	O	O
in	O	O
Arabidopsis	O	O
.	O	O

Both	O	O
loss	B-NegReg	B-NegReg
of	I-NegReg	I-NegReg
function	I-NegReg	I-NegReg
of	O	O
ROP2	B-Gene	O
and	O	O
knockdown	B-Var	O
of	O	O
MAP18	B-Gene	O
lead	O	B-Reg
to	O	I-Reg
a	O	O
decrease	B-NegReg	O
in	O	O
root	B-MPA	B-CPA
hair	I-MPA	I-CPA
length	I-MPA	I-CPA
A	O	O
Ras	O	O
GTPase	O	O
associated	O	O
protein	O	O
is	O	O
involved	O	O
in	O	O
the	O	O
phototropic	O	O
and	O	O
circadian	O	O
photobiology	O	O
responses	O	O
in	O	O
fungi	O	O
.	O	O

Light	O	O
is	O	O
an	O	O
environmental	O	O
signal	O	O
perceived	O	O
by	O	O
most	O	O
eukaryotic	O	O
organisms	O	O
and	O	O
that	O	O
can	O	O
have	O	O
major	O	O
impacts	O	O
on	O	O
their	O	O
growth	O	O
and	O	O
development	O	O
.	O	O

The	O	O
MadC	O	O
protein	O	O
in	O	O
the	O	O
fungus	O	O
Phycomyces	O	O
blakesleeanus	O	O
(	O	O
Mucoromycotina	O	O
)	O	O
has	O	O
been	O	O
postulated	O	O
to	O	O
form	O	O
part	O	O
of	O	O
the	O	O
photosensory	O	O
input	O	O
for	O	O
phototropism	O	O
of	O	O
the	O	O
fruiting	O	O
body	O	O
sporangiophores	O	O
,	O	O
but	O	O
the	O	O
madC	O	O
gene	O	O
has	O	O
remained	O	O
unidentified	O	O
since	O	O
the	O	O
1960s	O	O
when	O	O
madC	O	O
mutants	O	O
were	O	O
first	O	O
isolated	O	O
.	O	O

In	O	O
this	O	O
study	O	O
the	O	O
madC	O	O
gene	O	O
was	O	O
identified	O	O
by	O	O
positional	O	O
cloning	O	O
.	O	O

All	O	O
madC	O	O
mutant	O	B-Var
strains	O	O
contain	O	O
loss-of-function	O	B-NegReg
point	O	O
mutations	O	O
within	O	O
a	O	O
gene	O	O
predicted	O	O
to	O	O
encode	O	O
a	O	O
GTPase	O	O
activating	O	O
protein	O	O
(	O	O
GAP	O	O
)	O	O
for	O	O
Ras	O	O
.	O	O

The	O	O
madC	O	O
gene	O	O
complements	O	O
the	O	O
Saccharomyces	O	O
cerevisiae	O	O
Ras-GAP	O	O
ira1	O	O
mutant	O	O
and	O	O
the	O	O
encoded	O	O
MadC	O	O
protein	O	O
interacts	O	O
with	O	O
P.	O	O
blakesleeanus	O	O
Ras	O	O
homologs	O	O
in	O	O
yeast	O	O
two-hybrid	O	O
assays	O	O
,	O	O
indicating	O	O
that	O	O
MadC	O	O
is	O	O
a	O	O
regulator	O	O
of	O	O
Ras	O	O
signaling	O	O
.	O	O

Deletion	B-Var	B-Var
of	O	O
the	O	O
homolog	O	O
in	O	O
the	O	O
filamentous	O	O
ascomycete	O	O
Neurospora	O	O
crassa	O	O
affects	B-Reg	O
the	O	O
circadian	B-MPA	O
clock	I-MPA	O
output	I-MPA	O
,	O	O
yielding	B-Reg	O
a	O	O
pattern	O	O
of	O	O
asexual	B-MPA	O
conidiation	I-MPA	O
Paradoxical	O	O
gain-of-function	O	O
mutant	O	O
of	O	O
the	O	O
G-protein-coupled	O	O
receptor	O	O
PROKR2	O	O
promotes	O	O
early	O	O
puberty	O	O
.	O	O

The	O	O
human	O	O
genome	O	O
encodes	O	O
~750	O	O
G-protein-coupled	O	O
receptors	O	O
(	O	O
GPCRs	O	O
)	O	O
,	O	O
including	O	O
prokineticin	O	O
receptor	O	O
2	O	O
(	O	O
PROKR2	O	O
)	O	O
involved	O	O
in	O	O
the	O	O
regulation	O	O
of	O	O
sexual	O	O
maturation	O	O
.	O	O

Previously	O	O
reported	O	O
pathogenic	O	O
gain-of-function	O	O
mutations	O	O
of	O	O
GPCR	O	O
genes	O	O
invariably	O	O
encoded	O	O
aberrant	O	O
receptors	O	O
with	O	O
excessive	O	O
signal	O	O
transduction	O	O
activity	O	O
.	O	O

Although	O	O
in	O	O
vitro	O	O
assays	O	O
demonstrated	O	O
that	O	O
an	O	O
artificially	O	O
created	O	O
inactive	O	O
mutant	O	O
of	O	O
PROKR2	O	O
exerted	O	O
paradoxical	O	O
gain-of-function	O	O
effects	O	O
when	O	O
co-transfected	O	O
with	O	O
wild-type	O	O
proteins	O	O
,	O	O
such	O	O
a	O	O
phenomenon	O	O
has	O	O
not	O	O
been	O	O
observed	O	O
in	O	O
vivo	O	O
.	O	O

Here	O	O
,	O	O
we	O	O
report	O	O
a	O	O
heterozygous	O	O
frameshift	O	B-Var
mutation	O	O
of	O	O
PROKR2	O	O
identified	O	O
in	O	O
a	O	O
3.5-year-old	O	O
girl	O	O
with	O	O
central	O	O
precocious	O	O
puberty	O	O
.	O	O

The	O	O
mutant	B-Var	O
mRNA	O	O
escaped	B-NegReg	O
nonsense-mediated	B-MPA	O
decay	I-MPA	O
and	O	O
generated	O	O
a	O	O
GPCR	O	O
lacking	B-NegReg	O
two	B-MPA	O
transmembrane	I-MPA	O
domains	I-MPA	O
and	O	O
the	O	O
carboxyl-terminal	O	O
tail	O	O
.	O	O

The	O	O
mutant	O	O
protein	O	O
had	O	O
no	O	O
in	O	O
vitro	O	O
signal	O	O
transduction	O	O
activity	O	O
;	O	O
however	O	O
,	O	O
cells	O	O
co-expressing	O	O
the	O	O
mutant	O	O
and	O	O
wild-type	O	O
PROKR2	O	O
exhibited	O	O
markedly	O	O
exaggerated	O	O
ligand-induced	O	O
Ca(2	O	O
+	O	O
)	O	O
responses	O	O
.	O	O

The	O	O
results	O	O
indicate	O	O
that	O	O
certain	O	O
inactive	O	O
PROKR2	B-Gene	O
mutants	B-Var	O
can	O	O
cause	O	O
early	O	O
puberty	O	O
by	O	O
enhancing	B-PosReg	O
the	O	O
functional	B-MPA	O
property	I-MPA	O
of	I-MPA	O
coexisting	I-MPA	O
wild-type	I-MPA	O
proteins	I-MPA	O
The	O	O
Tension-sensitive	O	O
Ion	O	O
Transport	O	O
Activity	O	O
of	O	O
MSL8	O	O
is	O	O
Critical	O	O
for	O	O
its	O	O
Function	O	O
in	O	O
Pollen	O	O
Hydration	O	O
and	O	O
Germination	O	O
.	O	O

All	O	O
cells	O	O
respond	O	O
to	O	O
osmotic	O	O
challenges	O	O
,	O	O
including	O	O
those	O	O
imposed	O	O
during	O	O
normal	O	O
growth	O	O
and	O	O
development	O	O
.	O	O

Mechanosensitive	O	O
(	O	O
MS	O	O
)	O	O
ion	O	O
channels	O	O
provide	O	O
a	O	O
conserved	O	O
mechanism	O	O
for	O	O
regulating	O	O
osmotic	O	O
forces	O	O
by	O	O
conducting	O	O
ions	O	O
in	O	O
response	O	O
to	O	O
increased	O	B-PosReg
membrane	O	B-MPA
tension	O	I-MPA
.	O	O

We	O	O
previously	O	O
demonstrated	O	O
that	O	O
the	O	O
MS	O	O
ion	O	O
channel	O	O
MscS-Like	O	O
8	O	O
(	O	O
MSL8	O	O
)	O	O
is	O	O
required	O	O
for	O	O
pollen	O	O
to	O	O
survive	O	O
multiple	O	O
osmotic	O	O
challenges	O	O
that	O	O
occur	O	O
during	O	O
the	O	O
normal	O	O
process	O	O
of	O	O
fertilization	O	O
,	O	O
and	O	O
that	O	O
it	O	O
can	O	O
inhibit	O	O
pollen	O	O
germination	O	O
.	O	O

However	O	O
,	O	O
it	O	O
remained	O	O
unclear	O	O
whether	O	O
these	O	O
physiological	O	O
functions	O	O
required	O	O
ion	O	O
flux	O	O
through	O	O
a	O	O
mechanically	O	O
gated	O	O
channel	O	O
provided	O	O
by	O	O
MSL8	O	O
.	O	O

We	O	O
introduced	O	O
two	O	O
point	O	O
mutations	B-Var	O
into	O	O
the	O	O
predicted	O	O
pore-lining	O	O
domain	O	O
of	O	O
MSL8	B-Gene	O
that	O	O
disrupted	B-NegReg	O
normal	B-Pathway	O
channel	I-Pathway	O
function	I-Pathway	O
in	O	O
different	O	O
ways	O	O
.	O	O

The	O	O
Ile711Ser	B-Var	O
mutation	I-Var	B-Var
increased	B-PosReg	B-PosReg
the	O	O
tension	B-MPA	O
threshold	I-MPA	O
of	O	O
the	O	O
MSL8	B-Gene	O
channel	O	O
while	O	O
leaving	B-Reg	O
conductance	B-MPA	O
unchanged	I-MPA	O
,	O	O
and	O	O
the	O	O
Phe720Leu	B-Var	O
mutation	I-Var	O
severely	O	O
disrupted	B-NegReg	O
the	O	O
MSL8	B-Gene	O
channel	B-Pathway	O
.	O	O

Both	O	O
of	O	O
these	O	O
mutations	B-Var	B-Var
impaired	B-NegReg	B-NegReg
the	O	O
ability	B-MPA	O
of	I-MPA	O
MSL8	I-MPA	O
to	I-MPA	O
preserve	I-MPA	O
pollen	I-MPA	O
viability	I-MPA	O
during	I-MPA	O
hydration	I-MPA	O
and	O	O
to	O	O
maintain	B-Reg	O
the	O	O
integrity	B-MPA	O
of	I-MPA	O
the	I-MPA	O
pollen	I-MPA	O
tube	I-MPA	O
RACK1	O	O
cooperates	O	O
with	O	O
NRAS(Q61	O	O
K	O	O
)	O	O
to	O	O
promote	O	B-PosReg
melanoma	O	B-Disease
in	O	O
vivo	O	O
.	O	O

Melanoma	O	O
is	O	O
the	O	O
deadliest	O	O
skin	O	O
cancer	O	O
.	O	O

RACK1	O	O
(	O	O
Receptor	O	O
for	O	O
activated	O	O
protein	O	O
kinase	O	O
C	O	O
)	O	O
protein	O	O
was	O	O
proposed	O	O
as	O	O
a	O	O
biological	O	O
marker	O	O
of	O	O
melanoma	O	O
in	O	O
human	O	O
and	O	O
domestic	O	O
animal	O	O
species	O	O
harboring	O	O
spontaneous	O	O
melanomas	O	O
.	O	O

As	O	O
a	O	O
scaffold	O	O
protein	O	O
,	O	O
RACK1	O	O
is	O	O
able	O	O
to	O	O
coordinate	O	O
the	O	O
interaction	O	O
of	O	O
key	O	O
signaling	O	O
molecules	O	O
implicated	O	O
in	O	O
both	O	O
physiological	O	O
cellular	O	O
functions	O	O
and	O	O
tumorigenesis	O	O
.	O	O

A	O	O
role	O	O
for	O	O
RACK1	O	O
in	O	O
rewiring	O	O
ERK	O	O
and	O	O
JNK	O	O
signaling	O	O
pathways	O	O
in	O	O
melanoma	O	O
cell	O	O
lines	O	O
had	O	O
been	O	O
proposed	O	O
.	O	O

Here	O	O
,	O	O
we	O	O
used	O	O
a	O	O
genetic	O	O
approach	O	O
to	O	O
test	O	O
this	O	O
hypothesis	O	O
in	O	O
vivo	O	O
in	O	O
the	O	O
mouse	O	O
.	O	O

We	O	O
show	O	O
that	O	O
Rack1	B-Gene	O
knock-down	B-Var	O
in	O	O
the	O	O
mouse	O	O
melanoma	O	O
cell	O	O
line	O	O
B16	O	O
reduces	B-NegReg	B-NegReg
invasiveness	B-MPA	B-CPA
and	O	O
induces	B-Reg	O
cell	B-MPA	O
differentiation	I-MPA	O
Identification	O	O
and	O	O
characterization	O	O
of	O	O
a	O	O
novel	O	O
DGAT1	O	O
missense	O	O
mutation	O	O
associated	O	O
with	O	O
congenital	O	B-Disease
diarrhea	O	I-Disease
.	O	O

Acyl-CoA	O	O
:	O	O
diacylglycerol	O	O
acyltransferase	O	O
(	O	O
DGAT)1	O	O
and	O	O
DGAT2	O	O
catalyze	O	O
triglyceride	O	O
(	O	O
TG	O	O
)	O	O
biosynthesis	O	O
in	O	O
humans	O	O
.	O	O

Biallelic	O	O
loss-of-function	B-NegReg	B-NegReg
mutations	B-Var	B-Var
in	O	O
human	O	O
DGAT1	B-Gene	O
result	O	O
in	O	O
severe	O	B-Disease
congenital	B-Disease	I-Disease
diarrhea	I-Disease	I-Disease
and	O	O
protein-losing	B-Disease	O
enteropathy	I-Disease	O
.	O	O

Additionally	O	O
,	O	O
pharmacologic	O	O
inhibition	O	O
of	O	O
DGAT1	O	O
led	O	O
to	O	O
dose-related	O	O
diarrhea	O	B-Disease
in	O	O
human	O	O
clinical	O	O
trials	O	O
.	O	O

Here	O	O
we	O	O
identify	O	O
a	O	O
previously	O	O
unknown	O	O
DGAT1	O	O
mutation	O	O
in	O	O
identical	O	O
twins	O	O
of	O	O
South	O	O
Asian	O	O
descent	O	O
.	O	O

These	O	O
male	O	O
patients	O	O
developed	O	O
watery	O	O
diarrhea	O	B-Disease
shortly	O	O
after	O	O
birth	O	O
,	O	O
with	O	O
protein-losing	O	O
enteropathy	O	O
and	O	O
failure	O	O
to	O	O
thrive	O	O
.	O	O

Exome	O	O
sequencing	O	O
revealed	O	O
a	O	O
homozygous	O	O
recessive	O	O
mutation	O	B-Var
in	O	O
DGAT1	O	O
,	O	O
c.314T	O	B-Var
>	O	O
C	O	O
,	O	O
p	O	B-Var
.	O	O

L105P.	O	O
We	O	O
show	O	O
here	O	O
that	O	O
the	O	O
p	B-Var	B-Var
.	O	O

L105P	O	O
DGAT1	B-Gene	O
enzyme	O	O
produced	O	O
from	O	O
the	O	O
mutant	B-Var	O
allele	O	O
is	O	O
less	B-NegReg	O
abundant	O	O
,	O	O
resulting	O	O
in	O	O
partial	O	B-Gene
loss	B-NegReg	B-NegReg
of	O	O
TG	B-MPA	O
synthesis	I-MPA	O
activity	I-MPA	O
and	O	O
decreased	B-NegReg	O
formation	B-MPA	O
of	I-MPA	O
lipid	I-MPA	O
droplets	I-MPA	O
in	O	O
patient-derived	O	O
primary	O	O
dermal	O	O
fibroblasts	O	O
.	O	O

Thus	O	O
,	O	O
in	O	O
contrast	O	O
with	O	O
complete	O	O
loss-of-function	O	B-NegReg
alleles	O	O
of	O	O
DGAT1	O	O
,	O	O
the	O	O
p	B-Var	B-Var
.	I-Var	O
L105P	O	O
missense	O	O
allele	O	O
partially	O	O
reduces	B-NegReg	B-NegReg
TG	B-MPA	B-MPA
synthesis	I-MPA	I-MPA
activity	I-MPA	I-MPA
and	O	O
causes	B-Reg	O
a	O	O
less	B-MPA	O
severe	I-MPA	O
clinical	I-MPA	O
phenotype	I-MPA	O
.	O	O

Our	O	O
findings	O	O
add	O	O
to	O	O
the	O	O
growing	O	O
recognition	O	O
of	O	O
DGAT1	B-Gene	O
deficiency	B-Var	O
as	O	O
a	O	O
cause	B-Reg	B-Reg
of	O	B-Disease
congenital	B-Disease	I-Disease
diarrhea	I-Disease	I-Disease
with	O	O
protein-losing	B-Disease	O
enteropathy	I-Disease	O
and	O	O
indicate	O	O
that	O	O
DGAT1	B-Gene	O
mutations	B-Var	O
result	B-Reg	O
in	I-Reg	O
a	O	O
spectrum	B-Disease	O
of	I-Disease	O
diseases	I-Disease	O
Hydrocephalus	B-Disease	O
due	O	O
to	O	O
multiple	O	O
ependymal	O	O
malformations	O	O
is	O	O
caused	B-Reg	O
by	I-Reg	O
mutations	B-Var	B-Var
in	O	O
the	O	O
MPDZ	B-Gene	O
gene	O	O
.	O	O

Congenital	O	O
hydrocephalus	O	O
is	O	O
considered	O	O
as	O	O
either	O	O
acquired	O	O
due	O	O
to	O	O
haemorrhage	O	O
,	O	O
infection	O	O
or	O	O
neoplasia	O	O
or	O	O
as	O	O
of	O	O
developmental	O	O
nature	O	O
and	O	O
is	O	O
divided	O	O
into	O	O
two	O	O
subgroups	O	O
,	O	O
communicating	O	O
and	O	O
obstructive	O	O
.	O	O

Congenital	O	O
hydrocephalus	O	O
is	O	O
either	O	O
syndromic	O	O
or	O	O
non-syndromic	O	O
,	O	O
and	O	O
in	O	O
the	O	O
latter	O	O
no	O	O
cause	O	O
is	O	O
found	O	O
in	O	O
more	O	O
than	O	O
half	O	O
of	O	O
the	O	O
patients	O	O
.	O	O

In	O	O
patients	O	O
with	O	O
isolated	B-Disease	O
hydrocephalus	I-Disease	O
,	O	O
L1CAM	B-Gene	O
mutations	B-Var	O
represent	O	O
the	O	O
most	O	O
common	B-Reg	O
Short	O	O
hairpin	O	O
RNA	O	O
is	O	O
more	O	O
effective	O	O
than	O	O
long	O	O
hairpin	O	O
RNA	O	O
in	O	O
eliciting	O	O
pointed	O	O
loss-of-function	O	O
phenotypes	O	O
in	O	O
Drosophila	O	O
.	O	O

Pointed	O	O
(	O	O
Pnt	O	O
)	O	O
is	O	O
a	O	O
transcriptional	O	O
activator	O	O
that	O	O
functions	O	O
downstream	O	O
of	O	O
the	O	O
highly	O	O
conserved	O	O
Receptor	O	O
Tyrosine	O	O
Kinase	O	O
(	O	O
RTK	O	O
)	O	O
signaling	O	O
pathway	O	O
.	O	O

Pnt	O	O
is	O	O
an	O	O
ETS	O	O
family	O	O
transcription	O	O
factor	O	O
and	O	O
encodes	O	O
for	O	O
two	O	O
proteins	O	O
,	O	O
PntP1	O	O
and	O	O
PntP2	O	O
.	O	O

However	O	O
,	O	O
while	O	O
PntP1	O	O
is	O	O
constitutively	O	O
active	O	O
,	O	O
PntP2	O	O
is	O	O
only	O	O
active	O	O
after	O	O
being	O	O
phosphorylated	O	O
by	O	O
MAPK	O	O
in	O	O
the	O	O
RTK	O	O
pathway	O	O
.	O	O

As	O	O
mutations	B-Var	O
in	O	O
pnt	B-Gene	O
perturb	B-Reg	O
the	O	O
development	B-CPA	O
of	I-CPA	O
several	I-CPA	O
tissues	I-CPA	O
New	O	O
gain-of-function	B-PosReg	O
mutation	B-Var	O
shows	O	O
CACNA1D	B-Gene	O
as	O	O
recurrently	O	O
mutated	O	O
gene	O	O
in	O	O
autism	B-Disease	O
spectrum	I-Disease	O
disorders	I-Disease	O
and	O	O
epilepsy	B-Disease	B-Disease
.	O	O

CACNA1D	O	O
encodes	O	O
the	O	O
pore-forming	O	O
α1-subunit	O	O
of	O	O
Cav1.3	O	O
,	O	O
an	O	O
L-type	O	O
voltage-gated	O	O
Ca2	O	O
+	O	O
-channel	O	O
.	O	O

Despite	O	O
the	O	O
recent	O	O
discovery	O	O
of	O	O
two	O	O
de	O	O
novo	O	O
missense	O	B-Gene
gain-of-function	O	B-PosReg
mutations	O	B-Var
in	O	O
Cav1.3	O	O
in	O	O
two	O	O
individuals	O	O
with	O	O
autism	O	B-Disease
spectrum	O	I-Disease
disorder	O	I-Disease
(	O	O
ASD	O	O
)	O	O
and	O	O
intellectual	O	B-Disease
disability	O	I-Disease
CACNA1D	O	O
has	O	O
not	O	O
been	O	O
considered	O	O
a	O	O
prominent	O	O
ASD-risk	O	O
gene	O	O
in	O	O
large	O	O
scale	O	O
genetic	O	O
analyses	O	O
,	O	O
since	O	O
such	O	O
studies	O	O
primarly	O	O
focus	O	O
on	O	O
likely-disruptive	O	O
genetic	O	O
variants	O	O
.	O	O

Here	O	O
we	O	O
report	O	O
the	O	O
discovery	O	O
and	O	O
characterization	O	O
of	O	O
a	O	O
third	O	O
de	O	O
novo	O	O
missense	O	O
mutation	O	O
in	O	O
CACNA1D	O	O
(	O	O
V401L	O	O
)	O	O
in	O	O
a	O	O
patient	O	O
with	O	O
ASD	O	O
and	O	O
epilepsy	O	B-Disease
.	O	O

For	O	O
the	O	O
functional	O	O
characterization	O	O
we	O	O
introduced	O	O
mutation	O	O
V401L	O	O
into	O	O
two	O	O
major	O	O
C-terminal	O	B-MPA
long	O	I-MPA
and	O	O
short	O	O
Cav1.3	O	O
splice	O	O
variants	O	O
,	O	O
expressed	O	O
wild-type	O	O
or	O	O
mutant	O	O
channel	O	O
complexes	O	O
in	O	O
tsA-201	O	O
cells	O	O
and	O	O
performed	O	O
whole-cell	O	O
patch-clamp	O	O
recordings	O	O
.	O	O

Mutation	O	O
V401L	B-Var	O
,	O	O
localized	O	O
within	O	O
the	O	O
channel	O	O
's	O	O
activation	O	O
gate	O	O
,	O	O
significantly	O	O
enhanced	B-PosReg	B-PosReg
current	B-MPA	B-CPA
densities	I-MPA	I-CPA
,	O	O
shifted	O	O
voltage	O	O
dependence	O	O
of	O	O
activation	O	O
and	O	O
inactivation	O	B-Var
to	O	O
more	O	O
negative	O	O
voltages	O	O
and	O	O
reduced	O	B-NegReg
channel	O	B-MPA
inactivation	O	I-MPA
in	O	O
both	O	O
Cav1.3	O	O
splice	O	O
variants	O	O
.	O	O

Altogether	O	O
these	O	O
gating	O	O
changes	B-Var	O
are	O	O
expected	O	O
to	O	O
result	O	O
in	O	O
enhanced	B-PosReg	B-PosReg
Ca2	B-MPA	B-MPA
+	I-MPA	I-MPA
-influx	I-MPA	O
through	I-MPA	O
Proteomic	O	O
analysis	O	O
of	O	O
filaggrin	O	O
deficiency	O	O
identifies	O	O
molecular	O	O
signatures	O	O
characteristic	O	O
of	O	O
atopic	O	B-Disease
eczema	O	I-Disease
.	O	O

BACKGROUND	O	O
:	O	O
Atopic	B-Disease	O
eczema	I-Disease	O
(	O	O
AE	O	O
)	O	O
is	O	O
characterized	O	O
by	O	O
skin	O	O
barrier	O	O
and	O	O
immune	O	O
dysfunction	O	O
.	O	O

Null	B-Var	B-Var
mutations	I-Var	I-Var
in	O	O
filaggrin	O	O
(	O	O
FLG	B-Gene	B-Gene
)	O	O
,	O	O
a	O	O
key	O	O
epidermal	O	O
barrier	O	O
protein	O	O
,	O	O
strongly	O	O
predispose	B-Reg	O
to	O	O
AE	B-Disease	O
;	O	O
however	O	O
,	O	O
the	O	O
precise	O	O
role	O	O
of	O	O
FLG	O	B-Gene
deficiency	O	B-NegReg
in	O	O
AE	O	O
pathogenesis	O	O
remains	O	O
incompletely	O	O
understood	O	O
.	O	O

OBJECTIVES	O	O
:	O	O
We	O	O
sought	O	O
to	O	O
identify	O	O
global	O	O
proteomic	O	O
changes	O	O
downstream	O	O
of	O	O
FLG	O	B-Gene
deficiency	O	B-NegReg
in	O	O
human	O	O
epidermal	O	O
living	O	O
skin-equivalent	O	O
(	O	O
LSE	O	O
)	O	O
models	O	O
and	O	O
validate	O	O
findings	O	O
in	O	O
skin	O	O
of	O	O
patients	O	O
with	O	O
AE	O	O
.	O	O

METHODS	O	O
:	O	O
Differentially	O	O
expressed	O	O
proteins	O	O
from	O	O
paired	O	O
control	O	O
(	O	O
nontargeting	O	O
control	O	O
short	O	O
hairpin	O	O
RNA	O	O
[	O	O
shNT	O	O
]	O	O
)	O	O
and	O	O
FLG	O	B-Gene
knockdown	O	O
(	O	O
FLG	O	O
knockdown	O	O
short	O	O
hairpin	O	O
RNA	O	O
[	O	O
shFLG	O	O
]	O	O
)	O	O
LSEs	O	O
were	O	O
identified	O	O
by	O	O
means	O	O
of	O	O
proteomic	O	O
analysis	O	O
(	O	O
liquid	O	O
chromatography-mass	O	O
spectrometry	O	O
)	O	O
and	O	O
Ingenuity	O	O
Pathway	O	O
Analysis	O	O
.	O	O

Expression	O	O
of	O	O
key	O	O
targets	O	O
was	O	O
validated	O	O
in	O	O
independent	O	O
LSE	O	O
samples	O	O
(	O	O
quantitative	O	O
RT-PCR	O	O
and	O	O
Western	O	O
blotting	O	O
)	O	O
and	O	O
in	O	O
normal	O	O
and	O	O
AE	O	O
skin	O	O
biopsy	O	O
specimens	O	O
(	O	O
immunofluorescence	O	O
)	O	O
.	O	O

RESULTS	O	O
:	O	O
Proteomic	O	O
analysis	O	O
identified	O	O
17	O	O
(	O	O
P	O	B-Var
 	O	O
≤	O	O
 	O	O
.05	O	O
)	O	O
differentially	O	O
 	O	O
expressed	O	O
proteins	O	O
after	O	O
FLG	O	O
knockdown	O	O
,	O	O
including	O	O
kallikrein-7	O	O
(	O	O
KLK7	O	O
;	O	O
2.2-fold	O	O
)	O	O
,	O	O
cyclophilin	O	O
A	O	O
 	O	O
(	O	O
PPIA	O	O
;	O	O
0.9-fold	O	O
)	O	O
,	O	O
and	O	O
cofilin-1	O	O
(	O	O
CFL1	O	O
,	O	O
1.3-fold	O	O
)	O	O
.	O	O

Differential	O	O
protein	O	O
expression	O	O
was	O	O
confirmed	O	O
in	O	O
shNT	O	O
/	O	O
shFLG	O	O
LSEs	O	O
;	O	O
however	O	O
,	O	O
only	O	O
KLK7	O	O
was	O	O
transcriptionally	O	O
dysregulated	O	O
.	O	O

Molecular	B-Pathway	O
pathways	I-Pathway	O
overrepresented	B-PosReg	O
after	O	O
FLG	B-Gene	O
knockdown	B-Var	O
included	O	O
inflammation	O	O
,	O	O
protease	O	O
activity	O	O
,	O	O
cell	O	O
structure	O	O
,	O	O
and	O	O
stress	O	O
.	O	O

Furthermore	O	O
,	O	O
KLK7	O	O
(	O	O
1.8-fold	O	O
)	O	O
and	O	O
PPIA	O	O
(	O	O
0.65-fold	O	O
)	O	O
proteins	O	O
were	O	O
differentially	O	O
expressed	O	O
in	O	O
lesional	O	O
biopsy	O	O
specimens	O	O
from	O	O
patients	O	O
with	O	O
AE	O	O
relative	O	O
to	O	O
normal	O	O
skin	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
For	O	O
the	O	O
first	O	O
time	O	O
,	O	O
we	O	O
show	O	O
that	O	O
loss	B-Var	O
of	O	O
FLG	B-Gene	B-Gene
in	O	O
the	O	O
absence	O	O
of	O	O
inflammation	O	O
is	O	O
sufficient	O	O
to	O	O
alter	B-Reg	O
the	O	O
expression	B-MPA	B-MPA
level	I-MPA	O
of	I-MPA	O
proteins	I-MPA	O
TREM2	O	O
deficiency	O	O
impairs	O	B-NegReg
chemotaxis	O	O
and	O	O
microglial	O	O
responses	O	O
to	O	O
neuronal	O	O
injury	O	O
.	O	O

Sequence	O	B-Var
variations	B-Var	I-Var
in	O	O
the	O	O
triggering	O	O
receptor	O	O
expressed	O	O
on	O	O
myeloid	O	O
cells	O	O
2	O	O
(	O	O
TREM2	B-Gene	O
)	O	O
have	O	O
been	O	O
linked	B-Reg	O
to	I-Reg	O
an	O	O
increased	O	O
risk	O	O
for	O	O
neurodegenerative	O	O
disorders	O	O
such	O	O
as	O	O
Alzheimer	B-Disease	B-Disease
's	I-Disease	I-Disease
disease	O	O
and	O	O
frontotemporal	B-Disease	O
lobar	I-Disease	O
degeneration	I-Disease	O
.	O	O

In	O	O
the	O	O
brain	O	O
,	O	O
TREM2	O	O
is	O	O
predominantly	O	O
expressed	O	O
in	O	O
microglia	O	O
.	O	O

Several	O	O
disease-associated	O	O
TREM2	B-Gene	O
variants	B-Var	O
result	O	O
in	O	O
a	O	O
loss	O	B-NegReg
of	O	I-NegReg
function	O	I-NegReg
by	O	O
reducing	B-NegReg	O
microglial	B-CPA	O
phagocytosis	I-CPA	O
,	O	O
impairing	B-NegReg	O
lipid	B-MPA	O
sensing	I-MPA	O
,	O	O
preventing	B-NegReg	O
binding	B-Interaction	O
of	O	O
lipoproteins	B-Protein	O
and	O	O
affecting	B-Reg	O
shielding	B-MPA	O
of	I-MPA	O
amyloid	I-MPA	O
plaques	I-MPA	O
.	O	O

We	O	O
here	O	O
investigate	O	O
the	O	O
consequences	O	O
of	O	O
TREM2	O	O
loss	O	B-NegReg
of	O	I-NegReg
function	O	I-NegReg
on	O	O
the	O	O
microglia	O	O
transcriptome	O	O
.	O	O

Among	O	O
the	O	O
differentially	O	O
expressed	O	O
messenger	O	O
RNAs	O	O
in	O	O
wild-type	O	O
and	O	O
Trem2(-/-	O	O
)	O	O
microglia	O	O
,	O	O
gene	O	O
clusters	O	O
are	O	O
identified	O	O
which	O	O
represent	O	O
gene	O	O
functions	O	O
in	O	O
chemotaxis	O	O
,	O	O
migration	O	O
and	O	O
mobility	O	O
.	O	O

Functional	O	O
analyses	O	O
confirm	O	O
that	O	O
loss	B-Var	O
of	O	O
TREM2	B-Gene	O
impairs	B-NegReg	B-NegReg
appropriate	O	O
microglial	B-CPA	O
responses	I-CPA	O
to	I-CPA	O
injury	I-CPA	O
and	I-CPA	O
signals	I-CPA	O
Novel	O	O
loss	B-NegReg	B-NegReg
of	I-NegReg	I-NegReg
function	I-NegReg	I-NegReg
mutation	B-Var	B-Var
in	O	O
KRIT1/CCM1	B-Gene	O
is	O	O
associated	B-Reg	O
with	I-Reg	O
distinctly	O	O
progressive	O	O
cerebral	B-Disease	O
and	I-Disease	O
spinal	I-Disease	O
cavernous	I-Disease	O
malformations	I-Disease	O
after	O	O
radiochemotherapy	O	O
for	O	O
intracranial	O	O
malignant	O	O
germ	O	O
cell	O	O
tumor	O	O
.	O	O

PURPOSE	O	O
:	O	O
Cerebrospinal	B-Disease	O
cavernous	I-Disease	O
malformations	I-Disease	O
(	O	O
CCMs	O	O
)	O	O
are	O	O
vascular	O	O
lesions	O	O
characterized	O	O
by	O	O
dilated	O	O
and	O	O
leaky	O	O
capillary	O	O
caverns	O	O
.	O	O

CCMs	O	O
can	O	O
cause	O	O
seizures	O	B-Disease
,	O	O
focal	O	O
neurological	O	O
deficits	O	O
or	O	O
acute	O	O
intracranial	O	O
hemorrhage	O	O
;	O	O
however	O	O
,	O	O
most	O	O
patients	O	O
are	O	O
asymptomatic	O	O
.	O	O

CCMs	O	O
occur	O	O
either	O	O
sporadically	O	O
or	O	O
as	O	O
a	O	O
familial	O	O
autosomal-dominant	O	O
disorder	O	O
.	O	O

We	O	O
present	O	O
a	O	O
clinical	O	O
and	O	O
molecular	O	O
study	O	O
of	O	O
a	O	O
patient	O	O
with	O	O
distinctive	O	O
cerebral	O	O
and	O	O
spinal	O	O
cavernous	O	O
malformations	O	O
following	O	O
radiochemotherapy	O	O
for	O	O
a	O	O
malignant	O	O
brain	O	O
tumor	O	O
.	O	O

METHODS	O	O
:	O	O
The	O	O
patient	O	O
had	O	O
multiple	O	O
magnet	O	O
resonance	O	O
imaging	O	O
(	O	O
MRI	O	O
)	O	O
examinations	O	O
of	O	O
his	O	B-CPA
brain	O	I-CPA
and	O	O
spine	O	O
following	O	O
radiochemotherapy	O	O
for	O	O
a	O	O
primary	O	O
intracranial	O	O
germ	O	O
cell	O	O
tumor	O	O
(	O	O
GCT	O	O
)	O	O
,	O	O
as	O	O
part	O	O
of	O	O
his	O	O
oncologic	O	O
follow-up	O	O
.	O	O

The	O	O
MRI	O	O
sequences	O	O
included	O	O
susceptibility-weighted	O	O
imaging	O	O
(	O	O
SWI	O	O
)	O	O
.	O	O

The	O	O
coding	O	O
exons	O	O
and	O	O
their	O	O
flanking	O	O
intronic	O	O
regions	O	O
of	O	O
KRIT1/CCM1	O	O
gene	O	O
were	O	O
analyzed	O	O
for	O	O
mutations	O	O
by	O	O
polymerase	O	O
chain	O	O
reaction	O	O
(	O	O
PCR	O	O
)	O	O
and	O	O
direct	O	O
sequencing	O	O
.	O	O

RESULTS	O	O
:	O	O
MRI	O	O
revealed	O	O
numerous	O	O
cerebral	O	O
and	O	O
spinal	O	O
microhemorrhages	O	O
and	O	O
pronounced	O	O
cavernous	O	O
malformations	O	O
that	O	O
progressed	O	O
with	O	O
subsequent	O	O
follow-up	O	O
imaging	O	O
.	O	O

Genetic	O	O
analysis	O	O
demonstrated	O	O
a	O	O
novel	O	O
heterozygous	O	O
KRIT1/CCM1	B-Gene	O
two	O	O
base	O	O
pair	O	O
deletion	O	O
(	O	O
c.1535_1536delTG	B-Var	O
)	O	O
in	O	O
exon	O	O
14	O	O
.	O	O

This	O	O
deletion	O	O
leads	B-Reg	O
to	I-Reg	O
a	O	O
frameshift	B-Var	O
with	O	O
a	O	O
premature	B-MPA	O
stop	I-MPA	O
codon	I-MPA	O
at	O	O
nucleotide	O	O
position	O	O
1553	O	O
and	O	O
a	O	O
highly	O	O
likely	O	O
loss	B-NegReg	B-NegReg
of	I-NegReg	I-NegReg
function	I-NegReg	I-NegReg
of	O	O
the	O	O
KRIT1	B-Protein	O
protein	I-Protein	O
.	O	O

CONCLUSION	O	O
:	O	O
We	O	O
describe	O	O
a	O	O
patient	O	O
with	O	O
a	O	O
novel	O	O
heterozygous	O	O
germ	O	O
line	O	O
loss	B-NegReg	B-NegReg
of	I-NegReg	I-NegReg
function	I-NegReg	I-NegReg
mutation	B-Var	B-Var
in	O	O
KRIT1	B-Gene	O
,	O	O
which	O	O
is	O	O
associated	B-Reg	O
with	I-Reg	O
rapid-onset	O	O
and	O	O
highly	O	O
progressive	O	O
CCMs	B-Disease	O
Real-World	O	O
Data	O	O
on	O	O
Prognostic	O	O
Factors	O	O
for	O	O
Overall	O	O
Survival	O	O
in	O	O
EGFR	B-Gene	O
Mutation-Positive	B-Var	O
Advanced	O	O
Non-Small	O	O
Cell	O	O
Lung	O	O
Cancer	O	O
Patients	O	O
Treated	O	O
with	O	O
First-Line	O	O
Gefitinib	O	O
.	O	O

BACKGROUND	O	O
:	O	O
This	O	O
study	O	O
aimed	O	O
to	O	O
identify	O	O
independent	O	O
prognostic	O	O
factors	O	O
for	O	O
overall	O	O
survival	O	O
(	O	O
OS	O	O
)	O	O
of	O	O
patients	O	O
with	O	O
advanced	O	O
non-small	O	O
cell	O	O
lung	O	O
cancer	O	O
(	O	O
NSCLC	O	O
)	O	O
harboring	O	O
an	O	O
activating	O	O
epidermal	O	O
growth	O	O
factor	O	O
receptor	O	O
(	O	O
EGFR	O	O
)	O	O
mutation	O	B-Var
and	O	O
receiving	O	O
gefitinib	O	O
as	O	O
first-line	O	O
treatment	O	O
in	O	O
real-world	O	O
practice	O	O
.	O	O

MATERIALS	O	O
AND	O	O
METHODS	O	O
:	O	O
We	O	O
enrolled	O	O
226	O	O
patients	O	O
from	O	O
June	O	O
2011	O	O
to	O	O
May	O	O
2013	O	O
.	O	O

During	O	O
this	O	O
period	O	O
,	O	O
gefitinib	O	O
was	O	O
the	O	O
only	O	O
EGFR-tyrosine	O	O
kinase	O	O
inhibitor	O	O
reimbursed	O	O
by	O	O
the	O	O
Bureau	O	O
of	O	O
National	O	O
Health	O	O
Insurance	O	O
of	O	O
Taiwan	O	O
.	O	O

RESULTS	O	O
:	O	O
The	O	O
median	O	O
progression-free	O	O
survival	O	O
and	O	O
median	O	O
OS	O	O
were	O	O
11.9	O	O
months	O	O
(	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
[	O	O
CI	O	O
]	O	O
:	O	O
9.7-14.2	O	O
)	O	O
and	O	O
26.9	O	O
months	O	O
(	O	O
21.2-32.5	O	O
)	O	O
,	O	O
respectively	O	O
.	O	O

The	O	O
Cox	O	O
proportional	O	O
hazards	O	O
regression	O	O
model	O	O
revealed	O	O
that	O	O
postoperative	O	O
recurrence	O	O
,	O	O
performance	O	O
status	O	O
(	O	O
Eastern	O	O
Cooperative	O	O
Oncology	O	O
Grade	O	O
[	O	O
ECOG	O	O
]	O	O
≥2	O	O
)	O	O
,	O	O
smoking	O	O
index	O	O
(	O	O
≥20	O	O
pack-years	O	O
)	O	O
,	O	O
liver	O	O
metastasis	O	O
at	O	O
initial	O	O
diagnosis	O	O
,	O	O
and	O	O
chronic	O	O
hepatitis	O	O
C	O	O
virus	O	O
(	O	O
HCV	O	O
)	O	O
infection	O	O
were	O	O
independent	O	O
prognostic	O	O
factors	O	O
for	O	O
OS	O	O
(	O	O
hazard	O	O
ratio	O	O
[	O	O
95	O	O
%	O	O
CI	O	O
]	O	O
0.3	O	O
[	O	O
0.11-0.83	O	O
]	O	O
,	O	O
p	O	O
 	O	O
=	O	O
 	O	O
.02	O	O
;	O	O
2.69	O	O
[	O	O
1.60-4.51	O	O
]	O	O
,	O	O
p	O	O
 	O	O
<	O	O
 	O	O
.001	O	O
;	O	O
1.92	O	O
[	O	O
1.24-2.97	O	O
]	O	O
,	O	O
p	O	O
 	O	O
=	O	O
 	O	O
.003	O	O
;	O	O
2.26	O	O
[	O	O
1.34-3.82	O	O
]	O	O
,	O	O
p	O	O
 	O	O
=	O	O
 	O	O
.002	O	O
;	O	O
3.38	O	O
[	O	O
1.85-7.78	O	O
]	O	O
,	O	O
p	O	O
 	O	O
<	O	O
 	O	O
.001	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O

However	O	O
,	O	O
brain	O	O
metastasis	O	O
(	O	O
BM	O	O
)	O	O
at	O	O
initial	O	O
diagnosis	O	O
or	O	O
intracranial	O	O
progression	O	O
during	O	O
gefitinib	O	O
treatment	O	O
had	O	O
no	O	O
impact	O	O
on	O	O
OS	O	O
(	O	O
1.266	O	O
[	O	O
0.83-1.93	O	O
]	O	O
,	O	O
p	O	O
 	O	O
=	O	O
 	O	O
.275	O	O
and	O	O
0.75	O	O
[	O	O
0.48-1.19	O	O
]	O	O
,	O	O
p	O	O
 	O	O
=	O	O
 	O	O
.211	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O

CONCLUSION	O	O
:	O	O
HCV	O	O
infection	O	O
,	O	O
performance	O	O
status	O	O
(	O	O
ECOG	O	O
≥2	O	O
)	O	O
,	O	O
newly	O	O
diagnosed	O	O
advanced	O	O
NSCLC	O	O
without	O	O
prior	O	O
operation	O	O
,	O	O
and	O	O
liver	O	O
metastasis	O	O
predicted	O	O
poor	O	O
OS	O	O
in	O	O
EGFR	O	O
mutation-positive	O	O
advanced	O	O
NSCLC	O	O
patients	O	O
treated	O	O
with	O	O
first-line	O	O
gefitinib	O	O
;	O	O
however	O	O
,	O	O
neither	O	O
BM	O	O
at	O	O
initial	O	O
diagnosis	O	O
nor	O	O
intracranial	O	O
progression	O	O
during	O	O
gefitinib	O	O
treatment	O	O
had	O	O
an	O	O
impact	O	O
on	O	O
OS	O	O
.	O	O

The	O	O
Oncologist	O	O
2017;22:1-9	O	O
IMPLICATIONS	O	O
FOR	O	O
PRACTICE	O	O
:	O	O
The	O	O
finding	O	O
that	O	O
chronic	O	O
hepatitis	O	O
C	O	O
virus	O	O
(	O	O
HCV	O	O
)	O	O
infection	O	O
might	O	O
predict	O	O
poor	O	O
overall	O	O
survival	O	O
(	O	O
OS	O	O
)	O	O
in	O	O
epidermal	O	O
growth	O	O
factor	O	O
receptor	O	O
mutation-positive	O	O
advanced	O	O
non-small	O	O
cell	O	O
lung	O	O
cancer	O	O
(	O	O
NSCLC	O	O
)	O	O
patients	O	O
treated	O	O
with	O	O
first-line	O	O
gefitinib	O	O
may	O	O
raise	O	O
awareness	O	O
of	O	O
benefit	O	O
from	O	O
anti-HCV	O	O
treatment	O	O
in	O	O
this	O	O
patient	O	O
population	O	O
.	O	O

Brain	O	O
metastasis	O	O
in	O	O
the	O	O
initial	O	O
diagnosis	O	O
or	O	O
intracranial	O	O
progression	O	O
during	O	O
gefitinib	O	O
treatment	O	O
is	O	O
not	O	O
a	O	O
prognostic	O	O
factor	O	O
for	O	O
OS	O	O
.	O	O

This	O	O
study	O	O
,	O	O
which	O	O
enrolled	O	O
a	O	O
real-world	O	O
population	O	O
of	O	O
NSCLC	O	O
patients	O	O
,	O	O
including	O	O
sicker	O	O
patients	O	O
who	O	O
were	O	O
not	O	O
eligible	O	O
for	O	O
a	O	O
clinical	O	O
trial	O	O
,	O	O
may	O	O
have	O	O
impact	O	O
on	O	O
guiding	O	O
usual	O	O
clinical	O	O
practice	O	O
.	O	O

Loss	B-Var	O
of	O	O
the	O	O
homologous	O	O
recombination	O	O
gene	O	O
rad51	B-Gene	O
leads	B-Reg	O
to	O	O
Fanconi	B-Disease	O
anemia-like	I-Disease	O
symptoms	I-Disease	O
in	O	O
zebrafish	O	O
.	O	O

RAD51	O	O
is	O	O
an	O	O
indispensable	O	O
homologous	O	O
recombination	O	O
protein	O	O
,	O	O
necessary	O	O
for	O	O
strand	O	O
invasion	O	O
and	O	O
crossing	O	O
over	O	O
.	O	O

It	O	O
has	O	O
recently	O	O
been	O	O
designated	O	O
as	O	O
a	O	O
Fanconi	B-Disease	O
anemia	I-Disease	O
(	O	O
FA	O	O
)	O	O
gene	O	O
,	O	O
following	O	O
the	O	O
discovery	O	O
of	O	O
two	O	O
patients	O	O
carrying	O	O
dominant-negative	O	O
mutations	O	O
.	O	O

FA	O	O
is	O	O
a	O	O
hereditary	O	O
DNA-repair	O	O
disorder	O	O
characterized	O	O
by	O	O
various	O	O
congenital	O	O
abnormalities	O	O
,	O	O
progressive	O	O
bone	O	O
marrow	O	O
failure	O	O
,	O	O
and	O	O
cancer	O	O
predisposition	O	O
.	O	O

In	O	O
this	O	O
report	O	O
,	O	O
we	O	O
describe	O	O
a	O	O
viable	O	O
vertebrate	O	O
model	O	O
of	O	O
RAD51	O	O
loss	O	O
.	O	O

Zebrafish	O	O
rad51	B-Gene	O
loss-of-function	B-NegReg	B-NegReg
mutants	B-Var	B-Var
developed	O	O
key	O	O
features	O	O
of	O	O
FA	B-Disease	O
Gene	O	O
Co-Expression	O	O
Network	O	O
Analysis	O	O
for	O	O
Identifying	O	O
Modules	O	O
and	O	O
Functionally	O	O
Enriched	O	O
Pathways	O	O
in	O	O
SCA2	O	O
.	O	O

Spinocerebellar	B-Disease	O
ataxia	I-Disease	O
type	I-Disease	O
2	I-Disease	O
(	O	O
SCA2	O	O
)	O	O
is	O	O
an	O	O
autosomal	O	O
dominant	O	O
neurodegenerative	O	O
disease	O	O
caused	B-Reg	O
by	I-Reg	O
CAG	B-Var	O
repeat	I-Var	O
expansion	I-Var	O
in	O	O
the	O	O
ATXN2	B-Gene	O
Exposure	O	O
to	O	O
phenols	O	O
,	O	O
parabens	O	O
and	O	O
UV	O	O
filters	O	O
:	O	O
Associations	O	O
with	O	O
loss-of-function	O	B-NegReg
mutations	O	B-Var
in	O	O
the	O	O
filaggrin	O	O
gene	O	O
in	O	O
men	O	O
from	O	O
the	O	O
general	O	O
population	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Filaggrin	O	O
is	O	O
an	O	O
epidermal	O	O
protein	O	O
that	O	O
is	O	O
important	O	O
for	O	O
normal	O	O
skin	O	O
barrier	O	O
functions	O	O
.	O	O

Up	O	O
to	O	O
10	O	O
%	O	O
of	O	O
Europeans	O	O
and	O	O
Asians	O	O
carry	O	O
filaggrin	O	O
gene	O	O
(	O	O
FLG	B-Gene	B-Gene
)	O	O
loss-of	B-NegReg	O
function	I-NegReg	O
mutations	B-Var	B-Var
that	O	O
appear	O	O
to	O	O
facilitate	B-PosReg	O
trans-epidermal	B-CPA	O
penetration	I-CPA	O
of	I-CPA	O
certain	I-CPA	O
chemicals	I-CPA	O
GRIN2B	O	O
gain	O	B-PosReg
of	O	I-PosReg
function	O	I-PosReg
mutations	O	B-Var
are	O	O
sensitive	O	O
to	O	O
radiprodil	O	O
,	O	O
a	O	O
negative	O	O
allosteric	O	O
modulator	O	O
of	O	O
GluN2B-containing	O	O
NMDA	O	O
receptors	O	O
.	O	O

De	O	O
novo	O	O
gain	B-PosReg	B-PosReg
of	I-PosReg	I-PosReg
function	I-PosReg	I-PosReg
mutations	B-Var	B-Var
in	O	O
GRIN2B	B-Gene	O
encoding	O	O
the	O	O
GluN2B	O	O
subunit	O	O
of	O	O
the	O	O
N-methyl-d-aspartate	O	O
(	O	O
NMDA	O	O
)	O	O
receptor	O	O
have	O	O
been	O	O
linked	O	O
with	O	O
epileptic	B-Disease	O
encephalopathies	I-Disease	O
,	O	O
including	O	O
infantile	B-Disease	O
spasms	I-Disease	O
PAI-1	O	O
gain-of-function	O	O
genotype	O	O
,	O	O
factors	O	O
increasing	O	O
PAI-1	O	O
levels	O	O
,	O	O
and	O	O
airway	O	O
obstruction	O	O
:	O	O
The	O	O
GALA	O	O
II	O	O
Cohort	O	O
.	O	O

BACKGROUND	O	O
:	O	O
PAI-1	B-Gene	O
gain-of-function	O	B-PosReg
variants	B-Var	B-Var
promote	B-PosReg	B-PosReg
airway	B-CPA	B-CPA
fibrosis	I-CPA	I-CPA
and	O	O
are	O	O
associated	B-Reg	O
with	I-Reg	O
asthma	B-Disease	B-Disease
Severe	O	I-Disease
hypertriglyceridemia	B-Disease	I-Disease
due	O	O
to	O	O
two	O	O
novel	O	O
loss-of-function	B-NegReg	B-NegReg
lipoprotein	B-Enzyme	O
lipase	I-Enzyme	O
gene	O	O
mutations	O	O
(	O	O
C310R	B-Var	O
/	O	O
E396V	B-Var	O
)	O	O
in	O	O
a	O	O
Chinese	O	O
family	O	O
associated	B-Reg	O
with	I-Reg	O
recurrent	B-Disease	O
acute	I-Disease	O
pancreatitis	I-Disease	O
.	O	O

Lipoprotein	O	O
lipase	O	O
(	O	O
LPL	O	O
)	O	O
is	O	O
widely	O	O
expressed	O	O
in	O	O
skeletal	O	O
muscles	O	O
,	O	O
cardiac	O	O
muscles	O	O
as	O	O
well	O	O
as	O	O
adipose	O	O
tissue	O	O
and	O	O
involved	O	O
in	O	O
the	O	O
catabolism	O	O
of	O	O
triglyceride	O	O
.	O	O

Herein	O	O
we	O	O
have	O	O
systematically	O	O
characterized	O	O
two	O	O
novel	O	O
loss-of-function	O	B-NegReg
mutations	O	B-Var
in	O	O
LPL	O	O
from	O	O
a	O	O
Chinese	O	O
family	O	O
in	O	O
which	O	O
afflicted	O	O
members	O	O
were	O	O
manifested	O	O
by	O	O
severe	O	O
hypertriglyceridemia	O	O
and	O	O
recurrent	O	O
pancreatitis	O	O
.	O	O

DNA	O	O
sequencing	O	O
revealed	O	O
that	O	O
the	O	O
proband	O	O
was	O	O
a	O	O
heterozygote	O	O
carrying	O	O
a	O	O
novel	O	O
c	O	O
.	O	O

T928C	O	O
(	O	O
p	O	O
.	O	O

C310R	O	O
)	O	O
mutation	O	B-Var
in	O	O
exon	O	O
6	O	O
of	O	O
the	O	O
LPL	O	O
gene	O	O
.	O	O

Another	O	O
member	O	O
of	O	O
the	O	O
family	O	O
was	O	O
detected	O	O
to	O	O
be	O	O
a	O	O
compound	O	O
heterozygote	O	O
who	O	O
along	O	O
with	O	O
the	O	O
c	O	O
.	O	O

T928C	O	O
mutation	O	O
also	O	O
carried	O	O
a	O	O
novel	O	O
missense	O	O
mutation	O	O
c	O	O
.	O	O

A1187	O	O
T	O	O
(	O	O
p	O	O
.	O	O

E396V	O	O
)	O	O
in	O	O
exon	O	O
8	O	O
of	O	O
the	O	O
LPL	O	O
gene	O	O
.	O	O

Furthermore	O	O
,	O	O
COS-1	O	O
cells	O	O
were	O	O
transfected	O	O
with	O	O
lentiviruses	O	O
containing	O	O
the	O	O
mutant	O	B-Var
LPL	O	B-Gene
genes	O	O
.	O	O

While	O	O
C310R	B-Var	O
markedly	O	O
reduced	B-NegReg	B-NegReg
the	O	O
overall	O	O
LPL	B-MPA	O
protein	I-MPA	O
level	I-MPA	O
,	O	O
COS-1	O	O
cells	O	O
carrying	O	O
E396V	O	O
or	O	O
double	O	O
mutations	O	O
contained	O	O
similar	O	O
overall	O	O
LPL	O	O
protein	O	O
levels	O	O
to	O	O
the	O	O
wild-type	O	O
.	O	O

The	O	O
specific	O	O
activity	O	O
of	O	O
the	O	O
LPL	O	O
mutants	O	O
remained	O	O
at	O	O
comparable	O	O
magnitude	O	O
to	O	O
the	O	O
wild-type	O	O
.	O	O

However	O	O
,	O	O
few	O	O
LPL	O	O
were	O	O
detected	O	O
in	O	O
the	O	O
culture	O	O
medium	O	O
for	O	O
the	O	O
mutants	O	O
,	O	O
suggesting	O	O
that	O	O
both	O	O
mutations	B-Var	B-Var
caused	B-Reg	O
aberrant	O	O
triglyceride	B-MPA	O
catabolism	I-MPA	O
.	O	O

More	O	O
specifically	O	O
,	O	O
E396V	B-Var	O
and	O	O
double	B-Var	O
mutations	I-Var	O
dampened	B-NegReg	O
the	O	O
transport	B-MPA	O
of	I-MPA	O
LPL	I-MPA	O
to	I-MPA	O
the	I-MPA	O
cell	I-MPA	O
surface	I-MPA	O
,	O	O
while	O	O
for	O	O
the	O	O
C310R	B-Var	O
mutation	O	O
,	O	O
reducing	B-NegReg	O
LPL	B-MPA	O
protein	I-MPA	O
level	I-MPA	O
WNT10A	B-Gene	O
mutation	B-Var	O
causes	B-Reg	O
ectodermal	B-Disease	B-Disease
dysplasia	I-Disease	I-Disease
by	O	O
impairing	B-NegReg	O
progenitor	B-CPA	O
cell	I-CPA	O
proliferation	I-CPA	O
and	O	O
KLF4-mediated	B-CPA	O
differentiation	I-CPA	O
Loss	B-Var	B-NegReg
of	I-Var	I-NegReg
function	I-Var	I-NegReg
in	O	O
ROBO1	B-Gene	O
is	O	O
associated	B-Reg	O
with	O	O
tetralogy	B-Disease	O
of	I-Disease	O
Fallot	I-Disease	O
and	O	O
septal	B-Disease	O
defects	I-Disease	O
Human	O	O
IκBα	O	O
Gain	O	O
of	O	O
Function	O	O
:	O	O
a	O	O
Severe	O	O
and	O	O
Syndromic	O	O
Immunodeficiency	O	O
.	O	O

Germline	O	O
heterozygous	O	O
gain-of-function	B-PosReg	O
(	O	O
GOF	O	O
)	O	O
mutations	B-Var	B-Var
of	O	O
NFKBIA	B-Gene	O
,	O	O
encoding	O	O
IκBα	O	O
,	O	O
cause	O	O
an	O	O
autosomal	O	O
dominant	O	O
(	O	O
AD	O	O
)	O	O
form	O	O
of	O	O
anhidrotic	B-Disease	O
ectodermal	I-Disease	B-Disease
dysplasia	I-Disease	I-Disease
with	I-Disease	O
immunodeficiency	I-Disease	O
(	O	O
EDA-ID	O	O
)	O	O
.	O	O

Fourteen	O	O
unrelated	O	O
patients	O	O
have	O	O
been	O	O
reported	O	O
since	O	O
the	O	O
identification	O	O
of	O	O
the	O	O
first	O	O
case	O	O
in	O	O
2003	O	O
.	O	O

All	O	O
mutations	B-Var	O
enhanced	B-PosReg	B-PosReg
the	O	B-MPA
inhibitory	B-MPA	I-MPA
activity	I-MPA	I-MPA
of	O	O
IκBα	B-Protein	O
,	O	O
by	O	O
preventing	B-NegReg	O
its	O	O
phosphorylation	B-MPA	O
on	I-MPA	O
serine	I-MPA	O
32	I-MPA	O
or	I-MPA	O
36	I-MPA	O
and	O	O
its	O	O
subsequent	O	O
degradation	B-MPA	O
ARX	B-Gene	O
polyalanine	B-Var	O
expansion	I-Var	O
mutations	I-Var	O
lead	B-Reg	B-Reg
to	I-Reg	I-Reg
migration	B-CPA	O
impediment	I-CPA	O
in	I-CPA	O
the	I-CPA	O
rostral	I-CPA	O
cortex	I-CPA	O
coupled	I-CPA	O
with	O	O
a	O	O
developmental	B-CPA	O
deficit	I-CPA	O
of	I-CPA	O
calbindin-positive	I-CPA	O
cortical	I-CPA	O
GABAergic	I-CPA	O
interneurons	I-CPA	O
.	O	O

The	O	O
Aristaless-related	O	O
homeobox	O	O
gene	O	O
(	O	O
ARX	O	O
)	O	O
is	O	O
indispensable	O	O
for	O	O
interneuron	O	O
development	O	O
.	O	O

Patients	O	O
with	O	O
ARX	O	O
polyalanine	O	O
expansion	O	O
mutations	O	O
of	O	O
the	O	O
first	O	O
two	O	O
tracts	O	O
(	O	O
namely	O	O
PA1	O	O
and	O	O
PA2	O	O
)	O	O
suffer	O	O
from	O	O
intellectual	O	O
disability	O	O
of	O	O
varying	O	O
severity	O	O
,	O	O
with	O	O
seizures	O	B-Disease
a	O	O
frequent	O	O
comorbidity	O	O
.	O	O

The	O	O
impact	O	O
of	O	O
PA1	O	O
and	O	O
PA2	O	O
mutations	O	O
on	O	O
the	O	O
brain	O	B-CPA
development	O	I-CPA
is	O	O
unknown	O	O
,	O	O
hindering	O	O
the	O	O
search	O	O
for	O	O
therapeutic	O	O
interventions	O	O
.	O	O

Here	O	O
,	O	O
we	O	O
characterized	O	O
the	O	O
disturbances	O	O
to	O	O
cortical	O	O
interneuron	O	O
development	O	O
in	O	O
mice	O	O
modeling	O	O
the	O	O
two	O	O
most	O	O
common	O	O
ARX	O	O
polyalanine	O	O
expansion	O	B-Var
mutations	O	I-Var
in	O	O
human	O	O
.	O	O

We	O	O
found	O	O
a	O	O
consistent	O	O
∼40-50	O	O
%	O	O
reduction	O	O
of	O	O
calbindin-positive	O	O
interneurons	O	O
,	O	O
but	O	O
not	O	O
Stt+	O	O
or	O	O
Cr+	O	O
interneurons	O	O
,	O	O
within	O	O
the	O	O
cortex	O	O
of	O	O
newborn	O	O
hemizygous	O	O
mice	O	O
(	O	O
p=0.024	O	O
)	O	O
for	O	O
both	O	O
mutant	O	B-Var
strains	O	O
compared	O	O
to	O	O
wildtype	O	O
(	O	O
p=0.011	O	O
)	O	O
.	O	O

We	O	O
demonstrate	O	O
that	O	O
this	O	O
was	O	O
a	O	O
consequence	O	O
of	O	O
calbindin	O	O
precursor	O	O
cells	O	O
being	O	O
arrested	O	O
or	O	O
delayed	O	O
at	O	O
the	O	O
ventral	O	O
subpallium	O	O
en	O	O
route	O	O
of	O	O
tangential	O	O
migration	O	O
.	O	O

Ex-vivo	O	O
assay	O	O
validated	O	O
this	O	O
migration	O	O
deficit	O	O
in	O	O
PA1	O	O
cells	O	O
(	O	O
p=0.0002	O	O
)	O	O
suggesting	O	O
that	O	O
the	O	O
defect	O	O
is	O	O
contributed	O	O
by	O	O
intrinsic	O	O
loss	O	O
of	O	O
Arx	O	O
function	O	O
within	O	O
migrating	O	O
cells	O	O
.	O	O

Both	O	O
humans	O	O
and	O	O
mice	O	O
with	O	O
PA1	O	O
mutations	O	O
present	O	O
with	O	O
severe	O	O
clinical	O	O
features	O	O
,	O	O
including	O	O
intellectual	O	B-Disease
disability	O	I-Disease
and	O	O
infantile	O	O
spasms	O	O
.	O	O

Our	O	O
data	O	O
further	O	O
demonstrated	O	O
the	O	O
pathogenic	O	O
mechanism	O	O
was	O	O
robustly	O	O
shared	O	O
between	O	O
PA1	O	O
and	O	O
PA2	O	O
mutations	O	O
,	O	O
as	O	O
previously	O	O
reported	O	O
including	O	O
Arx	O	O
protein	O	O
reduction	O	O
and	O	O
overlapping	O	O
transcriptome	O	O
profiles	O	O
within	O	O
the	O	O
developing	O	O
mouse	O	O
brains	O	O
.	O	O

Data	O	O
from	O	O
our	O	O
study	O	O
demonstrated	O	O
that	O	O
cortical	B-CPA	O
calbindin	I-CPA	O
interneuron	I-CPA	O
development	B-CPA	O
and	O	O
migration	B-CPA	O
is	O	O
negatively	B-NegReg	O
affected	O	O
by	O	O
ARX	B-Gene	O
polyalanine	B-Var	O
expansion	I-Var	O
mutations	I-Var	O
Inducible	O	O
activation	O	O
of	O	O
FGFR2	O	O
in	O	O
adult	O	O
mice	O	O
promotes	O	O
bone	O	O
formation	O	O
after	O	O
bone	O	O
marrow	O	O
ablation	O	O
.	O	O

Apert	B-Disease	B-Disease
syndrome	I-Disease	I-Disease
is	O	O
one	O	O
of	O	O
the	O	O
most	O	O
severe	O	O
craniosynostoses	O	O
,	O	O
resulting	O	O
from	O	O
gain-of-function	B-PosReg	O
mutations	B-Var	O
in	O	O
fibroblast	O	O
growth	O	O
factor	O	O
receptor	O	O
2	O	O
(	O	O
FGFR2	B-Gene	O
)	O	O
.	O	O

Previous	O	O
studies	O	O
have	O	O
shown	O	O
that	O	O
gain-of-function	O	B-PosReg
mutations	O	B-Var
of	O	O
FGFR2	O	O
(	O	O
S252W	O	O
or	O	O
P253R	O	O
)	O	O
cause	O	O
skull	O	O
malformation	O	O
of	O	O
human	O	O
Apert	O	O
syndrome	O	O
by	O	O
affecting	O	O
both	O	O
chondrogenesis	O	O
and	O	O
osteogenesis	O	O
,	O	O
underscoring	O	O
the	O	O
key	O	O
role	O	O
of	O	O
FGFR2	O	O
in	O	O
bone	O	O
development	O	O
.	O	O

However	O	O
,	O	O
the	O	O
effects	O	O
of	O	O
FGFR2	O	O
on	O	O
bone	O	O
formation	O	O
at	O	O
the	O	O
adult	O	O
stage	O	O
have	O	O
not	O	O
been	O	O
fully	O	O
investigated	O	O
.	O	O

To	O	O
investigate	O	O
the	O	O
role	O	O
of	O	O
FGFR2	O	O
in	O	O
bone	O	O
formation	O	O
,	O	O
we	O	O
generated	O	O
mice	O	O
with	O	O
tamoxifen-inducible	O	O
expression	O	O
of	O	O
mutant	O	B-Var
FGFR2	O	B-Gene
(	O	O
P253R	O	O
)	O	O
at	O	O
the	O	O
adult	O	O
stage	O	O
.	O	O

Mechanical	O	O
bone	O	O
marrow	O	O
ablation	O	O
(	O	O
BMX	O	O
)	O	O
was	O	O
performed	O	O
in	O	O
both	O	O
wild-type	O	O
and	O	O
Fgfr2	B-Gene	O
mutant	B-Var	O
(	O	O
MT	O	O
)	O	O
mice	O	O
.	O	O

Changes	O	O
in	O	O
newly	O	O
formed	O	O
trabecular	O	B-CPA
bone	O	I-CPA
were	O	O
assessed	O	O
by	O	O
micro-computed	O	O
tomography	O	O
and	O	O
bone	O	O
histomorphometry	O	O
.	O	O

We	O	O
found	O	O
that	O	O
MT	O	O
mice	O	O
exhibited	O	O
increased	B-PosReg	B-PosReg
trabecular	B-CPA	B-CPA
bone	I-CPA	I-CPA
formation	I-CPA	I-CPA
and	O	O
decreased	B-NegReg	B-NegReg
bone	B-CPA	B-CPA
resorption	I-CPA	I-CPA
after	O	O
BMX	O	O
accompanied	O	O
with	O	O
a	O	O
remarkable	O	O
increase	B-PosReg	O
in	O	O
bone	B-CPA	O
marrow	I-CPA	O
stromal	I-CPA	O
cell	I-CPA	O
recruitment	B-CPA	O
and	O	O
proliferation	B-CPA	O
,	O	O
osteoblast	B-CPA	B-CPA
proliferation	B-CPA	I-CPA
and	O	O
differentiation	B-CPA	O
,	O	O
and	O	O
enhanced	B-PosReg	B-PosReg
Wnt/?-catenin	B-CPA	B-MPA
activity	I-CPA	I-MPA
.	O	O

Furthermore	O	O
,	O	O
pharmacologically	O	O
inhibiting	O	O
Wnt/β-catenin	O	O
signaling	O	O
can	O	O
partially	O	O
reverse	O	O
the	O	O
increased	O	B-PosReg
trabecular	O	B-CPA
bone	O	I-CPA
formation	O	I-CPA
and	O	O
decreased	O	B-NegReg
bone	O	B-CPA
resorption	O	I-CPA
in	O	O
MT	O	O
mice	O	O
after	O	O
BMX	O	O
.	O	O

Our	O	O
data	O	O
demonstrate	O	O
that	O	O
gain-of-function	B-PosReg	B-PosReg
mutation	B-Var	B-Var
in	O	O
FGFR2	B-Gene	O
exerts	B-MPA	O
a	I-MPA	O
Wnt/β-catenin-dependent	I-MPA	O
anabolic	I-MPA	O
effect	I-MPA	O
on	O	O
trabecular	O	B-CPA
bone	O	I-CPA
by	O	O
promoting	B-PosReg	O
bone	B-CPA	O
formation	I-CPA	O
and	O	O
inhibiting	B-NegReg	O
bone	B-CPA	O
resorption	I-CPA	O
at	I-CPA	O
the	I-CPA	O
adult	I-CPA	O
stage	I-CPA	O

